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Abstract
cAMP is a ubiquitous second messenger which conveys its cellular effects mainly 
through the activation of protein kinase A (PKA). Within a cell, activated PKA serves to 
phosphoiylate, and alter the conformational change of a wide variety of proteins. Cyclic- 
phosphodiesterases (PDEs) play a pivotal role in the regulation of cAMP signalling by 
determining the breakdown of cAMP to 5’-AMP. It is now well-accepted that cAMP 
signalling is a compartmentalised response, with PKA being tethered to distinct 
subcellular regions by A-kinase anchoring proteins (AKAPs). The PDE4 family 
exclusively hydrolyse cAMP.
I studied the PKA phosphorylation of the two sites within PDE4D3 and found that the 
phosphorylation of Ser54 (responsible for activation) precedes that of Ser 13. I showed, 
for the first time, that long form PDE4s from each subfamily can be phosphoiylated and 
consequentially activated by PKA in intact cells. I used a novel approach to appreciate 
the functional consequences of the compartmentalisation of PDE4 cAMP- 
phosphodiesterases. To do this, I overexpressed different catalytically inactive long form 
PDE4s which, I hypothesised, would alter distinct cAMP ‘pooL’ by displacing the 
cognate endogenous active PDE4s from their anchor sites. By detecting the 
phosphorylation of the inactive PDE4 by PKA, the catalytically inactive PDE4 itself 
acted as readout of localised PKA activity. Through this approach, I found that different 
PDE4 isoforms are capable of controlling distinct pools of cAMP generated by different 
Gs-coupled receptors. Specifically I showed that the PDE4D3 and PDE4C2 may be held 
in close proximity to, and play a role in the regulation of discrete sub-populations of PKA 
under basal levels of cAMP generation.
Through microarray analysis, I studied the effect of altering compartmentalised cAMP 
signalling on gene expression. This was again done by overexpressing catalytically 
inactive PDE4s in HEK293 cells. My experiments suggest that specific PDE4 isoforms 
can selectively influence gene regulation in these cells.
Additionally, I analysed the function of distinct PDEs within cardiac myocytes. I showed 
that manipulation of cAMP levels with PDE inhibitors alone, or with PDE inhibitors and 
selected GPCR activation, selectively altered ability of phospholamban (PLB) and 
ERKl/2 to be regulated by PKA, suggesting that PLB and ERKl/2 can be differentially 
controlled by specific PDE families.
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General introduction
Cells respond to extracellular stimulatory molecules, such as hormones and 
neurotransmitters, through the activation of signal transduction cascades. Such 
stimulatory molecules, also known as first messengers, usually initiate the signal cascade 
at the level of the plasma membrane via a transmembrane receptor protein. Signal 
transduction involves the extracellular signal being propagated to its target effector via a 
defined signal transduction pathway. However, studies over the last few decades have 
revealed that no one signal transduction pathway acts in isolation, in fact a great deal of 
complexity exists through the integration of different signalling pathways. The range of 
possible networks of ‘cross-talk’, and the orchestration of compartmentalised signalling 
events within specialised cells, is only now becoming apparent. I will give a general 
overview of the cyclic AMP signalling system, focusing on the cyclic AMP-specific 
phosphodiesterases and finally discuss the importance of cAMP within the cardiovascular 
system.
1.1 cAMP signalling
The nucleotide cyclic adenosine 3’, 5’-monophosphate (cAMP) was discovered in 1958 
(Sutherland & Rail, 1958) and is regarded as the classical second messenger molecule. 
Cyclic AMP has been implicated in the mediation of many cellular processes such as 
certain metabolic events, muscle contraction, cytokine-inflammatory events, 
differentiation and growth (Houslay and Milligan, 1997). Various components are 
involved in its synthesis, detection and degradation (Houslay and Milligan, 1997). Over 
the decades, studies have defined some of the molecular machinery involved in the basic 
cAMP signalling system; many transmembrane receptors, heterotrimeric G-proteins, over 
nine different adenylyl cyclase (AC) species, multiple protein kinases/phosphatases and, 
to date, eight phosphodiesterase (PDE) families. All of the above enzymes are involved 
in the relay of the signal from the plasma membrane, conversion of the signal to the 
second messenger cAMP and the tailoring of the cellular response and also in signal 
termination through degradation of cAMP to 5’ AMP (Houslay and Milligan 1997;
Houslay, 1998; Antoni, 2000), A cell can exploit this choice of multiple forms of cAMP 
signalling machinery to achieve a specific response to a variety of different ligands, or 
achieve different responses to the same ligand.
1.1.1 G-proteins and G-protein coupled receptors
G-protein coupled receptors (GPCRs) consist of a family of over 1000 receptors which 
mediate biological responses of a wide array of different stimuli. These receptors are 
often referred to as heptahelical or serpentine receptors, as the best-known family of 
GPCRs contains a conserved structure of seven transmembrane helices. Activation of 
GPCRs causes a change in the transmembrane a  helices, which unmasks G protein 
binding sites (Bourne, et al., 1997). The interaction of the GPCR-G-protein promotes the 
release of guanosine diphosphate (GDP) bound to the G protein a  sub-unit and exchange 
for guanosine triphosphate (GTP). Ga and GPy sub-units of the G-proteins then 
dissociate and thus serve to initiate intracellular signalling responses by acting on a 
variety of different effector molecules (Bourne, et al., 1997).
To date, 20 different Ga sub-units have been identified, and, according to sequence 
similarity, can be divided into four families: Gg, Gi, Gq and G12. The Ga sub-units can 
regulate the generation of several different second messengers (Bourne, et al., 1997; 
Wilkie, et al, 1992). Members of the Gq family_ for example, can control the regulation of 
phospholipase C-p(PLC-P) which hydrolyses phosphatidylinositol 4,5-bisphosphate to 
two second messengers, namely inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG) (Rliee & Bae, 1997). The generation of IP3 and DAG can lead to an increase in 
free intracellular Ca^^ and activation of a number of protein kinases including protein 
kinase C (PKC).
Members of the Gg and G, family can regulate the adenylyl cyclases (AC) family of 
enzymes, and thereby control cAMP levels. Members of the Gg activate ACs (figure 1.1), 
while members of the Gj inhibit ACs. So far, nine different ACs have been cloned and 
each seems to be distinctly regulated by Gg, Gj, Py-sub-units, [Ca^”^] and PKCs (Sunahara
et al, 1996). Thus, the impact of cAMP levels on the cell following stimulation of 
GPCRs will depend on which forms of AC are expressed in the cell.
However, cAMP signalling specificity may also be achieved at the level of the GPCR 
itself as it has been shown by various researcher groups that compartmentalisation exists 
at the level of the plasma membrane and GPCR. For example, in the cardiac myocytes, a 
different distribution patterns have been seen for the prostanoid receptor EP3, as well as 
the p i-A d and p2 -Ad receptors within the plasma membrane. This research shows that 
P2-Ad receptors are enriched in caveolae (defined as membrane invaginations and 
classed as a subset of lipid rafts) yet p i-A d and EP3 receptors are excluded (Easley & 
Smart, 2001; Xiang etal, 2002).
Additionally, 12 different Gy sub-units and 6 Gp sub-units have been cloned. When 
GPy dimers are released upon Ga-activation, they can also regulate the activity of a 
variety of signalling molecules such as phosphatidylinositol kinases, ACs, 
phospholipases and receptor kinases (Bourne, et ah, 1997).
1.1.2 Adenylyl cyclase
1.1.2.1 Regulation of adenylyl cyclases
Over nine different mammalian isoforms of the cAMP producing enzymes, named ACs, 
have been cloned and identified (Sunahara et al, 1996). The ACs can be broadly sub­
divided based on their relatedness and their responsiveness to Ca^ "^ . The first AC to be 
cloned was termed ACl and was found to be stimulated by Ca^Tcalmoduliii, with the 
similarly regulated AC3 and AC8 being cloned quite soon afterwards (Cali et al, 1994). 
However, the regulation of AC3 by Ca^Vcalmodulin remains uncertain, as reports have 
provided ambiguous results (Cooper, 2003). Certain adenylyl cyclases are inhibited by 
Ca^  ^without the requirement of calmodulin, namely AC5 and AC6 (Cooper, et al, 1995). 
AC2, AC4 and AC7 are insensitive to Ca^ '*', however they can be stimulated as a result of
the activation of the phosphoinositide signalling pathway and through PKC activation 
(Cooper, 2003). PKC has also been reported to inhibit the activity of AC6 by 
phosphorylation of its N-terminus (Lai et al, 1999).
Desensitisation of the AC system can occur at the level AC itself, as it has been shown 
that PKA can directly phosphoiylate and reduce the activity of ACS (Iwami et al, 1995), 
Nitric Oxide (NO) has also been reported to be a regulator of AC activity as NO donors 
inhibit the forskolin simulated activation of AC5/AC6 (Cooper, 2003).
1.1.2.2 Localisation of adenylyl cyclase in caveolae and rafts
The plasma membrane is comprised of ‘microdomains’ of different lipid and protein 
composition. The microdomains are often termed lipid rafts, with distinct G-protein 
coupled receptors (GPCRs) and transmembrane proteins including ACs being found 
enriched in such rafts. Caveolae are described as membrane invaginations and are 
regarded as a subset of lipid rafts. In cardiac myocytes, AC5/AC6 and P2-adrenergic are 
enriched in caveolae, and thereby provide the production of distinct pools of cAMP 
(Rybin et al, 2000; Ostrom et al, 2000).
1.1.3 Effectors of cAMP
1.1.3.1 Protein kinase (PKA)
Protein kinases are a family of enzymes, which can phosphoiylate and alter the activation 
state of a plethora of protein targets (Ki'ebs & Beavo, 1979). Protein phosphoiylation is a 
fundamental mechanism through which cells can respond to, and transduce 
intracellularly, the effect of extracellular stimuli. One of the most studied and best- 
understood protein kinases is the cAMP-dependent protein kinase (PKA). First 
characterised in 1968 (Walsh et al, 1968) it is activated through the cooperative binding 
of cAMP (figure 1.2). The inactive holoenzyme consists of two regulatoiy (R) sub-units 
and two catalytic (C) sub-units. The cooperative binding of two cAMP molecules to each 
of the R sub-units exerts a conformational change which results in the release of the C
sub-units to phosphoiylate their target proteins (figure 1.2 ) (Johnson et al, 2001). More 
and more proteins that can be phosphoiylated and activated by PKA are still being 
identified; in fact, the list of PKA substrates has increased dramatically over the last two 
decades (Shabb, 2001). The consensus sites for PKA phosphoiylation have been 
identified as: Arg-Arg-(|)-Ser/Thr (c|): hyrophobic), Arg/Lys-(j) -cji-Ser/Thr ((j>: hydrophobic) 
and Arg/Lys-{|)-Ser/Thr ((]): hydrophobic) (Kennelly & Ki’ebs, 1991; Shabb, 2001).
It is now known that three different genes encode the catalytic sub-units of PKA: 
Ca, Cp and Cy, and four genes express the regulatoiy sub-units: Rla, Rip, R lla and 
Rllp ( Jahnsen et al., 1986; Scott et al, 1987; Chrivia et al, 1988). Two types of 
heterotetramers have been reported to exist in vivo: PKA holoenzyme type 1 (Rla and 
Rip) and type II (Rlla and Rllp ). The type I PKA is predominantly cytosolic, while 
over 80% of type II PKA associates with cellular structures and organelles (Taylor et al, 
1990; Michel & Scott, 2002). PKA, along with other signalling proteins, can be targeted 
to distinct subcellular regions through the interaction with A-kinase anchoring protein 
(AKAPs) (figure 1.2).
1.1.3.2 ERK and cAMP signalling cross-talk
It is now widely accepted that cross-talk between the cAMP and ERK mitogen-activated 
protein kinase pathways occurs at a number of distinct points (Houslay & Baillie, 2003). 
The effects of such cross-talk can be mediated in a cell-type specific manner by the 
selective expression of specific isoforms of enzymes positioned at specific control points 
(Houslay & Kolch, 2000).
The identification ERK/cAMP signalling cross-talk originated from studies based on the 
protein kinase Raf. The cell-type specific expression of the Raf isoforms, Raf-1 or B-Raf, 
allow either the inactivation or activation of ERK ( Houslay & Kolch, 2000; Houslay & 
Baillie, 2003). Inhibition of Raf-1 and hence inhibition of ERK can be achieved by 
elevated cAMP and activation of PKA. On the other hand, elevation of cAMP can lead
the activation of B-Raf and hence activation of ERK. Although the precise mechanism 
for activation has still to be elucidated, it is suggested that activation of B-Raf in response 
to elevation of cAMP occurs via the activation of the monomeric G-protein Rap-1 
(Houslay & Baillie, 2003). It was originally suggested that Rap-1 activation is achieved 
upon binding of cAMP to Epac (exchange proteins activated by cAMP), however, the 
recent emergence of an Epac-specific inhibitor indicates that this unlikely (Bos, 2003). 
Thus many questions regarding cAMP activation of the ERK pathway remain 
unanswered.
1.1.3.3 Epac
A general consensus exists that cAMP exerts its intracellular effects mainly by activating 
cAMP. However, cAMP can also act in a PKA-independent manner via the direct 
activation of ion channels (Shabb, 2001) or by cyclic nucleotide-regulated guanine 
nucleotide exchange factors (cAMP-GEFS), also referred to as Epacs (exchange protein 
activated by cAMP) (Kawasaki et al, 1998; de Rooi et al, 1998).
Two Epac isoforms, Epacl and Epac2, upon direct binding of cAMP activate the small 
G-proteins Rap-1 and Rap-2 (figure 1.3) (Kawasaki et al, 1998; de Rooi et al, 1998). 
Several studies have indicated that Rap-1 is a mediator in the cAMP-induced inhibition 
of Raf-1 (Schmitt & Stork, 2002; Bos, 2003). It was initially believed that Rap-1 
antagonises Ras signalling towards ERK by tapping the Ras effector, Raf-1 in an 
inhibitoiy complex (Schmitt & Stork, 2002). However, it appears that Epac mediates the 
cAMP induced-activation of Rap-1, whilst the inhibition of Raf-1 is mediated by PKA 
(Bos, 2003). Additionally, studies using the Epac-specific activator 8-pCPT-2’-0-Me- 
cAMP did not result in an inactivation of the Ras-Rafl-ERK pathway (Enserink et al, 
2002).
Rap-1 has also been implicated in the cAMP-induced activation of ERK (Vossler et al, 
1997). It is proposed that Epac mediates the binding of Rap-1 to, and activation of, B- 
Raf. However, that this effect also requires PKA and the use of 8-pCPT-2’-0-Me-cAMP 
activator casts doubt on the involvement of Epac (Bos, 2003).
Epac is known to be involved in the control of cAMP-regiilated integrin-mediated cell 
adhesion (Rangarajan et al, 2003). There is also increasing evidence that Epac is 
involved in the cAMP-mediated modulation of insulin secretion (Ozaki et al, 2002; Bos, 
2003). Since the development of the Epac-specific activator (8-pCPT-2’-0-Me-cAMP), it 
is anticipated that the recognised list of functions of Epac will grow rapidly.
1.1.3.4 Cyclic nucleotide-gated channels
Cyclic nucleotide-gated (CNG) cation channels on the cell membrane are biological 
effectors of cyclic nucleotide action. To date, over 20 genes encoding different subtypes 
of CNGs have been cloned from invertebrates and vertebrates (Wei et al, 1997). 
Functionally, CNG channels belong to the class of ligand-gated cation channels and are 
activated by the binding of cAMP or cGMP. The best-studied cAMP gated channel is the 
olfactoiy cyclic nucleotide channel, which is activated equally by both cAMP and cGMP 
(Shabb, 2001). This nonselective ion channel is activated in response to odorant binding 
to G protein-coupled olfactory receptors which, in turn, results in the activation of 
adenylyl cyclase (Shabb, 2001).
1.2 The phosphodiesterase superfamily
Cyclic nucleotide phosphodiesterases (PDEs) are represented by a large super family of 
enzymes which hydrolyze both cAMP and cGMP. To date, the PDE superfamily includes 
21 different genes encoding over 30 different PDEs, which are sub-grouped into 11 
different PDE families (Houslay & Milligan, 1997; Conti & Jin, 1999; Soderling & 
Beavo, 2000; Houslay & Adams, 2003). The nomenclature of the PDE superfamily is 
indicated as follows; the family is indicated as an Arabic numeral, a capital letter 
indicating a gene within the family and a second Arabic numeral indicating a splice 
variant e.g. PDE4D3: family 4, gene D and 3'^ '^  splicing variant. Each sub-family of PDE 
is distinguished by different enzymatic characteristics, different regulatory properties 
(table 1.1) and differential inhibitory pharmacological profiles (see table 1.2 for list of
available PDE inhibitors) (Houslay-review, 1998; Houslay and Koich, 2000; Soderling 
and Beavo, 2000).
1.2.1 The PDE1 family
Variants of the PDEl family are activated upon binding of Ca^^/CaM. Three PDEl genes 
encode PDEl A, PDE IB and PDE 1C sub-families. The variants of PDE 1C hydrolyse 
both cAMP and cGMP with high affinity, while variants of the PDEl A and PDE IB 
genes selectively hydrolyse cGMP. The PDEl A and PDE IB encode two splice variants 
each, PDEl A 1 and PDE1A2, and PDEIBI and PDE1B2 respectively. The PDE 1C gene 
provides five products, PDElC1-5.
Antagonists of CaM inhibit PDEl activity but are not only selective for PDEl. Catalytic 
site inhibitors such as vinpocetine (table 1.2) inhibit all PDEl, but PDE 1C with less 
potency, and are not specific for any individual variant (Kakkar et al, 1989; Zhao et al, 
1997).
PDE 1C variants have been implicated in VSMC proliferation (Rybalkin et al, 1997), 
insulin secretion (Han et at, 1999), and in cardiac tissue (Maurice et al, 2003), PDEl A 
variants have also been identified the cardiovascular system (Rybalkin et al, 1997; Zhao 
et al, 1997), while PDE1B2 has also been identified in VSMC (Rybalkin et al, 1997).
1.2.2 The PDE2 family
The splice variants of PDE2 are encoded by a single gene and these enzymes can 
hydrolyse both cAMP and cGMP (Yang et al, 1994; Rosman et al, 1997). The 
activation of PDE2 enzyme occurs following the binding of cGMP to the N-terminally 
located GAP domains (table 1.1) (Martinez et al, 2002). A few selective inhibitors exist, 
of which EHNA is the best recognised (Mery et al, 1995), although it does also serve as 
an inhibitor of adenosine deaminase (table 1.2). A role for PDE2 within the 
cardiovascular system has been proposed, and PDE2 has been shown to be expressed in 
cardiac myocytes, VSMC and vascular endothelial cells (Sandhu et al, 1999). One
PDE2A variant, PDE2A2, is expressed in cardiac myocytes (Sandhu et al, 1999). In 
cardiac myocytes, direct inhibition of PDE2 by EHNA increases L-type Ca^  ^ currents 
(Vandcasteele et al, 2001), cGMP-activation of PDE2, in conjunction with PDE3, has 
been implicated in the regulation of Ca^^ currents and contractility (Vandcasteele et al, 
2001).
1.2.3 The PDE3 family
Two genes encode the PDE3 family, PDE3A and PDE3B. Through alternative start 
codons, three PDE3A isoforms exist (PDE3A1-3), while only one isoform of the PDE3B 
gene exists (Movsesian et al, 2002; Wechsler et al, 2002). The analysis of inRNA 
expression to determine tissue distribution has shown differential expression. PDE3A 
enzymes have been reported to be expressed in blood vessels, cardiovascular system and 
oocytes (Reinhardt et al, 1995; Maurice et al, 2002; Movsesian et al., 2002). The 
highest level of PDE3B has been reported in brain, renal collecting duct epithelium, 
hepatocytes, adipocytes and developing spermatocytes (Reinhardt et al, 1995; Maurice et 
al, 2002; Movsesian et al, 2002).
1.2.3.1 Regulation and targeting of the PDE3 family
Full length PDE3A and PDE3B possess two N-terminal hydrophobic membrane 
association domains, named NHl and NH2. These regions allow the different PDE3A 
variants which possess NHl and NH2, or only NH2, or neither, the ability to localise to 
different cellular regions. PDE3A1 possesses both NHl and NH2 regions is found mainly 
in the particulate fraction, PDE3A2 possesses only NH2 is found both in the cytosol and 
the particulate fraction, and PDE3A3 which lacks both domains is cytosolic (Maurice et 
al, 2002; Movsesian et al, 2002; Wechsler et al, 2002). PDE3A and PDE3B enzymes 
can be phosphorylated and activated by PKA and PKB (Manganiello & Degerman,
1999).The hydrolysis of cAMP by PDE3 enzymes is directly inhibited by the binding of 
cGMP to the catalytic unit (Manganiello & Degerman, 1999). A number of PDE3 
inhibitors exist, such as cilostamide, milirone and amrinone (table 1.2). Inhibitors that
distinguish between PDE3A and PDE3B are not available, and given their similarity, are 
unlikely to be achievable.
The use of PDE3 inhibitors has been discussed in the treatment of type 2 diabetes and 
cardiac myopathies. Insulin-induced activation of PDE3B in 3T3-L1 adipocytes has been 
shown to occur via the phosphorylation of PDE3B by Akt/protein kinase B (PKB) 
(Kitamura et al, 1999). It has also been reported the selective inhibition of PDE3 activity 
in pancreatic p-cells stimulates insulin secretion (Harndahl et al., 2002). In this study, 
PDE3B has been implicated in the cAMP-dependent insulin secretion from the p-cells of 
pancreatic islets (Harndahl et al, 2002). Enzymes of the PDE3 family also play an 
important role in the regulation the cyclic nucleotide-mediated responses in cardiac and 
vascular smooth muscle myocytes (Movsesian, 2003). In the case of dilated 
cardiomyopathy, PDE3 inhibitors have both inotropic and vasodilatoiy properties, and 
were shown in early studies to have beneficial effects on myocardial contraction and 
vascular relaxation in clinical trials (Jaski et al, 1985; Movsesian, 2003). However, 
subsequently it was shown that chronic clinical application of these inhibitors, such as 
milrinone, resulted in an increase in mortality (Movsesian, 2003). From these trials, it has 
been suggested that increases in cAMP within cardiac myocytes have beneficial effects in 
the short term and adverse effects in the long term. It is now thought that milrinone exerts 
an effect on PDE4 as well as PDE3 (Shakur et al, 2002).
1.2.4 The PDE4 family
The PDE4 phosphodiesterase family exclusively hydrolyses cAMP. To date over 16 
different isoforms of the PDE4 family have been identified (table 1.3) (Houslay et al, 
1998; Conti et al, 2003). Four PDE4 genes (A, B, C, D) encode the PDE4 isoforms and 
can produce a number of different isoforms through alternative mRNA splicing and the 
use of alternative promoters. Within each PDE4 family, each isoform possesses unique 
N-terminal., common catalytic region, and a common C-terminal region. PDE4 isoforms 
can be classed as short or long forms depending on the absence of presence of upstream
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conserved regions (UCRs). Long form PDE4s possess both UCRl and UCR2, short 
forms lack UCRl (figure 1.4).
1.2.5 The PDE5 family
The cGMP-specific PDE5 family plays a pivotal role in the control of smooth muscle 
relaxation (Corbin & Francis, 1999). PDE5 is highly specific for cGMP both in its 
catalytic site and within two allosteric binding sites within the N-terminal GAF domains 
of the protein (McAllister-Lucas et al, 1995). PDE5 is a multi-domain protein that is 
regulated by phosphorylation as well as by the allosteric binding of cGMP to the GAF 
domains. cGMP-binding to the GAF domains has been shown to be required for the 
phosphorylation of PDE5 by PKA or PKG (Thomas et al, 1995). The important 
physiological role of PDE5 in the regulation of smooth muscle tone has been shown by 
the clinical use of sildenafil (Viagra®) to treat erectile dysfunction (Ballard et al, 1998). 
Recently other drugs, such as tadafil (Cialis™) and vardenafil (Levitra™), which target 
PDE5 in vascular smooth muscle have been reported (de Tejada, et al, 2001; Eardley & 
Cartledge, 2002). It has also been reported that PDE5 plays a role in the development and 
maintenance of pulmonary hypertension. Murray et al show that, following chronic 
hypoxic treatment of rats, PDE5A1/A2 and PDE3A mRNA transcript and protein levels 
are increased in the main intrapulmonary and resistance pulmonary arteries (Murray et 
al, 2 0 0 2 ).
1.2.6 The PDE6 family
The cGMP-specific PDE6 family is also known as the photoreceptor cGMP 
phosphodiesterases. This family of PDEs are exclusively expressed in the rod and cone 
photoreceptors of the retina and play a pivotal role as an effector protein in vertebrate 
signal transduction, which is mediated by the rhodopsin-coupled G protein, transducin 
(Yarfitz & Hurley, 1994; Beavo, 1995). Retinal rod PDE6 is composed of two catalytic 
sub-units, a  and (3, each is tightly associated with the inhibitory y sub-unit (Deterre et al, 
1988). Cone PDE6 consists of two a  sub-units associated with two of the cone-specific
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Y sub-units (Hamilton & Hurley, 1990). The y sub-units inhibit cGMP hydrolysis in the 
dark, and upon light stimulation of photoreceptors PDE6 is activated by GTP-bound 
transducin, which displaces y from the catalytic domain (Beavo, 1995). PDE5 and PDE6 
display a homology of 45-48% identity between catalytic domains and are similarly 
inhibited by competitive inhibitors, zaprinast, dipyridamole, and sildenafil (table 1.2 ) 
(Ballard et al,, 1998; Turko et al, 1999).
1.2.7 The PDE7 family
The PDE7 family encodes a cAMP-specific PDE that is insensitive to cGMP, have an 
amino acid sequence that is distinct from the other cAMP phosphodiesterases, and are 
insensitive to PDE3 and PDE4 inhibitors (Michaeli, et al, 1993). Two genes, PDE7A and 
PDE7B encode, through alternative mRNA splicing, different PDE7 isoforms. Three 
isoenzymes, PDE7A1, PDE7A2 and PDE7A3 have been identified (Bloom & Beavo, 
1996). PDE7A1 is expressed in multiple tissues, and PDE7A2 is expressed mainly in 
skeletal muscle and cardiac myocytes (Wang et al, 2000).
1.2.8 The PDES family
PDE8A has been shown to be expressed in testis, eye, liver, kidney, skeletal muscle and 
brain in mice and humans (Soderling et a/., 1998; Fisher et al, 1998).The non-selective 
PDE inhibitor IBMX does not inhibit this cAMP-specific PDE (Soderling & Beavo,
2000). PDE8 has been shown to contain a PAS (Period, Arnt, Sim) domain, but the 
function of this domain has yet to be discovered.
1.2.9 The PDE9 family
PDE9 is specific for hydrolysis of cGMP and is not inhibited by the general PDE 
inhibitor, IBMX (Soderling et al, 1998). To date, four variants of the PDE9 family has 
been identified (Guipponi et al, 1998). PDE9 is expressed in the small intestine, kidney, 
liver, lung, brain, skeletal muscle, heart, thymus and spleen (Soderling & Beavo, 2000).
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1.2.10 The PDEl 0 family
Studies have shown that the PDE 10 family can hydrolyse both cGMP and cAMP, but 
may function as a cAMP-inhibited cGMP-hydrolysing phosphodiesterase (Loughney et 
al, 1999; Soderling et al, 1999). Like PDE2, PDE5, PDE6 and PDEl 1 A, PDEIOA 
contains two GAF domains. PDEIOA transcripts have been found in the testis, caudate 
nucleus and putaraen (Matsumoto et al, 2003).
1.2.11 The PDE11 family
The PDEll family is represented by PDEl 1A and hydrolyses both cGMP and cAMP 
(Fawcett et al, 2000). It has unique splice variants, PD EllA l possesses an incomplete 
GAF domain, PD Ell A3 has one complete GAF domain and one incomplete GAF 
domain, and PDEl 1A4 contains two complete GAF domains (Yuasa et al., 2000; Fawcett 
et al, 2000). PDEll A3 transcripts are specifically expressed in the testis, and PDEll A4 
transcripts are most abundant in the prostrate (Yuasa et al, 2 0 0 0 ).
1.3 PDE4 cAWlP-specific phosphodiesterases
To date, eleven PDE families have been identified, of which PDE4, PDE7 and PDE8 
specifically hydrolyse cAMP. However, it is the PDE4 family that accounts for the most 
cAMP hydrolysing activity of many cell types (Conti et al, 2002). The Drosophila dunce 
gene was the first PDE gene to be characterised, and soon thereafter four PDE4 
paralogues were identified on different mammalian chromosomes (Houslay & Adams,
2003).
1.3.1 PDE4 isoforms
The four PDE4 genes encode four different sub-families, PDE4A, PDE4B, PDE4C and 
PDE4D. Over 16 different isoforms are generated through the use of different promoters 
and alternative mRNA splicing and each isoform is characterised by a unique N-terminal 
region (figure 1.4) (Houslay & Adams, 2003).
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PDE4 isoforms also possess a C-terminal region, which is unique to each sub-family. The 
highly conserved catalytic region is flanked at its N-terminal side by regulatoiy domains 
termed Upstream Conserved Region 1 (UCRl) and Upstream Conserved Region 2 
(UCR2) (Conti et al, 2003; Houslay & Adams 2003). The PDE4 isoforms can be 
divided into sub-groups; long forms, short forms or super short forms, depending on the 
presence or absence of UCRl and the size of UCR2, Long forms possess both UCRl and 
UCR2, short forms lack UCRl, whilst ‘super’ short forms possess only a truncated UCR2 
(figure 1.4). In the case of long forms, the UCRl is joined to the UCR2 by linker region 1 
(LRl), and the UCR2 module is joined to the catalytic unit by linker region 2LR2 (figure 
1.4).
UCRl and UCR2 appear to function as a regulatory module that controls the functioning 
of the catalytic region. Indeed, yeast two-hybrid analysis and pull-down studies have 
shown that UCRl can interact with UCR2 (Lim et al, 1999; Beard et al, 2000), and 
UCR2 is thought to interact with the catalytic domain (Lim et al, 1999). The 
UCR1/UCR2 module is also considered to influence the quaternaiy structure of PDE4 
whereby isoforms possessing both modules behave as dimers, yet isoforms lacking UCRl 
behave as monomers (Richter & Conti, 2002).
1.3.2 Catalytic domain
A key insight into the structure of the catalytic site was provided following the 
determination of the crystal structure of the PDE4B2 isoform [Brookhaven Protein Data 
Bank (PDB) accession number IFOJ] (Xu et al, 2000). The crystal structure of residues 
152-528 of the active PDE4B2, which is conserved throughout the PDE4 family, revealed 
that the compact PDE4 catalytic unit is comprised of 17 ahelices folded into three 
subdomains. Helices 6-13 contain residues critical for substrate binding, bind tightly a 
Zn^ "^  ion, and loosely bind an Mg^ "^  ion (Xu et al, 2000; Houslay & Adams, 2003). Since 
the publication of the crystal structure of the catalytic site of PDE4B2, a number of other 
crystal structures of PDE4 isoforms have been published which provide further
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understanding of the catalytic mechanism (Lee et al, 2002; Huai et al, 2003; Xu et al,
2004).
With regards to PDE4 activity, the physiological relevant state is thought to be an 
enzyme having both a tightly bound Zn^  ^ and exchangeable Mg^ "^  at sites within the 
catalytic site itself (Houslay & Adams, 2003). Thus, the Mg^ "^  ion binds to the metal ion 
binding site 2 (Me2) and is believed to be the subject to rapid exchange, which is 
attributable to the number of reported different conformational states of the catalytic 
domain (Lui et al, 2001;Conti et al, 2002). PDE4 inhibitors bind to the enzyme with 
kinetics suggesting the presence of multiple conformational states, and it is now accepted 
that prototype PDE4 inhibitor rolipram binds to two or more conformers of the catalytic 
domain (Conti et al, 2002). It has been suggested that the high affinity rolipram binding 
state requires the presence of Mg^ "^ , whereas the low affinity rolipram binding state was 
seen in the apoenzyme , although this will be inactive (Laliberte et al, 2000; Conti et al,
2002). It is now well recognised that PDE4 enzymes can switch their conformational 
states through interacting with other proteins, such as PDE4A enzyme with SRC family 
tyrosyl kinases and the immunophilin, XAP2 and that PDE4D3 can alter its conformation 
and sensitivity to rolipram upon phosphorylation by PKA (McPhee et al, 1999; Hoffman 
etal, 1998).
1.3.3 Regulation of PDE4 activity by PKA
PKA phosphorylation of PDE4 long forms results in activation, altered rolipram 
sensitivity, altered Mg^ "^  sensitivity and the re-programming of the functional output of 
ERK phosphorylation (Houslay & Adams, 2003).
As discussed above, the UCR1/UCR2 of PDE4 functions as a regulatory module. It is 
now known that PDE4s from all four sub-families can be phosphoiylated at a single 
serine residue within the UCRl and activated (Sette et al, 1994; Sette & Conti, 1996; 
Hoffman et al, 1998; MacKenzie et al, 2002). UCRl possesses the PKA consensus
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sequence RRESF, and PKA activation of PDE4 can be mimicked by replacing the target 
serine with either aspartate or glutamate residues (Hoffman et al, 1998). In mammalian 
cells, PKA phosphoiylation of PDE4 enzymes has been shown to increase their activity 
by some 60% (Hoffman et al, 1998). However, such PKA phosphoiylation of PDE4D3 
produces a much larger increase in activity (2-3 fold) than is seen in PDE4A4 (50%), 
which may suggest a regulatoiy role for their N-terminal regions, or they undergo an 
additional modification which enhances the ability of PKA phosphoiylation to increase 
PDE4D3 activity (Houslay & Adams, 2003).
It has been postulated that the glutamate residue, adjacent to the target serine of PKA, is 
involved in an ion-pair interaction that holds the enzyme in a low affinity state (Hoffman 
et al, 1998). As a mutation of the glutamate residue to a neutral amino acid mimics 
activation, the phosphorylation of the serine residue is believed to disrupt the ion-pair 
interaction, resulting in activation (Hoffman et al, 1998). PKA phosphorylation of the 
UCRl is also believed to cause a conformational change that disrupts the UCR1/UCR2 
interaction (Beard et al, 2000) and, in the case of PDE4D3, this results in increase in its 
sensitivity to inhibition by rolipram (Sette et al, 1994; Hoffman et al, 1998; MacKenzie 
etal, 2 0 0 2 ;).
UCR2 has been suggested to exert a tonic inhibitory function upon the PDE4 enzyme, 
and phosphorylation of the UCRl by PKA has been suggested to disrupt the interaction 
of UCR2 and the catalytic domain (Lim et al, 1999). A similar activation of PDE4D3, as 
observed with PKA phosphorylation, was shown following the use of an antiserum 
generated to a C-terminal portion of the UCR2 (Lim et al, 1999). This antiserum is 
thought, like PKA phosphorylation, to disrupt the interaction of UCR2 and the catalytic 
domain (Lim et al, 1999).
PKA phosphoiylation of PDE4D3 enhances the sensitivity of the enzyme to Mg^ "^  ions. 
The Mg^ "^  ion binds to the metal ion binding site 2 (Me2) within the catalytic domain and 
is essential for catalysis (Xu et al, 2000).
1 6
1.3.4 Regulation of PDE4 by ERK
The third subdomain of the catalytic unit of all PDE4 sub-families, with the exception of 
PDE4A, contains an ERK consensus motif (Pro-Xaa-Ser-Pro). It has been shown both in 
vitro and in vivo, that the serine residue within this sequence can be phosphorylated by 
ERK (MacKenzie et al, 2000; Hoffman et al, 1999). Further, the ERK consensus site 
within the catalytic domain has been shown to be flanked by a kinase docking site, 
namely KIM, and a FXF motif which allows ERK specificity (MacKenzie et al, 2000) 
(figure 1.5).
The phosphorylation of long form PDE4s by ERK leads to inhibition of the PDE4, where 
the serine target within the ERK consensus sequence is the only phosphoiylated residue 
(Hoffman et al, 1999; MacKenzie et al, 2000). Such inhibition of long form PDE4s can 
cause a localised increase in cAMP (Houslay & Adams, 2003). However, the ERK- 
mediated inhibition of PDE4 long forms is transient, as the localised increase in cAMP 
allows PKA phosphoiylation and activation of the long PDE4 isoform (figure 1.6) 
(Hoffman et al, 1999; Houslay & Kolch, 2000). In contrast, PDE4 short forms, which 
lack UCRl, are activated by ERK (MacKenzie et al., 2000). It was shown that ERK 
phosphoiylation of short form PDE4D1 caused a small increase in cAMP levels 
(MacKenzie et al, 2000). Interestingly, ERK has been shown exert either no effect or 
inhibits the ‘super’ short from PDE4D2, which lacks UCRl and possesses a truncated 
UCR2, and on a catalytic unit construct that is free of both UCRl and UCR2 (MacKenzie 
etal, 2 0 0 0 ).
1.3.5 Activation of PDE4s by negatively charged phospholipids
Various studies have shown that negatively charged phospholipids such as phosphatidic 
acid (PA) or phospholipids phosphatidyl-serine (PS) can increase PDE4 activity (DiSanto 
et al, 1995; Nemoz et al., 1997). An increase in activation of some 0.7-3 fold was 
observed for various PDE4 long forms, but activation of PDE4 short forms or ‘super’ 
short forms was not observed (DiSanto et al, 1995; Nemoz et ah, 1997). The UCRl
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region of long forms is ideally suited to interact with PA or PS as it is an amphipatic 
structure with a polar N-terminal half (positive net charge) and an apolar C-terminal half 
(Houslay & Adams, 2003). Thus, it is the placing of a negative charge by PKA 
(phosphorylation of RRESF), or by the binding of an acidic phospholipids that causes a 
similar conformational change and leads to the activation of the PDE4 (Houslay & 
Adams, 2003)
1.3.6 Signalling complexes and PDE4s
PDE4s can be targeted to specific subcellular regions and can interact with other 
signalling proteins to form distinct signalling modules (Houslay & Adams, 2003). The 
formation of such spatially confined signalling modules allows the generation and 
monitoring of ‘pools’ of cAMP (figure 1.7)
1.3.6.1 PDE4 and AKAPs
PKA can be held in discrete subcellular locations by interaction of the R sub-units with 
A-kinase anchoring proteins (AKAPs). AKAPs provide a means of compartmentalised 
signalling complexes which allow the close association of upstream signalling proteins 
with downstieam targets. They were first discovered as contaminants of PKA type II 
holoenzyme preparations (Michel & Scott, 2002), and since this initial discovery, over 
fifty different members of the AKAP family have been identified (Michel & Scott, 2002).
The discrete localisation of type II PKA has mainly been attributed to association of the 
R sub-unit with an AKAP. Each AKAP contains an amphipathic helix that binds to the 
N-terminus of the Rll sub-units and each contains a unique subcellular targeting domain, 
which allows localisation to discrete cellular regions (Carr et al, 1991; Colledge & Scott, 
1999). Although the association of RII-AKAP occurs at 100-fold greater affinity than RI- 
AKAP interaction (Burton et al, 1997), AKAP interaction is not exclusive to the RII sub­
unit. A number of “dual” specificity AKAPs which bind both RI and RII sub-units have
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been identified, such MAP2d expressed in rat ovarian granulosa cells (Salvador et 
(77,2004) and AKAPVy in oocytes (Brown et al, 2003).
The ability of PDE4s to interact with AKAPs, and thus the overall signalling module, 
provides a control for the PKA activity. To date, the long form PDE4D3 has been shown 
to bind to several different AKAPS (Dodge et al, 2001; Tasken et al, 2001; Kapiloff et 
al, 2001). In cardiac myocytes, PDE4D3, through its unique N-terminal binds to muscle 
selective AKAP (mAKAP) (Dodge et al, 2001). The PDE4D3-mAKAP-PKA complex 
provides a self-regulatory module whereby cAMP levels rise, PKA bound to mAKAP is 
activated and will phosphoiylate and activate PDE4D3. As the activity of PDE4D3 
increases rapidly following PKA phosphorylation of UCRl, PDE4D3 amplifies the de­
activation of the niAKAP-bound PKA and then PDE4D3 itself becomes de- 
phosphoiylated (Houslay & Adams, 2003). Under hypertrophic conditions a 
redistribution of the PDE4D3-mAKAP-PKA complex from the cytosol to the perinuclear 
compartment is observed (Dodge et al, 2001). Such ‘reprogramming’ of PDE4D3 may 
contribute to altered cellular functioning in the hypertrophic process (Dodge et al, 2001; 
Houslay & Adams, 2003). It has also been suggested that PDE4D3 is part of the mAKAP 
complex associated with the Ca^  ^ channel RyR (ryanodine receptor) within cardiac 
myocytes (Mark et al, 1999; Kapiloff et al, 2001). A publication, which appeared while 
writing my thesis, indicates that the PKA phosphoiylation of Seri3 within the N-terminal 
of PDE4D3 facilitates its binding to mAKAP (Michel et al, 2004).
In Sertoli cell primary complex, PDE4D3 has been found to co-immunoprecipitate with 
AKAP450 and R lla sub-units (Tasken et al, 2001).The PDE4D3-AKAP450-RIIa signal 
complex is localised to the centrosonial area and implies a tight regulation of the 
phosphoiylation state of centrosonial proteins,
1.3.6.2 Arrestin
Arrestins are scaffolding proteins, whieh play an important role in desensitisation of 
GPCR signalling. To date, four members of the arrestin family have been identified, (3- 
arrestinl, p-arrestin2 and two visual arrestins (Luttrell et al, 2001). Following agonist 
occupancy of the P2 -adrenergic receptor, desensitisation of the process of AC activation
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has been shown by the means of the decoupling the Gs protein from the GPCR (Luttrell 
et al, 2001). In this process the rapid desensitisation occurs when G-protein-receptor 
kinases (GRK) phosphorylates the p-AR, allowing the recruitment of cytosolic 
P-arrestin to the P-AR and thus uncoupling the receptor from Gs (Luttrell et al, 2001).
Challenge of cells with a p-agonist shows a recruitment of a PDE4-arrestin complex to 
the P2 -A R (Perry et al, 2002). This formation of a complex including p-arrestin 1/2 and 
a PDE4 thus provides a means of cAMP degradation directly to the active site of cAMP 
synthesis (Perry et al, 2002). In cardiac myocytes the recruitment of PDE4D3 and 
PDE4D5 to the plasma membrane is shown following p-adrenergic stimulation (Baillie et 
al, 2003). Further, the recruitment of PDE4D to the P2 -A R in cardiac myocytes 
regulates the switching of the receptor coupling from Gs to Gi (Baillie et al, 2003). In 
this report, it is suggested that the PDE4 controls the PKA-mediated switching of the 
P2 -A R coupling to the Gs, thus activation of AC, to coupling to Gi and thus activation of 
ERK (figure 1.8).
1.3.6.3 RAGK1
The scaffold protein RACKl (receptor for activated C kinase 1) was originally shown to 
bind protein kinase C (Ron et al, 1994). However, RACKl has now been shown to 
interact with a variety of proteins (McCahill et al, 2002) including PDE4D5, to which it 
binds through a helical domain named RAIDl (RACKl interaction domain) in the unique 
N-terminal PDE4D5 (Yarwood et al, 1999; Boiger et al, 2002), The functional 
consequence of the interaction of PDE4D5 with RACKl has yet to be determined. 
Although, it has been proposed that most probable role of the recruitment of PDE4D5 to 
the RACKl complex, is to control cAMP levels in the vicinity of the complex and thereby 
the activity of any putative associated Epac/PKA (Houslay & Adams, 2003).
1.3.6.4 Src, Lyn and Fyn
Src, Lyn and Fyn are protein-tyrosine kinases, which play important roles in controlling a 
wide variety of cellular processes, and they contain SH3 domains. SH3 domains are 
globular units of -60 residues which allow protein-protein interaction by binding proline-
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containing motifs that have PXXP at their core (Pawson, 1995). The PDE4 isoforms, 
PDE4A4, PDE4A5 and PDE4D4 have been to interact with these tyrosine kinases via 
PXXP motifs (O’Connell et al, 1996; Beard et al, 1999; McPhee et al, 1999). A role of 
this interaction is intracellular targeting, such as the localisation of PDE4A5 to peripheral 
membrane ruffles, and also localisation to the perinuclear region (Beard et al, 2002).
It is believed that PDE4 enzymes exist in distinct conformational states that can be 
detected by alterations in sensitivity to rolipram (Houslay, 2003). Binding of Src family 
tyrosyl kinases through their SH3 domains to the LR2 region of PDE4A4 increases its 
sensitivity to rolipram (Beard et al, 1999; McPhee et al, 1999).
1.3.6.5 XAP2
XAP2, also known as ARA9 or AIP, is an immunophilin which has been shown to 
interact with Hsp90 as part of a complex containing the aryl hydrocarbon (dioxin) 
receptor (Caiwer & Bradfield, 1997). Recently, a novel function of XAP2 was identified, 
whereby it binds to PDE4A5 via its immunophilin domain. This interaction inhibits the 
activity of PDE4A5 and attenuates the ability of PDE4A5 to be phosphorylated by PKA 
(Boiger et al, 2003). The functional significance of such interaction has yet to be 
determined. However, as other immunophilin domains have been shown to interact with 
different signalling components, it is thought that the PDE4A5-XAP2 interaction may act 
as a means of recruitment to distinct cellular regions (Boiger et al, 2003).
The interaction of XAP2 with PDE4A5 may provide an additional mechanism of 
changing the conformation of this enzyme to alter its rolipram sensitivity (Boiger et al,
2003).
1.3.6.6 TAPAS-1
The unique N-terminal region of PDE4A1 contains a novel microdomain called TAPAS- 
1 which allows this PDE4 to be exclusively membrane-associated (Baillie et al, 2002). 
TAPAS 1 selectivity interacts with phosphatidic acid (PA), which has been shown to be 
Ca^^ dependent, and allows the anchoring of PDE4A1 to lipid bilayers (Baillie et al, 
2002). This unique means of targeting may serve to shape gradients of cAMP. Also, the
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unique structural feature of TAPAS-1 may also, in the future, play an important role in 
the identification and interpretation of other putative phospholipid binding domains 
(Baillie et al, 2002).
1.3.6.7 Myomegalin
Myomegalin is a scaffold protein which is localised to the Goigi/centrosomal region. It 
has a domain similar to that dynactin/centractin, which can bind to activator protein-1, a 
SH3-like domain, a leucine-zipper region and a helix-loop-helix domain (Houslay and 
Adams, 2003). Yeast two-hybrid analysis done on PDE4D3 identified myomegalin as a 
potential binding partner (Verde et al, 2001). Truncation analyses have shown that the 
extreme C-terminal of myomegalin interacts with N-terminal portion of UCR2 and 
confers targeting to perinuclear Golgi/centrosomal region (Verde et al, 2001). It has yet 
to be reported if other PDE4 isoforms can interact with myomegalin.
1.4 cAMP signalling and PKA phosphorylation of proteins regulating 
cardiac function.
The function of the heart is regulated by the sympathetic nervous system. During 
sympathetic stimulation, activation of p-adrenergic receptors by adrenaline and other 
P-agonists initiate the production of cAMP and hence activation of PKA.
1.4.1 Interaction of cAMP and Ca^^ signalling within the myocardium
Cardiac myocytes comprise the majority of the cellular mass of the heart, they also 
account for over 60% of the number of cells of the heart. In cardiac myocytes, PKA 
plays a central role in many cellular processes, including contraction and relaxation, ion 
fluxes and gene expression (Walsh & Van Patten, 1994; Kapiloff et al, 2002). PKA can 
phosphorylate and alter the function of several cardiac proteins, which in turn alters the 
overall function of the heart. PKA substrates in cardiac myocytes include the lyanodine
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receptor (RyR), the cAMP-responsive element binding protein (CREB), troponin I (Tnl), 
L-type channel or the dihydropyridine receptors (DHPR), and phospholamban to 
name but a few. In the case of relaxation and contraction, the cAMP signalling pathway 
can interact with and control some facets of the Ca^  ^signalling pathway (figure 1.9).
Phospholamban (PLB) is an important protein, which is regulated by PKA and is 
involved in the regulation of cardiac contraction. This protein is found located in the 
cardiac sarcoplasmic reticulum (SR) and, depending on its phosphorylation state it 
regulates the Ca^^ pump SERCA2A; sarcoplasmic reticulum Ca^  ^ATPase (MacLennan & 
Ki’anias, 2003). SERCA2A determines the rate of removal of Ca^ '  ^from the cytosol into 
the SR, which is the intracellular Ca^ "^  ‘store’ (figure 1.9). This ATP-facilitated uptake of 
Ca^Tnto the SR by SERCA2A accounts for over 70% of cytosolic Ca^  ^ removal, and 
determines the rate of relaxation of the heart (MacLennan & Kianias, 2003). SERCA2A 
can also influence cardiac contractility by determining the actual size of the Ca^’*' store 
that is available for release for the next beat. Phospholamban (PLB), which means 
“phosphate receptor”, in its dephosphorylated state binds to and inhibits SERCA2A at 
resting Ca^  ^ concentrations. Phosphorylation of PLB by either PKA (Ser 16) or by CaM 
kinase (Tin 17) results in a disruption of the interaction between PLB and SERCA2A, 
thus relieving the inhibition of SERCA2A and enhancing the relaxation rate of the heart 
(Simmerman & Jones 1998; MacLennan & Kraiiias, 2003).
The trigger for cardiac contraction is the elevation of Ca^  ^concentration in the cytosol. A 
number of different receptors and channels are involved in the elevation of cytosolic 
Ca^ '^ , namely the ryanodine receptors (RyRs), the L-type Ca^ "^  channels (dihydropyridine 
receptors; DHPRs), plasma membrane Ca^ "^  -ATPases (PMCAs) and NaVCa^^ exchangers 
(NCXs). It is known that both the RyRs and the L-type Ca^  ^channels are phosphoiylated 
and their function altered by PKA. The L-type Ca^ "^  is a voltage channel which allows the 
influx of Ca^ "^  into the cytoplasm in response to membrane depolarisation (Bers, 2002). 
The lyanodine receptor opening is stimulated primarily by Ca^  ^influx through the L-type 
Ca^  ^channel (Bers, 2002). Both the conductance of the L-type Ca^^ channels and RyRs 
can be potentiated by PKA phosphoiylation (Kapiloff, 2002).
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1.4.2 Compartmentalisation of cAMP signalling within cardiac myocytes
With respect to cAMP signalling, cardiac myocytes appear to be highly 
compartmentalised. Zaccolo and colleagues have shown by use of a fluorescence- 
resonance-transfer (FRET) reporter, the presence of distinct pools of cAMP and the 
spatial confinement of PDEs (Zaccolo & Pozzan, 2002; Mongillo et al., 2004). To date, 
13 different AKAPs, which play an important role in compartmentalisation, have been 
identified in cardiac myocytes. These include ezrin, AKAP-Lbc, AKAP 15/18, mAKAP, 
AKAP79, gravin, yotiao, BIG2, AKAP220, AKAP95, AKAP149, AKAP121 and D- 
AKAP-1 (Ruehr et al, 2004). Figure 1.10 depicts the intracellular targeting of some of 
these AKAPs within cardiac myocytes. The PDE4 isoform, PDE4D3 is believed to 
interact with the mAKAP complex, which is targeted to the RyR (Kapiloff et al, 1999; 
Kapiloff et al, 2001). The conductance of Ca^’^ from the SR into the cytosol is increased 
by the PKA phosphorylation of the RyR (Ruehr et al, 2003). The specific targeting of 
PDE4D3, via its interaction with mAKAP, provides a localised source of cAMP 
degradation and thus implicates PDE4D3 in the control of the phosphoiylation status of 
RyR.
1.5 Assessment of intracellular cAMP gradients
The recent development of fluorescence resonance energy transfer (FRET) reporters 
provides a method studying the compartmentalisation of cAMP signalling in live cells. A 
sensor monitoring changes in cAMP has been generated and has played an important role 
in studying the compartmentalisation of cAMP signalling (Zaccolo & Pozzan, 2002; 
Mongillo et al, 2004). This sensor is based on FRET between a donor fluorophore (CFP) 
and an acceptor fluorophore (YFP) fused to the regulatoiy (R) and catalytic (C) sub-units 
of PKA (figure 1.11). Zaccolo et al have been able to show, following {3-adrenergic 
stimulation, the generation of microdomains of cAMP in neonatal cardiac myocytes 
(Zaccolo & Pozzan, 2002). Furthermore, by the use of such a reporter, they revealed the 
prominent role of PDE4s in the regulation of increases in cAMP within cardiac myocytes 
(Mongillo et al, 2004).
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A FRET reporter of PKA activity, named A-kinase activity reporter (AICAR), has also 
been developed (Zhang et al, 2001). This reporter consists of a cyan fluorescence 
protein, a phosphoamino acid binding domain (14-3-3%), a consensus substrate for PKA., 
and a yellow fluorescence protein. FRET changes are observed upon activation of PKA, 
and the phosphorylation of the substrate peptide within AKAR.
More recently, an Epac based FRET reporter, named Epac-camps has been used to gain 
further insight into the spatio-temporal organisation of cAMP signalling in live cells 
(Nikolaev et al, 2004). Unlike the PKA FRET-reporter developed by Zaccolo et al, 
which is restricted by the binding to AKAPs, Epac-camps is distributed throughout the 
cellular cytosol and provides a novel method to image free cAMP concentrations. By use 
of Epac-camps, it was shown that following isoprenaline stimulation of hippocampal 
neurons, cAMP propagates from the site of the p^.adrenergic receptor throughout the 
whole cell in a matter of milliseconds. Overall, FRET-reporters provide an important tool 
in the study of compartmentalisation of cAMP signalling.
1.6 Aims and objectives
For the first part of my study, I aimed to analyse the time-dependent PKA 
phosphorylation of Ser54 and Seri3 sites within PDE4D3. In addition, I studied the 
ability of other PDE4 long forms to be phosphorylated by PKA. Overall, the aim of my 
research was study the compartmentalisation of PDE4s by means of a dominant negative 
strategy, and finally, to gain functional insight into the compartmentalisation of PDEs 
within cardiac myocytes.
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EPAC/cAMP GEFs
rap1 Protein phosphorylation
Figure 1.1. General schematic of initiation of cAMP signalling by G-protein 
coupled receptor activation. A ligand binds to the G-protein coupled receptor 
(GPCR) and leads the dissociation of the G sa  subunit. The G sa  subunit can 
stimulate adenylyl cyclase (AC) to produce cyclic AMP( cAMP). cAMP can exert its 
celluar effects via the activation of protein kinase A (PKA), Epac, or cyclic nucleotide 
gated ion channels.
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Figure 1.2. General schematics of PKA activation and AKAP interaction and 
function. (A) Binding of two molecules of cAMP to the regulatory (R) subunits of 
PKA induces the dissociation of the catalytic (C) subunits which are free to 
phosphorylate their target proteins. (B) (1) Represents the targeting domain which 
directs the AKAP to distinct subcellular regions (2) R epresents other signalling 
complexes, of which include various PKA substrates (3) indicates the conserved 
amphipatic helix of AKAP which binds to the N-termini of the regulatory subunits of 
PKA.
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cAMP DEP cAMP REM RA GEF
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Figure 1.3. The domains of Epaci and Epac2. The REM (Ras-exchanger motif) 
and GEF (guanine nucleotide exchange factor) form the catalytic region of Epac. The 
other indicated domains are : cAMP, cyclic AMP-binding domain; DEP, dishevelled 
Egl-10 Pleckstrin domain; RA , Ras association domain (adapted from Bos, 2003).
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PDE
family
Regulatory domains Nucleotide
Specificity
PDEl Ca/CaM cAMP/cGMP
PDE2 GAF cAMP/cGMP
PDE3 cAMP
PDE4 UCR1/UCR2 cAMP
PDE5 GAF cGMP
PDE6 GAF cGMP
PDE7 cAMP
PDE8 PAS/PAC cAMP
PDE9 cGMP
PDEIO GAF cAMP/cGMP
PD Ell GAF cAMP/cGMP
Table 1.1. PDE familles and their regulatory domains. The PDE1-PDE11 families 
are listed Including their regulatory domains and their nucleotide specificity (adapted 
from Houslay review, 2002).
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Family Inhibitor
PDEl Vinpocetine, 8-MeoM-IBMX
PDE2 EHNA
PDE3 Milirone, cilostamide, amrinone, enoximone (and many others)
PDE4 Rolipram, Ro 20-1724, denbufyline zadaverine, RP73401, CDP840, SB207499, 
RS25344, LAS31025
PDE5 Sildenafil, zaprinast, DMPPO, dipyramidole, E4021, GF248
PDE6 zaprinast, dipyridamole
PDE7 none known
PDE8 Dipyridamole
PDE9 Zaprinast, SCH 51866
PDEIO IBMX, ?
PDEll Dipyridamole
Table 1.2. Second-generation PDE isozyme inhibitors. The “second-generation” 
PDE inhibitors listed exhibit about 100-fold selectivity of PDE isozymes of a particular 
family (Dousa, 1999). However, at higher concentrations, the selective inhibitors are 
not absolutely specific. (Please see Dousa review for potencies and selectivity of the 
PDE inhibitors listed). The general PDE inhibitor IBMX, effectively inhibits Isoforms 
from all families (K, -1-1 OpM), with the exception of the PDE8 and PDE9 families 
(adapted from Francis review, 2001).
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PDE4 isoforms
Human Clone Rat Clone Type
4A1 (hRDl) 
4A4 (pde46) 
4A7 (2el) 
4A8
PDE4A11
4A10
U97584 
L20965 
U18088
L20967
AF073745
4A1 (RDI) 
4A4 (rpde6 ) 
4A7
4A8 (rpde39) 
PDE4A11 
4A10
L27Ü62
L27057
L36467
AF110461
Supershort
Long
Cataîytically inac
Long
Long
Long
4B1
4B2
4B3
4B4
L20966
L20971
U85048
4B1
4B2
4B3
4B4
J04563
L27058
U95748
AF202733
Long
Short
Long
Long
4C1
4C2
4C3
Z46632
U88712
U88713
4C1
4C2
4C3
L27061 LongLong
Long
4D1
4D2
4D3
4D4
4D5
4D6
4D7
4D8
4D9
U50157
U50158
U50159
L20969
AFÜ12073
AF536975
AF536976
AF536977
AY245867
4D1
4D2
4D3
4D4
4D5
4D6
4D7
4D8
M25349
U09456
U09457
AF031373
Short
Super-short 
Long 
Long 
Long
Super-short 
Long 
Long 
Long
Table 1.3. PDE4 Isoforms. All human and Rat PDE4 isoforms identified to date are 
listed (adapted from Houslay review, 2002).
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UCR1 UCR2
Isoform- 
specific N- 
termlnal region
Catalytic unit
Long 
Short 
Super - short
Figure 1.4. Schematic of the PDE4 enzyme family. PDE4 isoforms can be divided 
into categories of long, short or super-short isoforms depending the upstream 
conserved regions (UCR) regions. Long isoforms p ossess both UCR1 and UCR2, 
short isoforms lack UCRl and super-short isoforms possess only a truncated UCR2.
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Figure 1.5. The regulation of PDE4 long forms by ERK2. (A) Inhibitory regulation 
by ERK2 phosphorylation. (B) PKA phosphorylation uncouples the inhibitory 
regulation by ERK2.
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cAMP- PKA Raf-1 B-Raf ^
/
MEK
cAMP
rap1
ERK P-ERK
cAMP—► P KA  1
Long P0E4
/  Super-short PDE4
Short PDE4
Figure 1.6. Crosstalk between cAMP and ERK signalling pathways. This basic 
schematic shows the points at which cAMP can influence control of the ERK 
signalling pathway. Arrows indicated positive coupling; blunt ended lines indicate 
inhibitory coupling; p-ERK indicates phosphorylated ERK. (Adapted from Houslay & 
Baillie, 2003)
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Figure 1.7. Compartmentalisation of PDE4s. A hypothetical cell to show the 
subcellular localisation of known PDE4 complexes. The yellow coloured ‘barrels’ 
represent anchoring proteins. (Taken from Conti et ai, 2003).
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Figure 1.8. The role of recruitment of PDE4 by p-Arrestin in the regulation of 
the switching of Gs-Gi. Binding of ligand to the p, receptor results in the coupling to 
Gs, activation of AC, elevation of cAMP and activation of PKA. The PKA 
phosphorylation of the Pg receptor facilitates switching from Gs to Gi and results in 
the activation of ERK1/2. The p-arrestin recruitment of PDE4 to the Pg receptor 
attenuates the ability of PKA to phosphorylate the receptor and thus is involved in the 
control of the ‘switching’ (Taken from Baillie et ai, 2003).
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P -adrenergic receptor NCX DHPR PMCA
Adenylate 
I cyclase 1 Ca 2+
3 Na+
Receptor kinase RYR
Myofibril
cAMP
C-protein j  
© ^ T r o p o n in  I
SERCA2A
_Ca 2+
calsequestrin
SR
Figure 1.9. The interaction of the cAMP and Ca^* pathways in cardiac myocytes 
following p-agonist stimulation. SR: sarcoplasmic reticulum, Ca^+ store, RYR; 
ryanodine receptor, releases Ca^+ from SR to the cytosol, SERCA2A; ATP 
dependent transport of Ca^+ from cytosol to SR, PLB ; phospholamban, -ve 
regulator of SERCA2A, DHPR; L-type, voltage dependent Ca^^-entry channel 
(adapted from MacLennan & Kranias, 2003)
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Figure 1.10. An illustration of the location of AKAPs identified in cardiac 
myocytes. AKAPs are associated with ion channels including the L-type Ca^+ 
channel (L^g^^), the KCNQ1 delayed rectifier potassium channel (KvLQTI), ryanodine 
receptors (RyR), the cystic fibrosis transm em brane conductance regulator (CFTR), 
with the p 2 adrenergic receptor, sarcomeric proteins such as Troponin I and myosin 
binding protein- C (MBC) (taken from Kapiloff, 2003).
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Figure 1.11. Schematic of a cAMP probe. In low cAMP concentrations the GFP 
tagged PKA is in its inactive tetrameric form and the FRET signal is maximal. When 
cAMP rises, active PKA catalytic subunits (C) are released; CFP and YFP diffuse 
apart and FRET is abolished (taken from Zaccolo & Pozzan, 2002).
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Chapter 2
Materials and methods
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2.1 Mammalian cell culture
2.1.1 HEK-293 cell line
HEK-293 cell line (ATCC CRL 1573) is a human embiyonic cell with epithelial cell 
morphology. Cells were maintained in Dulbecco’s Modified Eagles Medium (DMEM) 
supplemented with 2mM glutamine, 10% foetal bovine serum (FBS), 100 units/ml 
penicillin and 100 pg/ml streptomycin in an atmosphere of 5% CO2 and 37 °C. Cells were 
passaged at 80-90% confluency, they were split 1:5. To passage the cells, they were 
rinsed with pre-warmed PBS and l-2mis of pre-warmed 0.25% tripsin/0.03% EDTA 
solution was added. Flasks were incubated at 37 °C until cells detached. Cells were 
collected by adding 10 mis of culture media and centrifugation at 1000 g for 3 min. The 
cells were then resuspended in fresh culture media and transferred into new culture flasks 
at approximately 10  ^cells/ml final volume.
2.1.2 COS-1/COS-7 cell lines
The COS-l/COS-7 cell lines (ATCC CRL 1650) are an African green-monkey derived 
cell line, with fibroblast morphology and are transformed with the SV40 virus. These cell 
lines were maintained and passaged as with HEK-293 cell line.
2.1.3 Neonatal rat ventricular myocytes
The ventricles were isolated fom 2-3 day old Spague-Dawley rat hearts enymatically 
digested at 37 °C using 0.48 mg/ml collagenase type II (Worthington) and 0.6 mg/ml 
pancreatin (Sigma) and suspended in a mix of 4 :1  DMEM :M199 supplemented with 
10% horse serum and 5% fetal calf serum (all Sigma or Life Teclmologies) and were 
plated for 1 h on plastic culture plates to deplete fibroblasts. The non-adherent myocytes 
were the plated out at concentration of 1 million cells/well in 1% (w/v) gelatin pre-coated 
6 -well plates. After 24 hs the medium was changed to low serum medium 
(DMEM:M199) containing 4% horse serum and no calf serum.
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2.2 Transfection of cells
2.2.1 DEAE-Dextran transfection of COS-1 cell line
The cells were passaged the day prior to transfection and allowed to grow to 50-70% 
confluency. The plasmid DNA (10 pg) was diluted to 250 pi with sterile TE buffer (1 
mM Ethylenediaminetetra-acetic acid (EDTA), 10 mM Tris/HCL, pH 7.5) in sterile 15 
ml centrifuge tube. To this tube, 200 pi sterile DEAE Dextran (10 mg/m I in PBS) was 
added, mixed and incubated at room temperature for 15 min. 10 ml of media 
supplemented with 10 % PCS, 2 mM glutamine and 100 units/ml penicillin and 100 
pg/ml streptomycin. 1 mM filter sterilised chloroquine was added to the DNA. This 
solution was mixed an added to the cells which were then incubated at an atmosphere of 
5% CO2 and 37 °C for 3-4 h. After incubation, the media was removed and replaced with 
10 ml sterile PBS supplemented with 10 % DMSO. Cells were incubated for 2 min, 
washed with PBS and fresh culture media was added. The transfected cells were 
incubated at an atmosphere of 5% CO2 and 37 °C for 24-48 h.
2.2.2 PolyFect® transfection of HEK-293 cells
Transfection of HEK-293 cells was carried using PolyFect® reagent (Qiagen). The cells 
were passaged into 100mm dishes the day prior to transfection and grown to 50%-80% 
confluency. DNA, 8pg was diluted to a total of 300pl in basal medium (DMEM) in a 
sterile 15ml centrifuged and mixed. 80 pi of PolyFect® was added to the DNA solution, 
and it was mixed by vortexing for 10 sec. The DNA solution was incubated at room 
temperaPire for 10-15 min. Growth medium, 1 ml was added to the DNA solution and 
mixed by gentle pipetting. The growth medium from the cells was aspirated and replaced 
with 7 ml of fresh growth medium. The total DNA mixture was then added to the cells 
and mixed by gentle swirling. The cells were harvested 24-48 h post transfection.
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2.3 Protein analysis
2.3.1 Whole cell lysate
Cell culture dishes were maintained on ice and all buffers used were ice-cold to minimise 
protein degradation and denaturing of enzymes. The cell growth media was aspirated and 
the cells washed with PBS. The PBS was drained and approx lOOpl/100 mm dish 3T3- 
lysis buffer (20 mM N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 
pH7.4, 50 mM NaCl, 50 mM NaF, 10 % glycerol, 1 % triton X-100, 10 mM 
Ethyleneglycol-bis(P-aminoethylether)-N,N,N’,N’-Tetra-acetic acid (EOTA), 30 mM 
sodium pyrophosphate proteases inhibitor cocktail) was added. The cells were scraped, 
transferred to a 1.5 ml eppendorf tube and snap-frozen. The cell samples were then 
thawed at 4 °C and subjected to mechanical disruption using a micropestle (Eppendorf). 
The cell debris was removed by centrifugation for 3 min at lOOOOg (4 °C). The cell 
lysates were stored at -80 °C until required for use.
2.3.1.1 Protein quantification (Bradford assay)
All protein assays were carried on 96 well titre plates. A standard curve of protein 
concentration was generated using 0.5 mg bovine serum albumin (BSA) diluted to 1 ml 
in distilled water. A protein concentration range of 1 pg/pl - 5 pg/pl was used for the 
assay. The protein quantification was carried out by taking 2 pi of lysate and placing 
(each sample in triplicate) in the microtitre plate. Bio-Rad Assay reagent was diluted 1/5 
with distilled water, 200 pi was added to each well of BSA and lysate sample. The 96 
well plate was then analysed using the Revelation program and an MRX microtitre plate 
reader (absorbance read at 590 nm). Protein concentrations were obtained by plotting the 
standard curve and using the least squared regression analysis to obtain the line of best 
fit. The equation of the line was used to determine the protein concentration of samples.
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2.3.2 Gel electrophoresis and Western blotting.
2.3.2.1 Sample preparation
Lysate obtained from cells were assayed for protein concentration and 25 —100 pg protein 
diluted 1/5 with 5 x laemmli sample buffer (260 mM Tris/HCl pH 6.7), 55.5 % Glycerol, 
8.8  % SDS, 0.007 % Bromophenol blue, 11.1 % 2-mercaptopethanol (Laemmli, Beguin 
et al, 1970). The sample was boiled for 3-5 min to allow dénaturation and reduction of 
the protein
2.3.5.2 SDS PAGE gels
Gels were run on a Bio-Rad Protean II xi cell. A resolving gel containing the appropriate 
percentage of acrylamide (determined by the molecular weight of the protein of interest), 
usually 8 % unless otherwise stated, was cast between the two plates of the gel apparatus 
(8  % 29 :1 aciylamide;N,N’-methylenebisaci'ylamide mix, 375 mM Tris/HCl (pH8 .8), 0.1 
% SDS, 0.1 % Ammonium persulphate, 0.06 % N,N,N',N',-tetramethylethylenediamine 
(TEMED)). This was overlaid with 1ml water and allowed to polymerise at room 
temperature, the water was then removed, the resolving gel overlaid with stacking gel (5 
% 29 :1 aciylamide:N,N’-methylenebisaciylamide mix, 125 mM Tris/HCl (pH6 .8), 0.1 % 
SDS, 0.1 % Ammonium persulphate, 0.1 % TEMED). A comb was then placed into the 
stacking gel and it was left for 30 mins to polymerise. The comb was removed and the 
wells were washed out with tris-glycine running buffer (192 mM Glycine, 25 mM Tris, 
0.15 % SDS) to remove un-polymerised aciylamide. The gels were then assembled onto 
the central running stand according to the manufacturer’s instructions and placed into the 
running tank containing tris-glycine running buffer. The pre-boiled samples were loaded 
into each well and a standard lane was loaded with 10 pi Bio-Rad prestained broad range 
precision protein markers to determined protein migration weight by gel electrophoresis. 
The top reservoir of the gel running tank was filled with running buffer and run for 
approximately 5 h at 35 mA per plate or 16 h at 8 mA per plate, until the dye front 
reached the bottom of the gel.
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2.3.2.3 Nu- Page™ gel system
Pre-cast 4-12% Bis-Tris 1.0mm gels (Invitrogen) were used unless otherwise stated. The 
gels were assembled in Xcell SureLock^^ tanks according to the manufacturer’s 
instructions. Depending on the molecular weight of protein of interest, either Nu- Page ™ 
MOPS buffer or Nu- Page ™ MBS buffer was used to fill the tank. The pre-boiled 
samples were loaded into each well and a standard lane was loaded with 5 pi Bio-Rad 
prestained broad range precision protein markers to determined protein migration weight. 
The gels were run at 190 V constant for 1 h.
2.3.2.4 Protein transfer
A piece of Whatmann 3 MM paper was soaked in transfer buffer (192 niM Glycine, 25 
mM Tris, 20 % Methanol). The SDS gel was placed on this and overlaid with a piece of 
nitrocellulose paper (Schleicher & Schuell) soaked in transfer buffer, ensuring that all air 
bubbles were excluded from between all layers. The nitrocellulose was in turn covered by 
another piece of Whatmann 3 MM paper and the resulting sandwich was placed in a 
cassette between two pieces of foam soaked in transfer buffer. The cassette was placed 
with the nitrocellulose to the positive electrode in the Hoefer TE series transphor 
electrophoresis unit, filled with transfer buffer. The proteins were transferred with an 
applied current of 0.7 amps for 90-120 mins or 0.05 amps overnight.
2.3.2.5 Immunoblotting
Once transferred onto the nitrocellulose, ponceau S stain (0.1% Ponceau S, 3 % 
Trichloroaceatic Acid) was used to visualise the proteins. The ponceau S was added to 
the nitrocellulose for a few mins until the proteins became stained, the nitrocellulose 
membrane was then washed with distilled water. The unoccupied protein binding sites on 
the nitrocellulose were blocked with 5 % skimmed milk powder in TBS-tween20 (137 
mM NaCl, 20 mM Tris/HCl (pH7.6), 0.1% tween20) for 1 h at room temperature with 
agitation. After blocking the membrane was washed several times in TBS-tween20 and 
the appropriate primary antibody added to the membrane diluted 1 :10000 , unless
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otherwise stated, in 1 % skimmed milk powder in TBS“tween20. This incubation was 
carried out for 2 hs with vigorous shaking. The nitrocellulose was washed several times 
in TBS-tween20 before adding the secondaiy antibody, diluted as with the primary, to the 
membrane. The secondaiy antibody was anti-immunoglobulin (IgG) antibody conjugated 
to horse-radish peroxidase (HRP) and directed against the primary antibody. This was 
incubated with the nitrocellulose membrane for 1 h with vigorous shaking, after which 
the nitrocellulose was washed several times in TBS-tween20.The membrane was then 
incubated with ECL reagents (Amersham), according to the manufacturer’s instructions. 
A piece of x-ray film (Kodak) was exposed to the membrane in a darkroom and then 
developed using a Kodak X-omat.
2.3.3 Immunoprecîptation
Depending on which antibody is used to immunoprecipitate the target protein, either 
protein G sepharose or protein A sepharose was used. If a monoclonal antibody or a 
polyclonal antibody raised in a sheep was required for the immunoprécipitation, protein 
G beads were used. Protein A beads were used when the target protein was being 
immunoprecipitated with any other polyclonal antibodies.
2.3.3.1 Pre-clearing
30 pi of the appropriate beads were washed in 200 pi of lysis buffer and recovered by 
centrifugation at 13,000 g for 2 min at 4 °C (Heraeus refrigerated bench-top centrifuge). 
This was carried out three times. The beads were then added to the cell lysate diluted to a 
total of 500 pi with lysis buffer (approx 300 pg of protein) and incubated with end-over- 
end rotation at 4 °C, for 30 mins. The samples were then centrifuged at 13,000 g for 2 
min at 4 °C to recover beads
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2.3.3.2 Pre-lmmune
If a pre-immune antibody was available, it was incubated with the cell lysate with eiid- 
over-end rotation at 4 °C for 30 mins. 30 pi of beads were then added to the lysate and 
again it was incubated with end-over-end rotation at 4 °C for 30 mins. The beads were 
recovered by centrifugation.
2.3.3.3 Binding of antibody and target protein complex to beads
After pre-clearing/incubation with pre-immune antibody the beads were collected by 
centrifugation at 13,000 g at 4 °C for 2 min, the supernatant was removed and placed into 
a fresh eppendorf tube. To this fresh tube 1-5 pi of the antibody was added and the tube 
rotated end-over-end at 4 °C for at least 2 hs, to enable the protein and antibody to bind. 
Then, 60 pi pre-washed protein beads was added to the sample and rotated end-over-end 
for at least 1 h at 4 °C. The beads were isolated from solution by centrifugation at 13,000 
g at 4 °C for 2 min and washed to remove any non-specifically bound protein. The beads 
were washed at least five times in lysis buffer. A final wash of the beads was carried out 
with PBS if the isolated protein was to be used in SDS-PAGE or final wash was carried 
out in 20 mM Tris (pH 7.4), when the protein was used in a PDE assay.
2.4 Assays
2.4.1 Phosphodiesterase activity assay
A cAMP hydrolysis assay was used to measure phosphodiesterase activity. This used a 
modification of the two step procedure of Thompson and Appleman (Thompson and 
Appleman, 1971) as described previously by Marchmont and Houslay (Marchmont and 
Houslay, 1980). The assay worked on the basis that a ^H-cyclic nucleotide (8  position of 
the adenine or guanine ring) was hydrolysed to form labelled nucleotide mono-phosphate. 
The nucleotide mono-phosphate ring was converted to the corresponding labelled
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nucleoside by incubation with snake venom which has 5'-nucleotidase activity. The 
conditions were such that complete conversion takes place within the incubation time. 
Unhydrolysed cyclic nucleotide was separated from the nucleoside by batch binding of 
the mixture to Dowex-1-chloride. This removes the charged nucleotides but not the 
uncharged nucleosides.
2.4.1.1 Activation of dowex
To activate, 4 1 of 1 M NaOH was added to 400 g of the Dowex 1 X8 -400 resin, and the 
mixture was incubated for 15 mins at room temperature with gentle mixing. The resin 
was allowed to settle by gravity and the IM NaOH removed. The resin was then 
extensively washed with 4 1 distilled water (30 washes). After its last wash the resin was 
resuspended in 4 1 1 M HCl and incubated for 15 mins at room temperature with gentle 
mixing before being allowed to settle by gravity. The HCl was removed and the activated 
resin resuspended 1:1 in distilled water and stored at 4°C until required.
2.4.1.2 Assay preparation
Samples of cell lysate ( 0.1 -50 pg depending on activity ) were placed into 1.5 ml 
eppendorf tubes and made up to a volume of 25pi with 20 mM Tris/HCl, pH7.4. Each 
sample was assayed in triplicate. All tubes were set up on ice, and remained on ice until 
all components for the assay had been added. To eveiy tube 50 pi 2 pM cAMP 
containing 3 pCi [^H]cAMP in 20 mM Tris/HCl and 10 mM MgCE pH7.4 was added, 
the tubes vortexed and incubated at 30 °C for 10 mins. After this time, the tubes were 
boiled for 2 mins to inactivate any PDE present and then cooled on ice. 25 pg snake 
venom (either Ophiophagiis Hannah or Crotalns atrox venom) in 25 pi 20 mM Tris/HCl, 
pH 7.4 was added to each tube, mixed by vortexing and incubated at 30 °C for 10 mins. 
The tubes were cooled on ice and 400 pi Dowex/ethanol/water, in a 1 :1 :1 ratio was 
added and mixed. The tubes were then ftuther incubated on ice for at least 20 mins. The 
tubes were vortexed and the dowex separated from supernatant by centrifugation at
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13000 g for 2 min (Heraeus bench top centrifuge). Finally, 150 pi of the clear supernatant 
was added to 1 ml Opti-scint scintillation fluid and counted on a Wallac 1409 liquid 
scintillation counter.
2.4.1.3 Determination of PDE4 and PDE3 activity
The PDE3 family is specifically inhibited by the drug cilostamide and the PDE4 family 
by rolipram. PDE inhibitors were dissolved in DMSO as 10 mM stocks and the inhibitors 
were diluted in PDE assay dilution buffer for use in assay. DMSO itself does not affect 
PDE activity at the concentrations used (Rena et al, 1995). Measurement of PDE activity 
with and without cilostamide (10 pM) and rolipram (10 pM) present gave the 
contribution of PDE3 and PDE4, respectively.
2.4.2 cAMP assay
Briefly, cells were stimulated and lysed, releasing the cyclic nucleotides. Following the 
release of the cyclic nucleotides, cAMP concentrations were determined using bovine 
crude PKA and 5’ 8 ’-^H cAMP.
2.4.2.1 Extraction of cAMP and neutralisation
Cells, plated in 6 -well culture dishes, were incubated in growth medium containing 100 
pM IBMX for 10 min. The cells were then stimulated with the named agonist for the 
indicated time, the growth medium removed and 100 pi of chilled 2% perchloric acid 
(PA) added. The cells were incubated on ice for 15 min, scraped and transferred to 1.5 ml 
eppendorf tubes. The precipitated protein was pelleted by centrifugation at 13000 g at 
room temperature.
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2.4.2.2 Neutralisation of sample
The supernatants were transferred to eppendorf tubes containing 5 pi of Universal 
Indicator (pH 4.0 -  11.0, BDH) and a pink colour was observed- indicating pH 4.0. 
Initially, 5 pi of a neutralisation solution (2 M KOH, 0.5 M Triethanolamine) was added 
and the samples vortexed. The neutralisation was then achieved by the gradual addition 
of the neutralisation solution and observation of a colour change of the sample to green, 
indicating pH 7.5. Samples were then stored at 4 °C for up to 1 week before continuation 
of next steps of the assay.
2.4.2.3 Reagent preparation
The following reagents were prepared on day of assay:
cAMP assay buffer. 50 mM Tris+4mMEDTA pH 7.4
Binding protein: (10 mg bovine crude fraction PKA (Sigma) +125 mg BSA)/ 25 ml 
cAMP assay buffer. Dilute 5-fold in cAMP assay buffer on day of use.
f ^HJ 5 \ 3 ’ cAMP: 8.7 pi of [ ^ H ] 5 ’, 3 ’ cAMP/ 10 ml of cAMP assay buffer
Charcoal solution: In assay buffer, 2% (w/v) activated charcoal and 1% BSA and was 
stirred on ice for at least 20  min before it was required.
cAMP standards: A  starting concentration of 16 pmol of cAMP was required. To obtain 
this, 16 pi of 10 pM cAMP was diluted to 500 pi in assay buffer. A series of 2-foId 
dilutions were then made.
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2.4.2.4 Assay procedure
A standard curve was obtained using a range of cAMP concentrations between 0.0625 
pmo I and 16 pmol. These tubes, along with the samples, were set up as follows:
Tube no. cAMP 
(pmol/50 pi)
Buffer
(fil)
[^H] cAMP 
(fil)
Binding protein
(Pl)
1 ,2 - 200 100 -
3,4 - 100 50 100
5,6 0.0625 100 50 100
7,8 0.125 100 50 100
9, 10 0.250 100 50 100
11, 12 0.500 100 50 100
13, 14 1.00 100 50 100
15, 16 2 .00 100 50 100
17, 18 4.00 100 50 100
19, 20 8.00 100 50 100
2 1 ,2 2 16.0 100 50 100
23- samples 100 50 100
The tubes were set up as described on ice, adding the binding protein to the tubes last. 
Each tube was vortexed, incubated on ice for 2 h. Following incubation, 250 pi of 
charcoal solution was added and vortexed. The tubes where then centrifuged at 13000 g 
for 3 min, 300 pi of supernatant was decanted and added to 1 ml of scintillant. The [^H ] 
cAMP was counted on a Wallac 1409 liquid scintillation counter. Curve-fitting software 
was used to calculate pmol unlabelled cAMP per sample.
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2.4.3 In vitro PKA phosphorylation assay
The PKA phosphorylation assay was set up in eppendorf tubes on ice as follows; the 
required concentration of purified recombinant PDE4, 1 unit of active PKA catalytic 
subunit (Promega), phosphorylation buffer (100 mM Tris, 10 niM MgCl2 pH 7.4) to a 
final volume of 45 pi. To each assay tube, 5 pi of radiolabelled substrate (10 pCi [y ^^P- 
ATP], 2 mM ATP) was added and the tubes were incubated at 30 “C for 15 min. The 
samples were prepared for gel electrophoresis as described previously, and 
phosphorylation was detected using a Biorad Personal Fx phosphoimager. All 
densitometiy was performed using Quantity One software.
2.6 Laser Scanning Confocal Microscopy (LSCM)
2.5.1 Preparation of slides
COSl cells were transfected as described previously. 48 h post-transfection, the cells 
were plated onto coverslips (22 mm x 22 mm) in 6 -well tissue culture plates. 72 h post­
transfection, the cells were stimulated as stated and fixed for 10 min using 4 % 
paraformaldehyde (dissolved in Tris buffered saline (TBS) (150 mM NaCl, 20 mM Tris, 
pH 7.4). The coverslips were then washed three times, for 5 min each time, in TBS. The 
cells were then permeabilised by incubating each slide for 15 min in 0.2 % Triton 
dissolved in TBS. Cells were then blocked for 1 h using a blocking solution (10 % goat 
serum, 4 % BSA dissolved in TBS). The primaiy antibody was diluted to the required 
concentration in diluant (Blocking buffer diluted 2-fold in TBS), 200 pi the antibody 
solution was added to each slide and incubated at room temperature for 1 h. The 
coverslips were washed three times with 5 min incubations in blocking solution and then 
incubated for 1 h with the relevant fluorescent probes at 1:200 dilution (Alexa 594- 
conjugated anti-mouse igG, Alexa 594-conjugated anti-rabbit or Alexa 488-conjugated
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anti-rabbit (Moiecular Probes). The cells were then washed five times in blocking 
solution before mounting the coverslips on slides with Immunomount (Sandon).
2.5.1.1 Visualisation of cells
The cells were visualised using a Plan-Apo 40 x 1.4 NA oil immersion objective and the 
Zeiss Axiovert 100 laser scanning confocal microscppe (Zeiss, Oberkochken, Germany). 
The Alexa 594-conjugated antibody was excited at 543 nm and detected at 590 nm. The 
Alexa 488-conjugated antibody was excited at 495 nm and detected at 518 nm.
2.6 Molecular biology techniques
All molecular biology techniques were carried out with sterilised equipment and buffers, 
to prevent contamination.
2.6.1 Large scale production of plasmid DNA
The antibiotic Ampicillin or Kanamycin (100 mg/ml), depending on the antibiotic 
resistance of the plasmid, was added to sterilised 500 ml LB growth media (170 mM 
NaCl, 0.5 % (w/v) BactoYeast Extract, 1 % (w/v) Bacto-Tryptone, pH7.5). A sample of 
DNA of interest was taken from a glycerol stock of transformed cells and transferred to 
to the 2 1 flask of culture medium by means of a sterile pipette. The culture was incubated 
at 37 °C overnight with agitation. The cells were harvested the next day by centrifugation 
at 6000 g for 15 min using the JA-14 rotor in the Beckman refrigerated centrifuge. The 
DNA was extracted from the cell pellet using the Wizard Maxi-prep kit (Promega) 
according to the manufacturer’s instructions.
DNA was precipitated from the eluted solution by the addition of 0.7 volumes room 
temperature isopropanol. The solutions were mixed and centrifuged at 15000 g for 30
53
min at 4 °C. The DNA pellet was washed with 5 ml room temperature 70 % ethanol and 
air-dried for 5-10 min before being resuspended in 500 pi dHgO.
2.6.2 RNA isolation
Mammalian cells were grown to 70 -  90% confluency in 75cnf tissue culture flasks. The 
cells were removed with Trypsin, transferred to 15 ml falcon tube and centrifuged at 
1000 g. The supernatant was removed, the pelleted cells snap frozen and stored at -  80 °C 
until required. Total RNA was isolated from the cell pellet using a RNeasy Kit (Qiagen) 
and QIAshredders (Qiagen) in accordance to the manufacturer’s instructions.
2.6.3 Quantification of DNA and RNA
Both DNA and RNA concentrations were measured using a WPA lightwave 
spectrophotometer blanked with distilled water. 5 pi DNA or RNA was diluted to 1ml 
with distilled water and absorbance measurements were taken at 260 nM and 280 nM.
The concentration of nucleic acid was then calculated using the following 
approximations:
An absorbance of 1 at 260 iiM corresponds to 50 pg/ml double stranded DNA
37 pg/ml single stranded DNA 
40 pg/ml of single stranded RNA
The ratio between the absorbance measurements at 260 nM and 280 iiM provided an 
indication of the purity of the nucleic acid. In solution, DNA or RNA have A260 :A2so 
ratios of 1.8 or 2.0, respectively. If the absorbance ratio is significantly less than this it 
indicates that the nucleic acid may be impure.
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2.6.4 Analysis of plasmid DNA
2.6.4.1 DNA restriction digest
The restriction enzyme and the optimum restriction buffer used in the reaction depended 
on the site of digestion of the DNA for subsequent manipulations. If two restriction 
enzymes were used and the optimum restriction buffers were not compatible ethanol, 
precipitation of the DNA between restriction digests was carried out. Each digest was 
carried out on 300 ng DNA in a total volume of 10 pi per restriction enzyme used in the 
reaction. 1 unit of restriction enzyme was used and the appropriate volume of 10 x 
restriction added to the mix. The digests were carried out for 1-2 hs at the optimal 
temperature for the enzyme, usually 37 °C.
2.6.4.2 Agarose gel analysis of DNA
DNA was visualised using agarose gel electrophoresis, the percentage of agarose used in 
the gel was dependent on the size of DNA fragment to be identified. Generally 1 % 
agarose was dissolved in 1 x TBE (9 M Tris base, 20 mM EDTA, 0.9 M Boric acid acid) 
by heating until the agarose dissolved. To this 0.01 % ethidium bromide was added, 
which enables visualisation of the DNA under a UV light source. The molten agar was 
poured into the gel apparatus, set up according to the manufacturer’s instructions and 
allowed to set completely. The comb and end stoppers were removed, the gel tank filled 
with Ix TBE and the samples loaded into the lanes. All DNA samples were diluted 6:1 in 
Blue/Orange 6X loading dye (Promega). 5 pi standard 1Kb DNA ladder markers (Roche) 
were added to one of the lanes, which enabled prediction of the size of DNA fragments 
run on the gel. The gel was run at 50 V until the dye front had migrated along the gel and 
the fragments of DNA were separated. The gel was removed from the tank and the DNA 
observed under UV light.
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2.6.5 Reverse transcription PCR
Total RNA was isolated as described previously. Frozen samples of total RNA were sent 
to Rachael Barber (Novartis) and she carried out the RT-PCR as follows;
Briefly, RNA samples were treated with Dnase (Qiagen) for 30 min at 37 °C and then 
tested by RT-PCR with and without reverse transcriptase. When this showed no 
contaminating DNA remained, samples were used to synthesise cDNA. 5pg of RNA was 
synthesised into first strand cDNA, and this was used for PCR profiling. Each PCR 
reaction mix used was tested with nuclease-free water as a negative control and brain 
cDNA as a positive control. All completed PCRs were run on 2 % agarose gels.
2.6.5.1 Dnase treatment
Each sample of RNA was made up to 75 pi with nuclease free water:
75 pi RNA
5 pi 20X DNase Buffer (0.6 mM Tris HCl, 72 mM MgCE, 120 mM NaCl)
20 pi RQl DNase
Reaction mix incubated for 30 min at 37 ”C. Each sample was then re-purified up using 
Qiagen’s RNeasy Mini Kit (Clean-Up protocol). The RNA was measured for 
concentration.
2.6.5.2 RT-PCR Test
The clean samples were then tested by RT-PCR with and without reverse transcriptase to 
ensure no contaminating DNA remained. Promega’s Access RT-PCR Kit was used. Only 
when a sample had passed this test was it used to synthesise cDNA. A small volume of 
each RNA sample was diluted to 20 ng/ pi, and the following reaction set up in duplicate, 
one with AMV-RT and one with the same volume of nuclease-free water in replacement:
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5 pi Reaction Buffer (kit)
0.5 pi dNTPs(kit)
1 pi 25mM Mg SO4 (kit)
0.5 pi Tfl DNA Polymerase (kit)
2.5 pi P-actin Forward primer at 10 pmol/ pi
2.5 pi P-actin Reverse primer at 10 pmol/ pi 
5 pi Nuclease-free water
5 pi RNA 20 ng/ ml 
3 pi AMV-RT or Nuclease-free water
These were run on the following PCR program (RT-PCR60):
Step 1 48 °C for 45 min Step 5 68 °C for 2 min
Step 2 94 °C for 2 min Cycle back to Step 3,39 times
Step 3 94 °C for 30 sec Step 6 68 °C for 7 min
Step 4 60 °C for 1 min Step 7 4 °C pause
Completed reactions were run on a 2% agarose gel and visualised using EtBr and UV 
light.
2.6.5.2 cDNA Synthesis
RNA was synthesised into first strand cDNA using Amersham Pharmacia Biotech’s First 
Strand cDNA Synthesis kit. 5 pi of each RNA was diluted to 20 or 40 pi with nuclease- 
free water, and then heated to 65 °C for 10 min to denature any RNA secondaiy structure. 
Then 14 or 28 pi of cDNA reaction mix was added, and incubated for 1 h at 37 °C. The
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completed reactions were made up to 100 p.1 with nuclease-free water so they would 
represent 50 ng of RNA per |ul.
2.7 Microarray
Total RNA was isolated as described previously. Frozen samples of total RNA were sent 
to Novartis (Basle, Switzerland) and micro array analysis using the U133A chip was 
carried out as follows:
There were a total of 27 chips, grouped into 9 groups, as follows :
- PDE4A4 (3 chips)
- PDE4D3 (3 chips)
- PDE4D5 (3 chips)
- PDE4B2 (3 chips)
- PDE4A_2EL (3 chips)
- Ariflo (3 chips)
Rolipram (3 chips) 
pCDNA control (3 chips)
HEK control (3 chips)
Each group was compared with each other. Regulated genes were identified based upon 
fold-change and p-value.
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Data Upload :
The data was downloaded from the DEMON database and then uploaded into 
GeneSpring for analysis.
Data Evaluation :
The data was plotted on box-plots to visualise the normality. The raw data displayed 
considerable variation. The following normalisation techniques were implemented :
Measurments below 0 were set to 0.
Each chip was normalised to the 50* percentile.
The normalised data, when viewed on a box-plot showed much less variation. In order to 
reduce the number of false positive results, the normalised data was used for the analysis 
procedure.
Data Cleaning :
Probes showing no expression in more than 50% of the experiments were excluded from 
the analysis.
The U133A chip contains probes for a total of 22283 genes. After filtering out the absent 
calls there were 14022 genes remaining. The analysis procedure is based upon these 
genes.
Data Analysis :
Fold-Change : Mean expression values for each group were used to calculate the fold 
change between any two groups.
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P-Value : A T-test was used to compare the mean values of each single gene between to 
groups. A heteroscedastic students t-test was used as this assumed unequal variances.
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Chapter 3
PKA phosphorylation and activation of PDE4 cAMP 
phosphodiesterases
6 1
3.1 Introduction
3.1.1 Protein kinase A (PKA)
In eukaryotic cells, protein phosphorylation namely the introduction of one or more 
negatively charged phosphate groups, invariably produces a conformational change 
which can affect protein functioning. Within the cAMP signalling system, PKA serves to 
activate a plethora of specific target proteins which ultimately lead to altered cellular 
functions. Protein kinase A (PKA) is regarded as the main target and detector of cAMP, 
and through binding of cAMP is activated and can phosphorylate its target protein(s), 
which usually have a consensus motif of R-R-(|)-S (c|): hydrophobic).
In the absence of cAMP, PKA is an inactive enzyme consisting of two catalytic subunits 
(C) bound to a dimerised regulatoiy subunit (R). Upon the cooperative binding of two 
cAMP molecules to each of the R subunits, the active C subunits dissociate and are free 
to phosphorylate serine and threonine residues on target proteins (Tasken and Skalhegg, 
2000). Multiple isoenzymes of PKA exist and are suggested to be targeted within the cell 
through association with different A kinase anchoring proteins (AKAPS). The R-I 
subunits are found mainly in the cell cytosol whilst the R-II subunits are mostly found 
associated with the cellular membranes and cytoskeleton. This association of R-II 
subunits with the cell membranes is generally considered to be mediated by interaction 
with AKAPs. Thus an anchored isoform of PKA R-II is able to sample gradients of 
cAMP created by localised adenylyl cyclase isoforms, and anchored and/or cytosolic 
PDEs (Houslay, 1998).
3.1.2 PKA phosphorylation of PDE4D3
The PDE4 family is encoded by four different genes (PDE4A, PDE4B, PDE4C and 
PDE4D) and can produce a number of different isoforms through alternative mRNA 
splicing and the use of different promoters. Within a specific PDE4 subfamily, each 
isoform possesses a common catalytic region and C-terminal region but each possesses a
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This chapter follows the time-dependent phosphoiylation by PKA, of both Ser 13 and 
Ser 54 within PDE4D3. For the first time, a phopho-specific antiserum has been 
generated to assess the individual PKA phosphoiylation state of each of these sites.
Sequence alignments (figure 3.2) have shown that the PKA consensus sequence (RRESF) 
found in the UCRl of PDE4D3 is also found in the UCR region of all PDE4 longforms 
from all PDE4 subfamilies. An antiserum was generated to the phosphopeptide sequence: 
SORRES *FLYSDSDYDLSP (which reflects the amino acid sequence 49-67 of 
PDE4D3). This antiserum was shown to be specific for Ser 54(P) and employed to assess 
the capability of long PDE4 isoforms from each of the subfamilies to be phosphoiylated 
by PKA. The over-expression of the selected PDE4 isoforms in the COSl cell line was 
chosen for all experiments.
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unique N-terminal region. Each isoform of the PDE4 family can be classed as short or 
long form depending of the presence or absence of UCRl; long form PDE4s possess both |
UCRl and UCR2, short form PDE4s lack UCRl. Truncation studies have shown that the 
UCRl and UCR2 can influence catalytic activity (Bolger et al, 2000). It is thought that 
these regions of PDE4s can interact directly with each other via electrostatic interactions 
forming a regulatory module (Bolger et al, 2000) and this regulatoiy effect can be altered 
by ERK MAP kinase and PKA (MacKenzie et al, 2000). Extensive studies have shown 
that the PDE4D3 long isofbrm is rapidly activated and uniquely phosphoiylated by PKA.
Such phosphorylation occurs at two sites, namely Ser 13 in its unique N-terminal region 
and Ser 54 in the UCRl (figure 3.1) (Conti and Sette, 1996; Hoffman et al, 1999; Lim et 
al, 1999; Liu and Maurice, 1999; Liu et al, 2000; MacKenzie et al, 2000; Saillie et aï.,
2000). Mutational studies have shown that only PKA phosphoiylation of Ser 54 is 
however required for activation (Sette and Conti, 1996), with the role of Ser 13 unknown.
Interestingly, several investigators have suggested that a decrease in mobility of PDE4D3 
is observed upon PKA phosphorylation and that mobility shift is related to enzyme 
activation.
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Results
3.2 Analysis of PKA phosphorylation of PDE4D3 and selected various 
other PDE4 long isoforms.
In this study, phospho-specific antibodies were used to assess the PKA phosphorylation 
state of PDE4D3 and other selected PDE4 long isoforms. Concerning the PKA 
phosphoiylation of PDE4D3, I showed that the phosphorylation of both the Ser 13 and 
Ser 54 sites are required to obtain the low mobility species of PDE4D3 commonly 
observed upon SDS-PAGE analysis (Sette and Conti, 1996). The PDE4D3 PKA 
phosphoiylation data also suggests that the phosphoiylation of the Ser 54 may even 
precede that of Ser 13. In this chapter, I show that long isoforms from each of the four 
sub-families can be phosphoiylated by PKA.
3.2.1 The detection of PKA phosphorylated at Ser 54 and Ser 13 sites by novel 
polyclonal antisera.
The phospho-specfic antibodies were generated to the phospho-peptide sequences 
SORRES*FLYSDSDYDLSP (reflects amino acids 49-67 of PDE4D3; within UCRl) and 
FRRHS*WISFDYDNGTSAGR (reflects amino acids 9-27 of PDE4D3; within unique N- 
terminal region). The antibodies were named PS54-UCR1 and PS13-4D3, respectively.
To test the novel antibodies for specificity, COSl cells were first transfected to express 
PDE4D3. In order to raise cAMP levels and thereby activate PKA, the cells were treated 
for 10 mill with the general PDE inhibitor IB MX (100 p,M) together with the general 
adenylyl cyclase activator forskolin (100 p.M) prior to harvesting. Lysates from untreated 
cells (basal) and IBMX/forskolin (IBMX/fsk) treated cells were subjected to SDS-PAGE 
electrophoresis. The immunoblots were then used to test the PS54-UCR1 and PS13-4D3 
antibodies (figure 3.3). Neither antibody detects any immunoreactive species of PDE4D3
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under basal conditions. However, both antibodies clearly detect an immunoreactive 
species at the PKA at raised cAMP levels (IBMX/fsk treated cells), consistent with 
PDE4D3 being PKA phosphorylated. Indeed, the detection of this species is blocked by 
treating the cells with the PKA inhibitor, H89 (IpM) and also by pre-incubating the 
antibodies with the peptide to which they were raised prior to blotting (MacKenzie et al, 
2002).
3.2.2 PKA phosphorylation and activation of PDE4D3
As the antibodies appeared specific for both PKA consensus sites in PDE4D3, they were 
used to study further the PKA phosphorylation and regulation of this PDE. To follow the 
phosphoiylation rates of both Ser 13 and Ser 54 sites, COSl cell were transfected with 
VSV-tagged PDE4D3 and subjected to an IBMX/forskolin time course (0-20 min) (figure 
3.4).
In the absence of IBMX/ forskolin, PDE4D3 migrated as a single ‘high-mobility’ species 
(panel A). At 1-2 min IBMX/forskolin challenge both a ‘high-mobility’ and ‘low- 
mobility' (doublet) was evident. The blots were stripped and reprobed with the PS54- 
UCRl and a veiy similar pattern was obseiwed (panel B). At 0 min a phosphorylated 
species was not detected, at l-2min a doublet was observed and PDE4D3 migrated 
identically to the ‘high-mobility’ and Tow-mobility' identified with the VSV antibody. 
However, at 0 min the PS13-UCR1-4D3 antibody did not detect a phosphorylated 
species. Each film exposure from the PS54-UCR1, VSV and PS13-UCR1-4D3 blots were 
overlayed. According to the overlay, and the direct comparison of the VSV and PS13- 
UCR1-4D3 blots, only a single reduced mobility species of Ser 13 was evident 
(MacKenzie et al, 2002).
The cAMP hydrolysing activity of PDE4D3 for the IBMX/Fsk time course described in 
the previous figure was assessed. COSl cell were transfected with VSV-tagged PDE4D3 
and subjected to an IBMX/forskolin time course (0-20 min). Cells were harvested at the 
indicated time points and the specific PDE activity was measured by PDE assay from
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developed by Marchmont and Houslay (Marchmont and Houslay, 1980). This shows that 
the activity of PDE4D3 increased 2-3 fold in response to IBMX/forskolin treatment.
3.2.3 Analysis of the putative PKA phosphorylation of PDE4 long isoforms
It has been pointed out that an identical PKA consensus sequence to that found in the 
UCRl of PDE4D3 is also found in the UCRl of all long isoforms from each PDE4 
subfamily (Sette & Conti, 1996; Souness & Rao, 1997) (figure 3.2). However, it had not 
been shown whether PKA could either phosphorylate or activate these various long 
isoforms from other PDE4 sub-families and it could not be simply be presumed that they 
are either able to be phosphoiylated by PKA, and if so, activated. Indeed, the linker 
regions which connect the UCRl, UCR2 and catalytic regions have different primary 
amino acid sequences which may affect the accessibility of PKA to these enzymes and 
generation of an active state. I set out to assess whether PKA can phosphorylate long 
isoforms from each subfamily and if they were then activated.
3.2.3.1 PKA can phosphorylate long isoforms from PDE4A, B, 0  and D sub­
families.
I wished to study if PKA did indeed phosphoiylate the target serine within the UCRl of 
long PDE4 isoforms from each sub-family in response to an IBMX/forskolin-induced 
increase in cAMP. COSl cells were transfected with selected PDE4 long isoforms or 
mutants of these long isoforms where the putative target serine was mutated to alanine. 
The transiently transfected cells were pretreated with H89 or not and challenged for 10 
min with IBMX/forskolin. The lysates analysed by western blot using PS54-UCR1 
antibody to detect PKA phosphoiylated species (figure 3,6a). In this experiment, after the 
challenge of the cells with IBMX/forskolin a PKA phosphorylated species was detected 
with the PS54-UCR1 antiserum for PDE4A8 (96 kDa), PDE4B1 (104 kDa), PDE4C2 (80 
kDa) and PDE4D3 (105 kDa). Phosphoiylation was not detected at basal cAMP levels, 
following pretreatment with H89 or in mutant isoforms.
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In a separate experiment (performed by Simon MacKenzie, Houslay laboratory), the in 
vitro PKA phosphorylation of the long isoforms used in the previous experiment was 
shown (MacKenzie et al, 2002). Here, COSl cells were transfected with either wild type 
or mutant PDE4 long isoforms as in the previous experiment. Lysates were treated with 
activated PKA catalytic sub-unit and [^ ^P] ATP and analysed by SDS-PAGE and a 
phosphorimager (figure 3.6b). Phosphorylation was detected in the presence of the active 
catalytic PKA sub-unit, however, phosphoiylation was not detected in the presence of the 
PKA inhibitor H89, in the PKA target serine mutants and in the absence of the PKA 
catalytic subunit.
3.2.3.2 PKA phosphorylation of the novel rat PDE4 long isoform PDE4B4.
During the study of the PKA phosphoiylation of long PDE4 isoforms, a new cDNA 
termed pRPDE90 was cloned. This encoded a novel PDE4B isoform which we called 
PDE4B4. This PDE4B isoform is a long isoform, which possesses UCRl and UCR2, and 
differs from the other PDE4B isoforms by a unique 17 amino acid N-terminal region 
(figure 3.7a). As it also possesses a PKA consensus sequence at the beginning of the 
UCRl, I set out to see if PKA phosphorylates PDE4B4 over-expressed in COS? in 
response to treatment of the cells with either a cAMP analogue or to elevate cAMP levels 
with IBMX/fsk.
In this set of experiments, the PS54-UCR1 antibody was used to detect the PKA 
phosphoiylated species of PDE4B4. COS? cells were transfected with Flag-tagged 
PDE4B4 (C-terminal epitope tag), and were treated with the cAMP analogue dibutiyl 
cAMP (dbcAMP; lOOpM) in the absence and presence of H89 (0.5 p,M). Lysates were 
analysed by western blotting with PS54-UCR1 and anti-Flag antibodies (figure 
3.7b&3.7c). A PKA phosphorylated species was observed in the presence of dbcAMP, 
and the phosphorylation was reduced upon pretreatment with H89. A phosphorylated 
species was not obseived in resting cell (basal) or in the mock control.
To analyse the PKA phosphoiylation and activation of PDE4B4 in response to an 
elevation in cAMP generated by adenylyl cyclase, COS? cells were transfected with
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Flag-tagged PDE4B4, subjected to 10 min with IBMX (100 pM)/forskolin (100 j.iM) 
challenge either with or without F189 (0.5 f.iM) pretreatment. The PDE4B4 isoform was 
immunoprecipitated with anti-Flag agarose beads, analysed for PDE activity and 
immunoblotted with PS54-UCR1 and anti-Flag antibodies (figure 3.7b). A 
phosphoiylated species was observed in the presence of IBMX/forskolin and was ablated 
with H89. The PDE activity of PDEB4 increased by approximately 50% in response to 
IBMX/forskolin challenge, and this activation was blocked with H89.
3.2.4 Analysis of endogenous PDE4D3 and PDE4D5 in C0S1 cells.
It is now recognised that cAMP signaling is compartmentalized and many studies suggest 
that PDE4s can be distributed in distinct subcellular locations (Houslay and Adams, 
2003) (See chapter 1). As compartmentalisation of PDE4s would allow the control of 
distinct pools of PKA, the PS54-UCR1 antibody may be useful in analysing the 
activation of different PDE4 long-forms phosphoiylated and activated in response to the 
generation of distinct cAMP pools and gradients.
In this experiment, I set out to assess the possibility of using the PS54-UCR1 antibody to 
detect the phosphorylation status of endogenous PDE4D3 and PDE4D5 endogenously 
expressed in COSl cells. To achieve near maximum cAMP levels and PKA activity, 
COSl cells were subjected to an IBMX (100p,M) /forskolin (100p,M) challenge with 
analysis over the indicated time course (figure 3.8). As a control, cells were pretreated 
with H89 (0.5 p,M) before being challenged for 10 min with IBMX/forskolin. Cells were 
lysed at the indicated time points, lysates analysed by SDS-PAGE and immunoblotting 
with PS54-UCR1 (panel A) and pan PDE4D antibodies (panel B). The PS54-UCR1 
antibody appeared to detect many other ‘non-specific’ bands, however using the pan- 
PDE4 immunoblot as an overlay, phosphoiylated PDE4D3 and PDE4D5 is indicated with 
arrows. A time-dependent increase in phosphorylation was observed, and 
phosphorylation of the 10 min time point was ablated by H89. Panel B shows a time-
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dependent mobility shift of PDE4D3, which was blocked by H89. However, from 0 to 8 
min of the time course (indicated by blue arrows), a non-specific phosphorylated band 
which migrated at the same weight of PDE4D3 was also observed,
3.3 Discussion
It had been previously established the long isoform PDE4D3 is a target for 
phosphoiylation and activation by PKA (Sette and Conti, 1996; Hoffman et al., 1998). 
This isoform is ubiquitously expressed in a variety of different tissues and cells. The 
PKA phosphorylation of PDE4D3 has been shown to result in a rapid 2-3 fold activation 
of this enzyme (Sette et al., 1994; Alvarez et al., 1995; Sette and Conti, 1996; Hoffman et 
al, 1998) and this rapid activation has been suggested to act as means of desensitization 
to the cellular cAMP response (Sette and Conti, 1996; Houslay review, 1998). 
Biochemical analysis has shown that Ser 13 within the unique N-terminal and Ser 54 
within the UCRl are phosphorylated by PKA (Ploffman et al, 1998; Sette and Conti, 
1996). For the first time antiserum had been developed to two specific PKA sites in 
PDE4D3, namely, Ser 54 in the UCRl and Ser 13 in the unique N-terminus. The 
development of these antisera provided me with the means to study the PKA 
phosphoiylation of PDE4D3.
PKA phosphorylation of PDE4D3 results in an altered electrophoretic mobility on SDS- 
PAGE. The reason for this mobility ‘shift’, which has been suggested to indicate the 
activation of this enzyme, has yet to be explained (Sette and Conti, 1996; Oki et al, 
1998). I show, through activation of adenylyl cyclase, a time-dependent decrease in the 
mobility of PDE4D3. At 1 min of IBMX and forskolin challenge both a low mobility and 
high mobility species existed and for the remainder of the time points, the majority of 
PDE4D3 shifts to a low mobility species. Within the same time course and, this ‘band 
shift’ was paralleled using the antisera specific for PKA phosphoiylated Ser 54 (PS54- 
UCRl) within the UCRl. At the 1 min time point, PS54-UCR1 detected a ‘band-shift’ 
which, following the overlay of the film exposures of VSV and PS54-UCR1 blots, is akin 
to both de-phosphorylated and phosphoiylated PDE4D3. However, the antiserum 
specific for PKA phosphoiylated Ser 13 (PS13-4D3) within the unique N-terminal,
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following the overlay of the film exposures of PS13-4D3 and VSV blots, only detected a 
single low mobility species at all time points. A time-dependent increase in 
phosphoiylation was also observed with PS13-UCR1. This suggests that in COSl cells 
the PKA phosphorylation of both sites are required for the mobility shift and that the 
phosphorylation of Ser 54 may even precede that of Ser 13. The notion that the 
phosphorylation of both sites is required for the ‘band-shift’ is further suggested by 
mutation of either these sites to alanine preventing the PKA mediated change in mobility 
of long-form PD4D3 (MacKenzie et al, 2002).
Other than the generation of PDE4D3 by the PDE4D gene, three other PDE4 gene 
families (A, B and C) also generate a range of long-form PDE4s. All long-forms contain 
a PKA consensus sequence Arg-Arg-Glu-Ser-Phe. I show, using selected long isoforms, 
that PKA can phosphoiylate the cognate target serine within the UCRl of long-form 
PDE4s from each sub-family. In intact cells the PS54-UCR1 antibody detected the PKA 
phosphorylation of transiently transfected PDE4A8, PDE4B1, PDE4C2 and PDE4D5 
following the activation of adenylyl cyclase. For each long-form, this phosphorylation 
was ablated using the PKA inhibitor H89 and by mutating the putative target serine to 
alanine. The PKA phosphorylation of these isoforms has been demonstrated in vitro 
(figure 3.6b). In this experiment, recombinant active catalytic unit of PKA is shown to 
phosphorylate the wild type but not the mutated alanine forms. Further experiments from 
our research group have shown that these isoforms are activated by PKA. Thus, it has 
been shown by two approaches that PKA phosphoiylates a cognate serine residue in 
UCRl, and that this phosphoiylation results in an activation of the PDE4. This analysis 
may serve as a model of the phosphorylation and activation of endogenous PDE4s where 
PKA is activated in response to localised increases in cAMP.
During my PKA studies, as discussed above, a new PDE4B long form (pRPDE90) was 
cloned from cDNA isolated from rat brain and characterized (Shepherd et al, 2003). This 
novel PDE4B long form was named PDE4B4 and differed from the other previously 
isolated PDE4B long forms due to its 17 amino acid N-terminus. It had been found to be 
more active than PDE4B1 and exclusively found in the cytosol. As with all the other
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previously characterized PDE4 long forms, PDE4B4 possesses a PKA consensus 
sequence within the UCRl, however, its unique N-terminal region might have conferred 
a conformational alteration which could prevent the access of PKA. I set out to ascertain 
if PDE4B4 was phosphoiylated and activated by PKA in response to elevated levels of 
cAMP. Using the PS54-UCR1 antiserum I found in COS7 cells transiently transfected 
with PDE4B4, that this novel PDE4 long form was indeed phosphoiylated by PKA in 
response to elevation of cAMP (via activation of adenylyl cyclase). This phosphorylation 
was ablated by pre-incubation with the general PKA inhibitor H89. An elevation in 
cAMP through the activation of adenylyl cyclase also resulted in a 1.5-2 fold increase in 
the activity of PDE4B4. Additionally, I show by treating cells with a cAMP analogue 
(dibutryl cAMP), PDE4B4 becomes phosphoiylated by PKA and that H89 ablated this 
phosphorylation.
There is growing evidence that PDE4s are anchored to specific subcellular locations 
(Houslay & Miligan, 1997; Houslay et ah, 1998; Houslay, 2001) and anchored, localised 
PKA can sample and respond to cAMP gradients (Colledge and Scott, 1999). Therefore, 
the PS54-UCR1 antiserum may provide an interesting tool to analyse the PKA 
phosphoiylation status of endogenous long form PDE4s in response to generation of 
localized cAMP pools by different Gs-coupled agonists. As a prelude to examining the 
putative differential PKA phosphorylation of PDE4 longforms in response to localized 
cAMP gradients, I devised a basic experiment to test the PS54-UCR1. I chose the COSl 
cell line which is known to endogenously express a range of PDE4 long forms including 
PDE4D3 and PDE4D5. In order to obtain a time-dependent near maximal increase in 
cAMP levels within these cells, I subjected them to IBMX/forskolin time course. The 
lysates were then analysed with the PS54-UCR1 antiserum in order to compare the 
phosphoiylation PDE4D3 and PDE4D5. After many changes in experimental conditions, 
the PS54-UCR1 antibody was decided to be inappropriate to use for the detection of 
PKA phosphoiylated PDE4s as it detected too many ‘non-specific’ bands upon western 
blotting.
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SQ RRES*FLYRSDSYDLSP 
(aa 49-67)
N-terminus UCR1 UCR2
FRRHS*WISFDVDNGTSAGR
(aa 9-27)
Catalytic unit
Figure 3.1 A schematic of long form PDE4D3. The novel antiserum PS13-4D3 and 
PS54-UCR1 were generated to the peptide sequences which represent amino acids 9-27 
(unique N-terminus) and 49-67 (UCR1) of 4D3, respectively. Underlined are the PKA 
consensus sequences, and the phosphorylated serine is indicated as  (S*).
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Figure 3.2 Sequence alignment of selected long PDE4 isoforms from each PDE4 
subfamily. The amino acid sequences of PDE4A4, PDE4B1, PDE4C2 and PDE4D3 are aligned, 
The PKA consensus sequence (RRSEF) is found in the upstream conserved region (UCR1) is 
highlighted in purple, the UCR1 and UCR2 regions are underlined. Sequences were obtained 
from Genbank and aligned using Clustal Program.
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Figure 3.3 Detection of PKA phosphorylated PDE4D3. C0S1 cells were 
transfected with wildtype PDE4D3 and were treated with IBMX (lOOpM) and forskolin 
(100 |iM) to increase cAMP levels. Cells were there then harvested and analysed by 
western blot. Blots were probed with PS54-UCR1 antiserum (panel A) and PD13-4D3 
(panel B). The antiserum was also treated with the phosphopeptide used to generate it 
(in 10 fold excess).
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Figure 3.4 Determination of the tim- dependent mobility shift of PDE4D3 using 
the PS13-4D3 and PS54-UCR1 antisera. COSl cells were transfected with VSV- 
tagged PDE4D3 and treated with IBMX (lOOpM) and forskolin (100 pM) over a time 
course of 0-20 min. Cells were harvested and analysed by western blot. Blots were 
probed with anti-VSV (panel A), PS54-UCR1 (panel B) and PD13-4D3 antisera (panel 
C). This data represents at three separate experiments using separate transfections.
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Figure 3.5 PDE4D3 activity in response to IBMX/forskolin challenge. COSl 
cells were transfected with VSV-tagged PDE4D3 and treated with IBMX (lOOpM) 
and forskolin (100 pM) over a time course of 0-20 min. Cells were harvested at the 
indicated time points for the analysis of PDE4 activity (pmol/min/mg). Data shown as 
the percentage of represents three experiments +/- S.E.
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Figure 3.6a PKA phosphorylation of longform PDE4s. COSl cells were 
transfected witfi the indicated PDE4 isoform. The cells were treated with IBMX (100 
|iM) and forskolin (100 pM) (indicated as fsk). Also, Cells were pre-treated with H89 
(0.5 pM) prior to fsk treatment. Wildtype (Wt) isoforms and isoforms were the 
putative serine target for PKA phosphorylation was mutated to alanine where used 
in this experiment. These mutants were ( A ) Ser 89 Ala- PDE4A8, ( B ) Ser 133 
Ala- PDE4B1, ( C ) Ser 13 Ala- PDE4C2 and ( D ) Ser 126 Ala- PDE4D5. Data 
represents three experiments. Blots were stripped ad re-probed for the appropriate 
isoform (data not shown)
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Figure 3,6b PKA phosphorylation of long form PDE4s. COSl cells were 
transfected with the indicated PDE4 isoform. The lysates were treated with a 
phosphorylation mixture including pzp] ATP in the presence of absence of active PKA 
catalytic subunit. Lysates were analysed by SDS-PAGE gel and phosphoimager. 
Isoforms where the putative serine target for PKA phosphorylation was mutated to 
alanine were used in this experiment. These mutants were as in previous figure (figure 
3.6). Data represents three experiments performed by S.J. MacKenzie (S.J. 
MacKenzie et al, 2002).
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Figure 3.7 PKA phosphorylation of the rat longform PDE4B4. (A) A schematic of rat PDE4 
transcripts and their encoded proteins. The four dark boxes represent the unique N-terminal 
regions of each isoform (taken from Shepherd et al, 2003). (B) C0S1 cells were transfected 
with Flag-tagged PBE4B4. The cells were treated with 100 pM dibutyri cAMP (dbcA) for 10 min 
with and without 0.5 pM H89 , analysed by SDS-PAGE and immunoblotted with PS54-UCR1 
(upper panel) and anti-flag antiserum (lower panel). (C) Also, transfected cells were treated with 
for 15 min with IBMX (100 pM) and forskolin (100 pM) with and without H89 (0.5 pM), PDE4B4 
was immunoprecipitated from the lysates using using anti-Flag agarose beads, and analysed by 
immunoblotting with PS54-UCR1 (upper panel) and anti-Flag antiserum (lower panel). Data 
represents n=3.
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Figure 3.8 Analysis of the PKA phosphorylation of endogenously expressed 
PDE4D3 and PDE4D5 . COSl cells were treated with IBMX (100 f.iM) and forskolin (100 
laM) for the indicated time points. Cell lysates were analysed by Western blot. Panel A was 
probed with PS54-UCR1 antiserum. The blot was stripped and re-probed with pan-PDE4D 
antiserum. In panel B, The arrows indicate endogenous PDE4D3 and PDE4D5 . In panel 
A, the arrows indicate bands which may represent PKA phosphorylated PDE4D3 and 
PDE4D5. The blue arrow indiactes a non-specific band which migrated at the sam e 
weight as PDE4D3 from 0 to 8 min of the time course.
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Chapter 4
The differential susceptibility of dominant negative/catalytically 
inactive PDE4 isoforms to PKA phosphorylation in COS1 cells
8 2
4.1 Introduction
The idea of signalling molecules being tethered to distinct subcellular compartments has 
long been discussed in the field of second messenger signalling, in particular cAMP 
signalling where the first notion of compartmentalisation of a signalling system was 
formulated (Brunton et ah, 1981).
Protein kinase A (PKA) is the main effector of cAMP. However, depending on the 
cellular response required, it has a large array of possible targets which are expressed in a 
cell-type specific fashion. Over the last decade, researchers have elegantly shown that a 
specific cellular response to cAMP can be achieved through the compaitmentalisation of 
signalling proteins (Brunton et ah, 1981; Zaccolo and Pozzan., 2002; Mongillo et ah, 
2004; Ruehr, 2004; Brunton). This requires that gradients of cAMP are formed and 
shaped within cells. Degradation of cAMP tlii’ough PDE activity provides a clear route to 
achieve this, especially so as both soluble and membrane-bound PDE forms have been 
noted. It has been shown that various members of the PDE4 cAMP specific 
phosphodiesterase family are targeted to distinct intracellular locations (Houslay & 
Adams, 2003). As such they are poised to tailor pools and gradients of cAMP in cells 
and, thereby, ‘control’ the activation of localised PKA. The family of AKAPs (A kinase 
anchoring proteins) has been shown to act as signalling scaffolds, able to organise PKA, 
protein phosphatases, protein kinase C, various PKA substiates and even PDE4s. Thus 
AKAPS may serve to recruit and organise signalling proteins including PKA and PDE4 
together in discrete regions of cells (Dodge et ah, 2001; Tasken et ah, 2001).
A large family isoforms provide adenylyl cyclase (AC) activity. Remarkably little 
detailed understanding is available concerning this important family. However, one key 
feature is their very different basal activity and different degrees of activation by Gs. That 
AC has a basal activity leads to the possibility that cells will slowly accumulate cAMP, 
thereby leading to the activation of PKA. Indeed, basal PKA activity is evident in many 
cells and investigators invariably assess the degree (fold) to which this is increased by the
83
action of G-protein coupled receptor (GPCR) agonist that activate AC through Gs. Of 
course the steady state level of cAMP that is reached in resting cells will depend not only 
on AC activity but also on the prevailing PDE activity in cells. Given that AC is localised 
to the cell plasma membrane, and even sub-domains within it, then anchored PDEs will 
have the role of creating and shaping cAMP gradients within resting cells. However, little 
is known about how PDEs may influence gradients of cAMP in unstimulated cells. This 
is despite the fact that PDE inhibitors are being developed for use therapeutically in, 
presumably attempting to regulate cell functioning under such conditions. The 
identification then of particular PDEs that may be specifically involved in regulating 
PKA activity in unstimulated cells may be of particular importance.
We hypothesised that in resting cells, PDE4s anchored either directly or indirectly to 
AKAPs may be particularly poised to regulate anchored PKA activity. For such anchored 
PDEs may be expected to exert spatial effects on signalling by controlling cAMP levels 
in the immediate vicinity of AKAP-anchored PKA, in this instance through the regulation 
of cAMP levels generated by basally active adenylyl cyclase. In order to investigate this 
possibility we need to have a specific readout for PDE action and for PKA activity. 
Fortunately, PDE4 long isoforms provide such a means for assessment. Firstly, they can 
be phosphorylated by PKA in their conserved UCRl, hence providing an immediate 
read-out for PKA action on a specific PDE. Secondly, we have developed an approach 
whereby a single minimal point mutation in the catalytic of PDE4 isoforms which can 
render them inactive. This has allowed us to develop a dominant negative strategy 
whereby catalytically inactive long PDE4 isoforms from each of the four sub-families 
can be chronically overexpressed in cells where they dominate native PDE4s by some 
100-fold. Under such conditions we surmise that according to the law of Mass Action 
these inactive species will replace the cognate, active endogenous PDE4 isoforms from 
any signalling complexes they are involved in forming in the transfected cells. We 
surmised that if such signalsomes involved anchored PKA where cAMP is channeled in 
resting cells, PKA would now be active as there is no active anchored PDE4 to constrain 
its activity by lowering cAMP levels. Consequently, the catalytically inactive PDE4 
would become phosphorylated by PKA. This approach may thus identify specifc PDE4
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isoform as being specifically involved in constraining the activity of a distinct pool of 
PKA from activating by basal AC activity in resting cells.
R e s u lts
4.2 A study of the differential susceptibility of catalytically/dominant negative 
PDE4 isoforms to phosphorylation by PKA.
Using the dominant negative strategy, I show that in the COSl cell model system, 
certain, but not all, dominant negative/catalytically inactive PDE4 isoforms detect active 
PKA under basal/resting conditions.
4. 2.1 The mRNA PDE4 profile of the COSl cell model
Previously, western blot analysis has shown the endogenous expression of long form 
PDE4A4, PDE4C2, PDE4D3 and PDED5. Also short forms PDE4B2, PDE4D1 and 
PDE4D2 have been identified. I confirm the presence of these isoforms by niRNA 
transcript analysis (figure 4.1). Total RNA was isolated from COSl cells and sent to 
Rachael Barber at Novartis (Horsham, UK) for analysis. PDE4 generic primers and 
primers designed to detect specific PDE4 isoforms (see Appendix for details) were used 
to build a PDE4 profile of this cell line. cDNA from brain tissue was used as a positive 
control and water as a negative control. AmpUcons for generic PDE4A, PDE4B, PDE4C, 
PDE4D, PDE3B and PDE7A were observed. The isoform specific primers identified the 
following PDE4 isoforms: PDE4A4, PDE4A10, 2EL, PDE4B1, PDE4B2, PDE4B3, 
PDE4D1, PDE4D1/D2, PDE4D3 and PDE4D5 (figure 4.1).
4.2.2 The generation of catalytically inactive/dominant negative PDE4s
A range of catalytically inactive/dominant negative PDE4s were generated by the 
Houslay laboratory. The laboratory took advantage of the publication of the X-ray crystal 
structure of the active catalytic unit PDE4B2 (Xu et al, 2000). As the catalytic domain is 
highly conserved throughout the PDE4 family, the crystal structure [Brookhaven Protein
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Data Bank (PDB) accession number IFOJ] provides an insight into the structure of the 
catalytic site of the PDE4 enzyme. Using the information from IFOJ, it was determined 
that the catalytic centre comprises a binuclear motif with a tightly held Zn^^ ion coupled 
to a more loosely held Mg^ "^  (figure 4.2) (Houslay and Adams, 2003). A single point 
mutation of D392 to A392 disrupts the Zn^^ ion binding and renders the enzyme inactive. 
This point mutation results in a veiy conseiwative change which prevents the hydrolysis 
of cAMP but does not alter the interaction of cAMP. It can be assumed that if the 
dominant negative species acts as a sink, cAMP-dependent processes would be inhibited 
and one would expect to observe a null effect. It has already been demonstrated by Baillie 
et al, that dominant negative PDE4D5 can enhance the PKA phosphorylation status of the 
p2-adrenoceptor (Baillie et al, 2003). To generate the dominant negative PDE4 isoforms 
used within this chapter, a point mutation was made in the cognate Zif"  ^ ion binding 
aspartate residue for each isoform.
I selected a range of long form dominant negative PDE4s from each sub family to study 
in COSl cell model system. Firstly, I tested the constructs for PDE activity, noting that 
wild type enzymes and their dominant negative counterparts are cloned into the same 
vectors (pcDNA3). COSl cells were transiently transfected with dominant negative and 
wild type PDE4A4, PDE4B1, PDE4C2 and PDE4D3 isoforms. PDE activity of the cell 
lysates was determined by phosphodiesterase assay (Marchmont and Houslay, 1980) and 
is given here as pmol of cAMP hydrolysed per min per mg of PDE (pmol/min/mg). This 
PDE assay clearly shows that the overexpressed dominant negative PDE4s have minimal 
activity compared to the wild type enzymes. Indeed, the dominant negative species have 
an activity that is comparable to that of the mock control (empty vector transfection). In 
order to establish whether the over expression of the dominant negative themselves 
altered basal cAMP levels within the COSl cells, cAMP assays were performed 
following the transfection of each dominant negative construct (figure 4.4). Total cAMP 
levels were measured for each population of cells over expressing each dominant 
negative and compared to a mock transfection. It was concluded from these assays, that 
the global, averaged cAMP levels did not significantly change following the expression
8 6
of any of the dominant negatives. A total cAMP level of approximately 10 pmol per 10 
cells was observed.
4.2.3 Phosphorylation status of catalytically inactive/dominant negative PDE4 
isoforms
In a COSl cell model, I studied the ability of the dominant negative long PDE4 isoforms 
to provide targets for PKA action using the phospho-specific PS54-UCR1 antibody (as in 
previous chapter). This specifically detects the phosphorylation of a single serine in a 
conserved PKA consensus motif (RRESF), located in the UCRl found in all long PDE4 
isoforms. For this study, cells were transfected with the dominant negative and wild type 
long PDE4 isoforms. It was surmised that the dominant negative PDE4s, compared to 
their respective wild-types, would be more accessible to PKA as they displace the 
cognate active PDE4 and they lack cAMP-hydrolysing activity. As a consequence of this, 
the dominant negative PDE4s, unlike their wild type counterparts, would allow an 
increase in the compartmentalised cAMP pool, an activation of PKA would ensue and 
subsequently PKA phosphoiylation of the dominant negative PDE4 would be observed.
Under resting conditions, cells transfected with either inactive PDE4A4 or PDE4A10, or 
wild type PDE4A4 or PDE4A10 show that none of the these species are phosphorylated 
by PKA (figure 4.5a). However, they clearly have the potential to be phosphoiylated by 
PKA as such PKA phosphoiylation of both wild type and inactive forms of PDE4A4 and 
PDE4A10 is clearly evident following the addition, to cells, of the general PDE inhibitor 
IBMX and direct activator of AC, forskolin (figures 4.5b&4.5c). In contrast, analysis of 
the phosphorylation status of catalytically inactive PDE4C2 and PDE4D3 showed that 
both of these species became highly phosphorylated under resting conditions (figure 
4.5a). Treatment of cells with forskolin, in either the absence or presence of IBMX, led 
only to a small further increase in phosphoiylation (figures 4.5b&4.5c). This suggests 
that in resting cells PDE4C2 and PDE4D3 come into contact with active PKA whereas 
PDE4A4 and PDE4A10 do not.
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4.2.3.1 Phosphorylation status of inactive PDE4D3 and PDE4C2 foilowing 
endogenous PDE4 and PDE3 inhibition
The other major PDE activity in COSl cells is provided by PDE3. In order to address 
possibility that PDE3 activity could influence the phosphorylation state of inactive 
PDE4D3 and PDE4C2, transfected cells were treated with the PDE3 inhibitor 
cilostamide. Additional studies were also done with the PDE4 inhibitor rolipram. It was 
obseiwed that upon inhibition of the entire PDE3 family, with cilostamide, the PKA 
phosphorylation status of the catalytically inactive PDE4C2 is increased, however, using 
rolipram to selectively inhibit the entire pool of active PDE4 enzymes causes little or no 
further increases in phosphoiylation of catalytically inactive PDE4C2 (figure 4.6). In 
contrast to this, inhibition of the entire pool of active PDE4 enzymes markedly increases 
the phosphorylation state of catalytically inactive PDE4D3 and whilst inhibition of the 
entire pool of PDE3 has little effect. These data strongly suggest that different pools of 
active PKA are able to phosphoiylate PDE4C2 and PDE4D3 in theses cells and thus, 
presumably, are being separately controlled by these particular enzymes. In the case of 
PDE4C2 other endogenous PDE4 enzymes in COSl cells do not feed into this, whilst 
PDE3 can. Whilst in the case of PDE4D3 other endogenous PDE4 enzymes in COSl 
cells can feed into this, whilst PDE3 cannot.
4.2.3.2 Action of GPCR stimulation by isoproterenol and PGE2 on the 
phosphorylation status of catalytically inactive/dominant negative PDE4 isoforms
I wished to determine whether differential phosphoiylation states of the inactive long 
PDE4 isoforms was evident following stimulation of different Gs-coupled receptors. I 
chose to evaluate one particular example of a catalytically inactive PDE4 from each sub 
family and determined their phosphoiylation status following stimulation of either 
(3-adrenergic receptors with isoproterenol or prostacyclin receptors with PGE2. As a 
control, transfected cells were also treated with forskolin which can be expected to 
activate the entire pool of AC in cells. The phosphoiylation status of catalytically inactive 
PDE4A4, PDE4B1, PDE4C2 and PDE4D3 is shown here in basal, forskolin.
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isoproterenol and PGE2 stimulated cells (figure 4.7a). The western blots of the PS54- 
UCRl were quantified using densitometiy software, and the phosphorylation states of 
each isoform shown as percentage control of the maximum value observed upon 
stimulation with forskolin stimulation (figure 4.7b). It is clear that the agonist stimulation 
of these two different receptors both increase the phosphoiylation of catalytically inactive 
PDEC2 and PDE4D3, where isoproterenol is as twice as effective as PGE2 in increasing 
the phosphorylation of both these enzymes . In contrast, isoproterenol causes a 5-fold 
increase in phosphorylation of inactive PDE4B1 compared to the PGE2 agonist. Both 
PGE2 and isoproterenol have a similar minimal effect on the phosphorylation of 
PDE4A4.
4.2.3.3 cAMP levels following Isoproterenol or PGE treatment in cells over 
expressing the inactive PDE4s
I wished to establish if the differences in phosphoiylation states of the inactive PDE4s 
observed upon isoproterenol stimulation and PGE2 stimulation are due differences in the 
abilities of these ligands to increase global cAMP levels. Cells were transfected with the 
catalytically inactive PDE4 species, and then stimulated with either isoproterenol or 
PGE2 and subsequently cAMP levels measured (figure 4.7c). The data is shown here as 
fold change compared to basal cAMP levels. It is clear that the cells overall cAMP 
response to PGE2 stimulation is similar in cells that over express any of the catalytically 
inactive PDE4s. Cells over expressing PDE4A4, PDE4C2 and PDE4D3 also respond 
similarly with respect to global cAMP levels in response to isoproterenol challenge (5- 
fold greater than response to PGE2), whereas a slightly higher cAMP level was observed 
in cells transfected with inactive PDE4B1 and stimulated with isoproterenol. The upper 
graph shows the fold changes of cAMP levels observed in native COSl cells following 
PGE2 or isoproterenol treatment (figure 4.7c). On comparing the cAMP levels observed 
following PGE2 or isoproterenol stimulation of COSl cells and COSl cells 
overexpressing each of the dominant negatives, it appears that the dominant negatives 
may reduce cAMP levels.
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4.2.4 Quantification of expression levels of catalytically inactive/dominant 
negative PDE4A4 and PDE4D3
As western blot analysis of the expression levels of the transfected inactive PDE4s relied 
on the use of PDE4 pan sub-family antibodies, the expression levels of the inactive 
PDE4s could not be directly compared to each other. I, therefore, wished to establish if 
the observed differences in phosphoiylation states between PDE4A4 and PDE4D3 may 
be simply due to different expression levels of these various catalytically inactive species 
expressed in cells. To quantify and compare the actual expression levels between these 
two isoforms I selected lysates used in the previous Gs-coupled agonist experiments. The 
lysates with the same protein concentration were subjected to electrophoretic separation 
alongside a range of protein concentrations of the pure recombinant form of the isoforms 
(figure 4.8a). From the range of purified recombinant PDE4, a standard curve was 
generated by densitometry analysis of the bands. The equation of the line and the 
densitometiy analysis of the cell lysates were used to calculate the number of pmol of the 
catalytically inactive PDE4 species present in 5pg of lysates (figure 4.8b). The mean 
expression levels of 0.026 +/- 0.002 pmol for PDE4A4 and 0.024 +/- 0.014 pmol for 
PDE4D3 were calculated. These data showed that the expression level of these various 
catalytically inactive PDE4 species was at very similar levels. Thus the differences in 
phosphoiylation seen in these studies are very unlikely to be due to any major differences 
in total concentration making one species rather than the other more likely to be 
phosphorylated by PKA.
4.2.5 Pharmacological analysis to determine whether it is Rl or Rll PKA isoform 
that phosphorylates catalytically inactive PDE4C2 and to assess AKAP 
involvement
From previous experiments, it was observed that inactive PDE4C2 and PDE4D3 were 
both phosphoiylated by PKA at basal cAMP levels. The interaction of PDE4D3 with an 
AKAP, namely mAKAP, has already been reported in cardiac myocytes (Dodge et al, 
2001). Also PDE4D3 has been shown to interact with AKAP 450 in Sertoli cells (Tasken
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et al, 2001). The basai phosphoiylation of PDE4D3 may be an indication of the 
association of this isoform with an AKAP as this would provide an ideal platform for the 
anchoring of both the PDE4 and PKA in close proximity to each other. As inactive 
PDE4C2 is also phosphorylated at basal cAMP levels, I wished to examine the possibility 
of the involvement of an AKAP-bound PKA and to identify which type, RI or RII PKA 
phosphoiylates this enzyme.
The type of PKA isoforms endogenously expressed in COSl cell model was determined 
by western blot analysis with the isoform specific antibodies (Signal Transduction 
Laboratories) (figure 4.9). Whole cell lysate was probed for the presence of 
RIa, R lla  and RII[3 forms of the PKA regulatory sub-units (RI(3 specific antibody was 
commercially unavailable). Immuonoreactive species corresponding to weights of 
RIa (48kD), R lla (51kD) and RII(3 (53kD) forms were observed following western 
blotting.
The preferential phosphorylation of inactive PDE4C2 by the RI agonist compared to the 
RI agonist was further examined. In this experiment, antagonists of the RI and RII forms 
were used, and the phosphorylation state of inactive PDE4C2 was analysed as with the 
previous agonist experiments. Cells were transfected with the inactive PDE4C2 and 
treated for 18-24 hr with the RI antagonist, R-Cl cAMPs or the RII antagonist R-Cpt 
cAMPs. Lysates were analysed by western blotting with the PS54-UCR1 antiserum and 
the phosphoiylation state of the inactive PDE4s quantified by densitometry (figures 4.10a 
&4.10b). This data shows that the RI antagonist reduces the basal phosphorylation level 
of PDE4C2 but the RII antagonist appears to have no effect on the phosphoiylation level. 
In the same experiment, the possibility of an AKAP-PKA complex regulating the 
phosphoiylation of this PDE4 was examined. A widely used AKAP-PKA complex 
‘disrupter’ was chosen to assess the involvement of any AKAP. If the PKA form 
responsible for the basal phosphoiylation of inactive PDE4C2 was held in an AKAP 
complex, Ht31 would be expected to reduce this basal phosphorylation as PKA would no 
longer be ‘held’ in close proximity to the PDE. Inactive PDE4C2 was co-transleeted with 
a plasmid which expressed a GFP-tagged Ht31 fiagment. It was shown via western
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3blotting with anti-GFP and pan PDE4C antibodies (figure 4.10a), and
immunofluorescence (figure 4.10c) that PDE4C2 and Ht31 were both expressed in the îj
same cell. Following densitometry analysis and correction for expression levels of i
PDE4C2 (figure 4.10b), Ht31 appeared to reduce the phosphorylation. RI- and RII- 
specific agonists (Biolog, Germany) were then employed in order to establish which 
isoforms of PKA phosphorylated inactive PDE4C2 and inactive PDE4D3 at basal
■Iadenylyl cyclase activity. Cells over expressing the inactive PDE4s were treated with the 
RI synergistic agonists (8-PIP-cAMP and 6-MBC-cAMP; Biolog, Germany) or RII 
synergistic agonists (8-HA-cAMP and 6-MBC-cAMP; Biolog, Germany) for 10 min. The T
phosphorylation status of the PDE4 isofbrms were then assessed by western blotting with 
the PS54-UCR1 antiserum and densitometry analysis (figure 4.11). The data is shown as 
fold change basal and indicates that a RI form, rather than a RII form of PKA 
preferentially phophosphorylated inactive PDE4C2. In contrast, it appears that neither 
form of PKA preferentially phosphorylated PDE4B1 as both the RI and RII agonists 
caused similar, but minimal, increases in phosphorylation.
4.3 Discussion
In this chapter I show, by utilising catalytically inactive PDE4 isoform, that of the 
selected PDE4 long-forms studied, only PDE4C2 and PDE4D3 are able to be 
phosphoiylated by PKA under basal adenylyl cyclase activity in COSl cells. This 
selectivity suggests that PDE4C2 and PDE4D3 may be held in close proximity to discrete 
PKA sub-populations whereby they regulate such activities at basal cAMP levels.
For this study, COSl cells were chosen as the model cell line. COSl cells endogenously 
express PDE4s from each sub family (A, B, C and D) as shown by mRNA expression 
profile (figure 4.1) and by western blot analysis (unpublished data, Houslay laboratory).
Dominant negative/ catalytically inactive long-form PDE4s from each sub family were 
chosen, tested for activity and shown to be inactive compared to their wild-types (figure 
4.3). As a control, to ensure that the catalytically inactive enzymes themselves do not 
alter basal adenylyl cyclase activity, global cAMP levels were measured following the
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over-expression of the catalytically inactive species (figure 4.4). Here it was shown that 
the over-expression and transfection process itself do not significantly alter global cAMP 
level within COSl cells.
Firstly, the PKA phosphorylation status of catalytically inactive PDE4A4, PD4A10,
PDE4C2 and PDE4D3 were compared to the respective wild types at basal cAMP levels 
(figure 4.5a). In this experiment, PKA phosphorylation of the UCRl PDE4s were 
detected with the phospho-specific PS54-UCR1 antiserum, the blots stripped and probed 
with the pan PDE4 subfamily antibodies to show loading between catalytically inactive 
PDE4 long isofbrms and the respective wild type species. The pan PDE4 antibodies are #
sub-family specific (generated to the C-terminal region) thus the level of over-expression 
between the PDE4A, PDE4C and PDE4D isofbrms described in this experiment cannot 
be directly compared. This is addressed later in this chapter as is the possibility that the 
different PDE4 isofbrms may have varying sensitivity to PKA. As shown in figure 4.5a, f
only the PKA phosphorylation of the catalytically inactive PDE4C2 and PDE4D3
isofbrms was observed. A non-specific band was detected for the PDE4A4 standard and #:{phosphorylation of the wild type isofbrms was not detected. In the next set of ; [
experiments, global cAMP levels were raised by the activation of the entire pool adenylyl 
cyclase using forskolin, and also by the inhibition of the entire pool of PDEs together 
with activation of adenylyl cyclase (IBMX & forskolin treatment). Following the addition 
of forskolin, phosphoiylation of catalytically inactive PDE4A4 was observed (figure 
4.5b), and a small increase in phosphorylation of catalytically inactive PDE4C2 and 
PDE4D3 was evident compared to basal conditions (figures 4.5a and 4.5b). Finally, 
following IBMX and forskolin treatment, phosphorylation of all catalytically inactive and 
all wild type isoforms was observed (figure 4.5c), and increases in phosphoiylation of the 
catalytically inactive PDE4C2 and PDE4D3 was observed. Although phosphoiylation of 
dominant negative PDE4A4 and PDE4A10 was not observed at basal cAMP levels, 
phosphoiylation was observed following the combination of forskolin and IBMX 
treatment. This suggests that PDE4A4 and PDE4A10 are accessible to PKA, but with 
reduced sensitivity. Overall, this ‘selective’ phosphorylation of PDE4C2 and PDE4D3
I-i
suggests that these isoforms may be sampling different pools of cAMP than PDE4A4 and 
PDE4A10, and may also be in close proximity to PKA.
As described in the previous experiment, catalytically inactive PDE4C2 and PDE4D3 
were phosphorylated by PKA at basal adenylyl cyclase activity and this phosphorylation 
only increased slightly by forskolin treatment. As a larger increase in phosphorylation of 
these isoforms was evident following general PDE inhibition, with IBMX together with 
forskolin, I decided to investigate if the selective inhibition of entire pools of PDE3 and 
PDE4 activities affected the phosphoiylation of PDE4C2 or PDE4D3. The mRNA profile 
(figure 4.1) showed that generic PDE3B and an array of PDE4s other than PDE4C2 and 
PDE4D3 were expressed endogenously in COSl cells. If PDE3 isoforms or other PDE4 
isoforms were also targeted to the same region as the catalytically inactive species, one 
would expect either the selective PDE3 inhibitor cilostamide or the selective PDE4 
inhibitor rolipram to increase the phosphoiylation of the catalytically inactive species. A 
simple experiment was performed where catalytically inactive PDE4C2 and PDE4D3 
were overexpressed in the COSl cell model, and the level phosphoiylation analysed with 
the PS54-UCR1 (figure 4,6). It is clear from this data that inhibition of PDE3s resulted in 
an increase in phosphoiylation of catalytically inactive PDE4C2 compared to basal. On 
the other hand, the inhibition of PDE4 resulted only in an increase in the phosphorylation 
of PDE4D3. This suggests that PDE4C2 may be targeted to a region of higher PDE3 
expression or activity, whereas PDE4D3 may be targeted to a region of higher PDE4 
expression or activity. As this data represents only two experiments, further experiments 
should be performed to provide fold changes in phosphorylation of statistical 
significance.
The differential effects of PDE3 and PDE4 inhibition on the phosphoiylation of the 
catalytically inactive PDE4C2 and PDE4D3 suggest that these PDE4s may be sampling 
different pools of cAMP, To investigate this further by means of the catalytically inactive 
PDE4 strategy, the effect of activating different Gs-coupled receptors on the 
phosphoiylation of selected catalytically inactive PDE4 species was studied. A 
catalytically inactive PDE4 long-form was selected from each sub-family and their
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phosphorylation in response to the activation of the (B-adrenergic receptor with 
isoproterenol or activation of the EP receptors with PGE2, was studied. It has been 
previously reported that these agonists can generate different cellular responses via the 
elevation on cAMP (Brunton, 2003), thus they provide an ideal way to investigate if the 
dominant negatives are indeed sampling distinct pools of cAMP. In this experiment, the 
effects of forskolin, PGE2 and isoproterenol stimulation on catalytically inactive 
PDE4A4, PDE4B1, PDE4C2 and PDE4D3 was studied (figures 4.7a & figure 4.7b). The 
western blot data was analysed by densitometry. As different basal phosphorylation 
levels were obseiwed between isoforms, the response of each isoform to the agonists was 
compared to the forskolin induced phosphorylation state and this allowed each isoform to 
be compared to one another. It is clear that following agonist stimulation, the 
phosphorylation pattern of catalytically inactive PDE4D3 and PDE4C2 was almost 
identical. However, the phosphorylation pattern of catalytically inactive PDE4A4 and 
PDE4B1 appeared to be quite different; PGE2 and isoproterenol had similar effect on 
PDE4A4, yet only isoproterenol stimulation resulted in phosphorylation of PDE4B1. The 
differential effects of the Gs coupled agonists may indicate that these PDE4s are being 
targeted to different sub-cellular regions.
I also set out to investigate if the actual over-expression of the different isoforms 
impaired the generation of cAMP by agonist treatment. The cells over-expressing each of 
the isoforms were subjected to agonist stimulation and global cAMP level measured 
(figure 4.7c). The data is represented as fold change over basal cAMP levels, and it is 
evident that the over-expression of any of catalytically inactive PDE4s did not alter total 
cAMP levels significantly. However, it appears that following overexpression of inactive 
PDE4B1, a larger response to isoproterenol was observed. Thus, it appears that the 
differences in phosphorylation of catalytically inactive PDE4A4 and PDE4B1 compared 
to catalytically inactive PDE4C2 and PDE4D3 observed is not due to the catalytically 
inactive species either impairing or enhancing the receptor activation and subsequent 
generation of cAMP.
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For the next control experiment I investigated the expression levels of the catalytically 
inactive species in COSl cells. As a pan PDE4 antibody was not available, I could not 
compare expression levels of each the catalytically inactive constructs by using the pan 
PDE4 sub-family antibody (used for normalisation of data). To address this problem, I 
chose to calculate the number of pmol of the catalytically inactive PDE4A4 and PDE4D3 
forms in whole cell lysates from the experiments involving GPCR challenge 
(isoproterenol stimulated lysates). Known concentrations of the lysates (calculated by 
Bradford assay) were subjected to SDS-PAGE analysis alongside a range of 
concentrations of recombinant E.coli expressed PDE4A4 and PDE4D3 (figure 4.8a). The 
purified E.coli expressed PDE4s were used to generate a standard cuiwe and following 
densitometry analysis, the approximate number of pmol of the catalytically inactive 
enzyme present in the cell lysates were calculated. From the previous agonist 
experiments it was clear that isoproterenol stimulation caused quite different levels of 
phosphorylation of the catalytically inactive PDE4A4 and PDE4D3, however, it is 
evident that the expression levels of catalytically inactive PDE4A4 and PDE4D3 did not 
vary significantly (figure 4.8b).
In summaiy, the PDE4C2 and PDE4D3 data suggests that the over-expression of the 
dominant negatives did not alter the cAMP generation in response to agonist treatment, 
the expression levels of each did not vary markedly. Therefore, the differential 
phosphoiylation of the catalytically inactive PDE4s observed at basal adenylyl cyclase 
activity and agonist stimulated adenylyl cyclase activity may be due to targeting and 
sampling of spatially distinct ‘pools’ or gradients of PKA that sample distinct gradients 
of cAMP.
It is now well established that PKA can be anchored to discrete sub-cellular locations by 
AKAPs, and can sample gradients of cAMP within the cell (Klauk & Scott, 1995; 
Colledge & Scott, 1999). The PDE4D3 isoform has also been shown to be anchored to 
AKAPs where it can regulate the activity of PKA by a feedback control mechanism 
involving the PKA phosphoiylation of the PDE itself (Dodge et al, 2001; Tasken et al, 
2001). At basal adenylyl cyclase activity in COSl cells, I observed PKA phosphorylation 
of both catalytically inactive PDED3 and PDE4C2, and hypothesised that this may be due
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to the close proximity of PKA. As mentioned above, PDE4D3 has already been reported 
to be anchored alongside PKA to an AKAP (Dodge et al, 2001; Tasken et al, 2001), yet 
no such anchoring has been reported for PDE4C2. I decided to investigate the possibility 
of an AKAP involvement in the PKA phosphorylation and control of activity of PDE4C2, 
and also to identify which PKA isofonn phosphorylated this PDE4 isoform at basal 
cAMP levels. Firstly, I identified which isoforms of PKA were endogenously expressed 
in the COSl cell model (figure 4.9). As both RI and RII isofbrms were expressed I used 
PKA isoform specific antagonist and agonists to alter the phosphoiylation of catalytically 
inactive PDE4C2 (figures 4.10 & 4.11). These data suggests that an RI-PKA isoform was 
the predominant form responsible for the phosphorylation of catalytically inactive 
PDE4C2. If an AKAP tethers the PKA responsible for the phosphoiylation of PDE4C2, 
one would expect to see an ablation of this phosphoiylation following the disruption of 
the AKAP-PKA interaction. To study the possible involvement of an AKAP, the 
catalytically inactive PDE4C2 was co-expressed with Ht31, a commonly used PKA- 
AKAP disrupter (figure 4.10), Although the over-expression of Ht31 reduced the level of 
expression of PDE4C2, following normalisation of the densitometry data, it appears that 
the disruption of all PKA-AKAP interactions did indeed ablate the phosphoiylation of 
catalytically inactive PDE4C2. Therefore this simple experiment may be an indication 
that the PDE4C2 isoform can associate with a PKA-AKAP complex. If time had allowed, 
I would have performed the same co-transfections with the other catalytically inactive 
species at basal cAMP levels and agonist induced cAMP levels.
Following the Ht31 experiments, I investigated the possibility of an actual interaction of 
the PDE4C2 isoform with a PKA-AKAP complex. Immunoprécipitations of PDE4C2 
were sent to two separate AKAP laboratories (Klussmann, FMP, Berlin & Tasken, Oslo.) 
for overlay analysis. Both RI and RII overlay assays were performed, and showed an 
AKAP of about 250 kD co-immunoprecipitated with PDE4C2. I have not shown the 
overlay results in this chapter as the blots were unclear, however they provided initial 
promising evidence of a possible PDE4C2-PKA-AKAP complex. Also, I would have 
liked to have pursued the study of the identification of the specific isofonn of PKA which 
phosphoiylated PDE4C2. My initial data suggests that an RI isoform was responsible, 
and I planned to further investigate using an approach involving PKA isofonn specific
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interfering RNA (siRNA). As a complex of a PDE4, RI-PKA and an AKAP has yet to be 
reported, a PDE4C2/RI PKA-AKAP complex would be potentially exciting. If the AKAP 
could be identified it may provide a functional role for PDE4C2 within a cell.
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Figure 4.1 mRNA PDE4 expression profile of COSl cells. The gel represents a typical 
PDE mRNA profile of C0S1 cells. Total RNA was isolated from C0S1 cells, synthesised to 
cDNA and subjected to PGR using primers designed to specific PDE isoforms (see appendix 
for primer details). The table shows a summary of 4 different PGR analyses; brain cDNA was 
used as a positive control, water as a negative control and ‘w’ indicates a weak band.
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Figure 4.2 Schematic structure of the PDE4B2 core catalytic unit illustrating 
metal Ion environment. The divalent cations (Zn^+ and IVIg^ +) involved in the 
catalytic mechanism are represented as  balls. A singal point mutation of amino acid 
D392 disrupts the binding of the metal ions and renders the PDE4 inactive. 
Diagram adapted from a Houslay review (Houslay and Adams, 2003)
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Figure 4.3. Comparison of PDE activities of wild type and dominant 
negative/catalytically inactive PDE4s. CO Sl cells were transiently transfected with wild type 
(wt) and dominant negative (DN) PDE4 isoforms, and the PDE activity of lysates was analysed 
by PDE assay (Marchmont & Houslay, 1980). Mock indicates the transfection of empty vector 
(pcDNA3). Represents one PDE assay.
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Figure 4.4 cAMP concentration per 10® cells following dominant negative over 
expression in COSl cells Mock indicates transfection of empty vector (pcDNA3). cAMP 
levels in COSl cells transiently transfected with the indicated dominant negative. n=3 +/- S.E.
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Figure 4.5a PKA phosphorylation of dominant negative/catalytically inactive PDE4 long 
form at basal cAMP levels. The indicated wild type and dominant negative PDE4 isoforms 
were overexpressed in C0S1 cell. Lysates of HEK cells transfected with the relevant wt PDE4 
isoforms are indicated as standards. Lysates were subjected to SDS-PAGE analysis and the 
PKA phosphorylation status was determined using PS54-UCR1 antiserum (upper panels). To 
check expression and loading, blots were stripped and re-probed with relevant pan PDE4 
subfamily antibodies (lower panel).
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Figure 4.5b PKA phosphorylation of dominant negative/catalytically inactive PDE4 long 
form at elevated levels of cAMP induced by forskolin. Lysates of HEK cells transfected 
with the relevant wt PDE4 isoforms are indicated as standards The indicated wild type and 
dominant negative PDE4 isoforms were over expressed in C0S1 cell. Two days post 
transfection, cells were treated with forskolin (100 pM) for 10 min, lysates were subjected to 
SDS-PAGE analysis and the PKA phosphorylation status was determined using PS54-UCR1 
antiserum (upper panels). To check expression and loading, blots were stripped and re­
probed with relevant pan PDE4 subfamily antibodies (lower panel).
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Figure 4.5c PKA phosphorylation of dominant negative/catalytically inactive PDE4 long 
form at near maximal cAMP levels. Lysates of HEK cells transfected with the relevant wt 
PDE4 isoforms are indicated as standards The indicated wild type and dominant negative 
PDE4 isoforms were over expressed in COSl cell. Two days post transfection, cells were 
treated with the general PDE inhibitor IBMX (100 pM) and forskolin (100 pM) for 10 min. 
Lysates were subjected to SDS-Page analysis and the PKA phosphorylation status was 
determined using PS54-UCR1 antiserum (upper panels). To check expression and loading, 
blots were stripped and re-probed with relevant pan PDE4 subfamily antibodies (lower panel).
105
Dom Neg PDE4D3 
Bsl Cil Rol
Dom Neg PDE4C2 
Bsl Cil Rol (A)
(B)
□ D3 DN 
nC 2 DN
basal cilostamide rolipram
Figure 4.6 Differential PKA phosphorylation of dominant negative PDE4D3 and PDE4C2 
following PDE4 or PDE3 inhibition. (A) C0S1 cells were transiently transfected with 
dominant negative/catalytically inactive PDE4D3 and PDE4C2 long forms. The cells were 
treated with the selective PDE4 inhibitor Rolipram (Rol) (10 pM), and the selective PDE3 
inhibitor Cilostamide (Cil) (10 pM) for 10 min. Bsl indicates resting cells. Lysates were 
subjected to western blot analysis; PS54-UCR1 (upper panel) and pan PDE4 subfamily (lower 
panel) antibodies. (B) Quantification of the PKA phosphorylation from the western blots 
(Quantity One software). Data was normalised for loading and represented as fold change 
basal. N=2 +/- S.E
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Figure 4.7a PKA phosphorylation of dominant negative PDE4s in response to 
different Gs-coupled agonists. C0S1 cells were transiently transfected with the indicated 
dominant negative PDE4 isoforms. Cells were treated for 5 min PGE2 (1 pM), Isoproterenol 
(Iso) (1 pM) and forskolin (Fsk) (100 pM). Bsl indicates basal adenylyl cyclase activity. Lysates 
were subjected to western blot analysis; PS54-UCR1 antibody (upper panels), pan PDE4 sub 
family antibody (lower panels). Represents three separate transfections.
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Figure 4.7b Quantification of level of PKA phosphorylation of catalytically inactive/ 
dominant negative PDE4s in response to different G-coupled agonists. The western blots 
from the previous experiment (figure 4.6a) were scanned and the phosphorylated bands were 
analysed by densitometry (Quantity One software analysis). All data corrected for loading and 
represented as percentage control (forskolin). N=3 +/- S.E.
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Figure 4.7c Comparison of cAMP levels following Gs-coupled receptor activation in 
C0S1 cells overexpressing the indicated catalytically inactive/dominant negative 
PDE4s. Upper graph represents global increases in cAMP level in C0S1 cells in response to 
Isoproterenol (10 nM) or PGE2 (IpM) stimulation. COS1 cells were transiently transfected 
with the indicated dominant negative PDE4s and subjected to 5 min stimulation with 
Isoproterenol (10 pM) or PGE2 (1 pM) (lower graph). Basal indicates resting cAMP levels. 
Results are shown as  fold basal change. N=3 +/- S.E.
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Figure 4.8a Quantification of expression levels of catalytically inactive/dominant 
negative PDE4D3 and PDE4A4 vectors transiently transfected into COS1 cells. A range 
of concentrations (pg) of lysates from a previous PKA phosphorylation experiment (figure 4.6) 
was subjected to SDS-PAGE analysis alongside a range of concentrations (ng) of purified 
recombinant E. coli expressed PDE4A4 (MBP tagged) and PDE4D3 (GST fusion protein). 
Western blots (top panels) were probed with the relevant pan PDE4 subfamily antibodies, and 
a standard curve was generated using densitometry software (Quantity One). This data 
represents one of two separate quantifications.
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Figure 4,8b Quantification of expression levels of catalytically inactive/dominant 
negative PDE4D3 and PDE4A4 vectors transiently transfected into C0S1 cells. Using 
the equation of the line calculated from the standard curves; (IVIBP-PDE4A4 y = 
4759.332LOG(x) + 3447.173 and GST-PDE4D3 y = 2657.607LOG(x) + 2760.134 ), the 
number of pmol of overexpressed PDE4A4 and PDE4D3 present in 5 pg of G0S1 lysate was 
calculated. Data represents two separate experiments.
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Figure 4.9 Endogenous expression of protein kinase A regulatory subunits In C0S1 
cells. C0S1 lysates were separated by gel electrophoresis and subjected to western blotting 
with regulatory subunit specific antibodies.
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Figure 4.10 Assessment of AKAP involvement and Identification of the PKA subtype 
responsible for the phosphorylation catalytically/dominant negative PDE4C2 at basal 
cAMP levels. S ee next page for full figure legend.
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Figure 4.10 Assessment of AKAP involvement and Identification of the PKA subtype 
responsible for the phosphorylation catalytically/dominant negative PDE4C2 at basal 
cAMP levels. (A) C0S1 cells were transiently transfected with dominant negative PDE4C2 
and subjected to 24 h treatment with Rl and Rll specific antagonists. Lysates were subjected 
electrophoresis and analysed with PS54-UCR1 (upper panel) and pan PDE4C (middle panel) 
antibodies. To asse s  AKAP involvement, GFP-tagged Ht31 was co-transfected with dominant 
negative PDE4C2 and the phosphorylation was assessed  at basal conditions. The middle and 
lower panels show co-transfection. Control indicates mock transfection. (B) The densitometry 
of the bands w as analysed, corrected for loading/expression and represented as a percentage 
change basal (n+3 =/- S.E ). (C) A confocal image indicating the co-expression of GFP-Ht31 
and dominant negative PDE4C2. Transfected cells were stained with pan PDE4C antibody 
and excited at 488 nm to show the expression of Ht31 (green fluorescence) and PDE4C2 
(rhodamine staining). The yellow colour shown in the overlay indicates co-expression. 
Represents one of three experiments.
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Figure 4.11 Pharmacological analysis and identification of the PKA subtype which is 
responsible for the phosphorylation of catalytically inactive/dominant negative PDE4C2 
and PDE4B2 isoforms . C0S1 cells were transiently transfected with dominant negative 
PDE4B1 or PDE4C2. On day two of transfection, cells were subjected to 10 min incubation 
with selective agonists of Rl and Rll forms of PKA. (A) Lysates were analysed by western blot; 
PS54-UCR1 (upper panels) and the relevant pan PDE4 subfamily antibodies (lower panels).
(B) Densitometry analysis was performed on the phospho bands and data corrected for 
loading. N=2 +/- S.E.
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Chapter 6
Analysis of gene expression following overexpression of 
catalytically inactive PDE4 isoforms
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5.1 Introduction
Protein-protein interaction is a reversible process subject to the law of Mass Action, 
where the rapidity at which equilibria can be altered depends upon the concentration of 
constituents and their affinity for each other. Our group (Houslay review, 2003) and 
various others (Tasken et al, 2001; Dodge et al, 2001) have previously demonstrated 
that specific PDE4 isoforms can interact with various anchor or signal scaffold proteins 
in cells. This is thought to be responsible for controlling compartmentalised cAMP 
signalling. Indeed, recent studies (Mongillo et al, 2004) using a genetically encoded 
cAMP sensor, show this to be the case at least for PDE4B and PDE4D in cardiac 
myocytes. My novel approach to evaluating this question has been using so-called 
‘dominant negative’ constructs. This is where specific PDE4 isoforms have been subtly 
engineered, by a single point mutation in the catalytic site to be catalytically inactive and 
then overexpressed in cells. The philosophy of such an approach is that when the 
dominant negative PDE4s are chronically overexpressed in cells then, given reversible 
equilibrium occurring between endogenous examples of PDE4s and its particular anchor, 
the catalytically recombinant isoform should serve to displace and so replace endogenous 
active examples of that specific PDE4 isoform at its targeted anchor site. We hypothesise 
that such a catalytically inactive PDE4 would now ablate control of a distinct cAMP pool 
previously controlled by the displaced particular PDE4 isoform. This is different from a 
siRNA approach directed at a specific isoform where all of that isoform, be it anchored or 
not, would be ablated. With my dominant negative approach functional ‘inactivation by 
displacement’ would be restricted to the anchored fraction of that specific isoform only.
Here then I set out to study if catalytically inactive PDE4s might exert specific 
differential effects upon on the model HEK 293 cell line at the level of gene expression. 
The advent of DNA microarray technology allows a quantitative read-out of relative gene 
expression of tens of thousands of different genes. For the experiments discussed in this
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chapter, U133A GeneChips® (Affymetrix, Inc, Santa Clara, CA) were used to analyse 
potential changes in gene expression following the overexpression of catalytically 
inactive PDE4s in HEK293 cells. The U133A oligonucleotide chip contained probes for a 
total of 22283 human genes.
5.1.1 DNA microarray overview
DNA microarray technology serves as an important tool to study regulation and function 
of genes, as it allows the generation of large amounts of data on thousands of genes in a 
single assay. Several methods have been described for producing microarrays 
(Harrington et al, 2000), with the most basic types including spotted microarrays and 
high-density oligonucleotide arrays. Generally, each array consists of thousands of 
different DNAs (PCR products or oligonucleotides) which are attached to a solid support 
(Schena et al, 1996; Harrington et al, 2000). The changes in gene expression are analysed 
by laser scanning, and thence the intensity of fluorescently labelled RNA or DNA 
(prepared from mRNA) hybridising to complementaiy DNA on the chip determined.
Spotted arrays allow the measurement of the relative gene transcript levels differing 
between control (reference) and experimental (test) RNAs. On spotted arrays, genes are 
represented by pre-synthesised single or double stranded DNA fragments of several 
hundred base pairs in length which are bound to glass slides (Harrington et al, 2000). 
Different fluorophores are incorporated into the cDNAs of control and test DNAs, and 
the labelled DNAs are mixed together prior to hybridisation to the array chip. By 
measuring the fluorophore signal intensities and calculating signal ratios, relative 
amounts of a gene transcript in the two samples can be calculated.
Commercially available oligonucleotide arrays consist of sets of oligomers synthesised in 
situ on glass wafers using a photolithographic manufacturing process (Harrington et al, 
2000). Oligonucleotide arrays involve the labelling of the test mRNA via conversion to 
biotinylated cRNA and each sample is hybridised to a separate arrays. These transcript 
levels are calculated by reference to cRNA spikes of known concentration added to the 
hybridisation mixture. This method allows differences in mRNA levels between samples
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Upon processing of the fluorescent array image, three basic steps are required for data 
analysis: data normalisation, data filtering, and pattern identification (Harrington et al, 
2000). Following normalisation, data reduction can be achieved by filtering out 
uninformative genes. Patterns within the data are identified and interpreted by computer 
analysis via data mining programs.
(produced on separate arrays of the same type) to be calculated by comparing their 
respective hybridisation patterns. High-density oligonucleotide arrays allow great 
flexibility in sample comparisons and the oligo probes are uniquely designed to represent 
the cognate gene thus minimising cross-hybridisation between similar sequences.
5
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Results
The U133A oligonucleotide GeneChip® (Affymetrix, Inc, Santa Clara, CA) allowed us to 
analyse the response of HEK293 cells to the chronic overexpression of different 
catalytically inactive PDE4s. Fold changes in gene expression were calculated by 
analysing the difference in gene expression between samples of mRNA isolated from 
HEK293 cells overexpressing a catalytically inactive PDE4 and mRNA isolated from 
HEK293 cells overexpressing empty vector (pcDNA) as the control sample.
I chose to study the individual effects of four different catalytically inactive PDE4s, 
namely PDE4A4, PDE4B2, PDE4D3 and PDE4D5 isoforms upon gene expression 
levels. These isoforms are all expressed endogenously in HEK293 cells which I set out 
to use here as a test case because the cells are easy to transfect and well characterised as 
far as PDE4s go. Furthermore, it has previously been shown that these specific PDE4 
isoforms are expressed in human U937 monocytic cells where they provide distinct 
functional roles consistent with compartmentalisation of cAMP signalling (MacKenzie et 
al, 2000). If specific PDE4s control discrete functional ‘pools’ of cAMP, one could 
reason that overexpression of a catalytically inactive PDE4 would cause cAMP signalling 
through that specific ‘pool’ to increase. This local increase in cAMP could either, (i)
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activate PKA, (ii) activate Epac, (iii) activate a cAMP gated ion channel or (iv) activate 
an unidentified cAMP signalling system. Therefore, I decided to investigate, by the use of 
catalytically inactive PDE4A4, PDE4B2, PDE4D3 and PDE4D5 constructs, the putative 
compartmentalisation of these PDE4 isoforms in a human derived cell line (HEK293 
cells).
5.2 PDE4 mRNA expression profile of HEK293 cells
The expression of these chosen PDE4 isoforms in HEK293 cells has previously been 
shown by western blot in our laboratory (unpublished data, Houslay laboratory). I 
decided also to obtain evidence for transcripts of these specific PDE4 isoforms in this cell 
line. In order to do this, RNA was isolated from HEK293 cells and sent to Rachael 
Barber (Novartis, Horsham) for analysis by RT-PCR. PDE4 generic primers and primers 
designed to detect specific PDE4 isoforms (see Appendix for details) were used to build a 
PDE4 profile of this cell line. cDNA from brain tissue was used as a positive control and 
water as a negative control. Amplicons for generic PDE4A, PDE4B, PDE4C, PDE4D, 
PDE3B and PDE7A were observed. The isoform specific primers identified the following 
transcripts for PDE4 isoforms: PDE4A4, PDE4A10, 2EL, PDE4B1, PDE4B2, PDE4B3, 
PDE4D1, PDE4D1/D2, PDE4D3 and PDE4D5 (figure 5.1). PDE4 isoforms, namely 
PDE4A4, PDE4B2, PDE4D3 and PDE4D5 chosen for microarray analysis are expressed 
endogenously in HEK293 cells.
5.2.1 Overexpression of catalytically inactive PDE4s and microarray analysis of 
gene expression
HEK293 cells were transfected with the selected catalytically inactive PDE4 cloned into 
the pcDNA vector (Invitrogen), and, as a control, HEK293 cells were also transfected 
with empty pcDNA vector. The transfections were performed in triplicate, mRNA 
isolated and sent to Novartis (Genomics Dept, Basle, Switzerland). The microarray data 
was normalized, and statistical analysis performed also at Novartis (Genomics
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Department Basle, Switzerland). The fold change in gene expression between cells 
overexpressing catalytically inactive and cells overexpressing the empty control vector 
(pcDNA) was calculated from the mean expression values. The p-values were calculated 
by performing a heteroscedastic student’s t-test.
The tables of micro array data provided in this chapter list all fold-changes of gene 
expression of greater than 5-fold and of p-values less than 0.05 (tables 5.1- tables 5.4). 
Furthermore, I have provided a CD within the appendix listing all fold changes of gene 
expression of p-values less than 0.05, and of p-values less than 0.01. However, from all 
the microarray data presented in this chapter, I will only discuss the most striking 
changes in expression of niRNA levels, including changes in levels of mRNA of proteins 
involved cAMP signalling.
5.2.1.1 Changes in gene expression unique to the overexpression of catalytically 
inactive PDE4A4
The changes in gene expression following the overexpression of PDE4A4 are shown in a 
tabular format (table 5.1). The left-hand column shows the fold-change in gene 
expression compared to the vector only control, the middle column provides the p-values 
and the last column details the gene description as provided by the manufacturer of the 
U133A oligonucleotide GeneChip® (Affymetrix, Inc, Santa Clara, CA). Up-regulation of 
gene expression is shown by a positive fold-change and down-regulation of gene 
expression is shown by a negative fold-change.
It can be seen that the overxepression of catalytically inactive PDE4A4 caused a greater 
than 5-fold up-regulation in levels of mRNA from 19 different genes and a down- 
regulation of mRNA expression levels of 8 different genes. Most strikingly, a 24-fold 
up-regulation in expression in mRNA for an inositol 1, 4, 5-triphosphate receptor (type 3) 
was observed. A change in the expression of mRNA for this receptor was not observed 
following the overexpression of catalytically inactive PDE4B2, PDE4D3 or PDE4D5
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(tables 5.2, 5.3 & 5.4). The inositol 1, 4, 5-triphosphate receptors (IP3 receptors) 
constitute as family of Ca^  ^ channels which facilitate the mobilisation of intracellular 
Ca^  ^stores. Cross-talk between cAMP signalling and Ca^  ^has been reported in cardiac 
myoctes (MacLennan & Kranias, 2003). IP3 receptors can be directly phosphorylated by 
PKA which alters, depending on the cell or tissue type, the flux of Ca^  ^ (Patel et al,
1999). The promoter region of the IP3 receptors does not contain a CRE site. Therefore, 
the overexpression of catalytically inactive PDE4A4 may, unlike the other catalytically 
inactive PDE4s, have increased the levels of cAMP in a distinct ‘pool’ resulting in the 
up-regulation of gene expression the IP3 receptor.
Both up-regulation and down-regulation of different G-protein coupled receptors was 
observed following the overexpression of catalytically inactive PDE4A4 and PDE4D3 
(tables 5.1 & 5.3). A change in the expression levels of mRNA of lysophosphatidic acid 
G-protein-coupled receptor 4 (EDG4) was only observed following the overexpression of 
catalytically inactive PDE4A4. The mRNA expression levels of EDG4 increased by some 
12-fold (table 5.2). This G-protein coupled receptor belongs to the lysophosphatidic acid 
(LPA) receptor family, and couples to the G,/o, G12/13 and Gq proteins (Contos et al,
2000). LPA stimulates cell proliferation through the activation of tyrosine kinase and 
MAP kinase (Moolenaar et al, 1997), it has also been shown to increase intracellular Ca^  ^
levels and inositol phosphates (Contos et al, 2000). The promoter region of EDG4 has not 
been shown to posses a CRE site. As only the overexpression of catalytically inactive 
PDE4A4 provides a change in the gene expression of EDG4, this suggests that only 
endogenous expressed PDE4A4 in HEK293 cells maybe controlling a distinct ‘pool’ of 
cAMP which, when manipulated with catalytically inactive PDE4A4, alters the 
transcriptional regulation of EDG4.
A striking down-regulation, of some 20-fold, was seen for the mRNA expression levels 
of PACE4C (kexin-like protease) only following the overexpression of inactive PDE4A4. 
PACE4C is a member of the subtilisin/Kex2p family (Nakayama, 1997). The 
subtilisin/Kex2p family are a family of endoproteases which are responsible for the 
conversions of precursors of peptide hormones, neuropeptides and many other proteins 
into their biologically active forms (Nakayama, 1997). PACE4 is responsible for the
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activation of transforming growth factor-P (TGFp)-related factors such as bone 
morphogenetic proteins (Tsuji et al, 2003). The biological activity of TGFp molecules 
can be regulated by PACE4 which anchors heparin sulphate proteoglycans to the 
extracellular matrix (ECM) (Tsuji et al, 2003). It is postulated that the interaction of 
PACE4 and heparin sulphate proteoglycans might play an important role in the spatial 
and temporal regulation TGFp-related factor’s biological activity (Tsuji et al, 2003).
5.2.1.2 Changes in gene expression unique to the overexpression of catalytically 
inactive PDE4B2
Overexpression of catalytically inactive PDE4B2 in HEK293 cells only resulted in the 
up-regulation of mRNA expression greater than 5-fold of one gene, and the down- 
regulation of mRNA expression greater than 5-fold of four different genes (table 5.2).
Interestingly, a 7-fold decrease in the expression of mRNA encoding RING finger protein 
22 (RNF22) was only observed following the overexpression of catalytically inactive 
PDE4B2 (table 5.3). Over the last 5 years, RING finger proteins have been identified as 
key mediators in the ubiquitinylation of proteins (Joazeiro & Weissman, 2000). 
Ubiquitinylation plays an important in the regulation of the levels of plasma membrane 
proteins through proteasomal degradation and by facilitating endocytosis (Joazeiro & 
Weissman, 2000). Protein ubiquitinylation begins with the formation of a thiol-ester 
linkage between ubquitin (Ub) and the Ub activating enzyme (El). Ub is then transferred, 
through a thiol-ester linkage, to an Ub conjugating enzyme (E2). Ubiquitin ligase (E3) 
interacts with E2 and the protein target allowing the transfer of Ub to the target protein, 
thus provide specificity to Ub conjugation (Joazeiro & Weissman, 2000). RING finger 
proteins now represent the largest class of E3s to date.
The overexpression of catalytically inactive PDE4B2 resulted in both the up-regulation 
and the down-regulation of a few genes. This suggests that the cAMP ‘pool’ controlled 
by endogenous PDE4B2 has little effect upon gene expression. However, the observation
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that the mRNA levels of RING finger protein 22 (RNF22) are down-regulated, suggests 
that PDE4B2 may serve to influence the ubiquitinylation of an as yet unidentified protein.
5.2.1.3 Changes in gene expression unique to the overexpression of catalytically 
inactive PDE4D3
Following the overexpression of catalytically inactive PDE4D3, a greater than 5-fold up- 
regulation in levels of mRNA was observed from 8 different genes and a greater than 5- 
fold down-regulation of mRNA expression levels of 4 different genes was observed 
(table 5.3).
Interestingly, upon comparison of the microarray data generated following 
overexpression of each of the catalytically inactive PDE4s, a down-regulation in the gene 
expression of a GPCR was only observed following the overexpression of catalytically 
inactive PDE4D3 (table 5.3). A down-regulation of two different types of GPCR was 
observed, 5-fold down-regulation of G-protein coupled channel (liGIRKl) and a neai’ 8- 
fold down-regulation of a GPCR (FIG38)
G-protein coupled inwardly rectifying potassium channel (GIRK) are expressed in heart, 
the nervous systems and endocrine tissues where they control post-synaptic inhibitoiy 
signalling and hormone secretion by pertussis toxin sensitive GPCRs (Sadja et al, 2003). 
GIRK channels are modulated by a variety of different factors such as 
phosphatidylinositol-4, 5-biphosphate (PIP2), Na"^ , Mg^ '*’, oxidation-reduction,
phosphorylation and acidification (Sadja et al, 2003).
HG38 is an orphan G-coupled receptor, which when its sequence is compared to those of 
other G-protein coupled receptor families, shares an overall identity of ~ 35% with the 
FSH, TSH and LH/hGC of the glycoprotein hormone receptor subfamily (McDonald et 
al, 1998). As with all glycoprotein receptors, HG38 is predicted to have a large 
extracellular domain with Leucine-rich repeats (LRR) which would potentially allow 
protein-protein interactions (McDonald et al, 1998). The in vivo function of ITG38 has 
yet to elucidated, but as the three other members of the glycoprotein receptor subfamily
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play pivotal roles in growth, development and reproduction, it is expected that HG38 will 
have a similar role.
With respect to the regulation of GPCR gene expression, only the overexpression of 
catalytically inactive PDE4D3 resulted in the down-regulation of hGIRK and HG38 
(table 5.3). However, in contrast, the overexpression of a different catalytically inactive 
PDE4, namely PDE4A4, resulted in an up-regulation of a GPCR, specifically EDG4 
(tables 5.1). These data suggests that PDE4A4 and PDE4D3 may act on distinct pools of 
cAMP and thus act on different signalling pathways resulting in differential gene 
regulation of specific GPCRs
5.2.1.4 Changes in gene expression unique to the overexpression of catalytically 
inactive PDE4D5
Overexpression of catalytically inactive PDE4D5 in HEK293 cells resulted in the up- 
regulation of mRNA expression greater than 5-fold of seven different genes and the 
down-regulation of mRNA expression greater than 5-fold of six different genes (table 
5.4).
Although PDE4D3 and PDE4D5 are splice variants from the PDE4D subfamily, and are 
both long isoforms, they are known to interact with distinct signalling scaffold proteins. 
Interestingly, here we see that analysis of the micro array data produces some clear 
differences in the regulation of the levels of gene expression following the 
overexpression of the catalytically inactive species of each of these specific isoforms. 
Most interestingly, an 8-fold down-regulation of the gene expression of phospholipase D, 
and a 7-fold down-regulation of the gene expression of Glucose Transporter-like Protein 
(SLC2A9) were only evident following the overexpression of catalytically inactive 
PDE4D5.
Phospholipase D (PLD) enzymes constitute a family of phosphodiesterases that catalyse 
the hydrolysis of phosphatidylcholine (PtdCho) to generate choline and phosphatidic acid 
(PtdOH). Phospholipase D is involved a variety of physiological processes such as
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endocytosis, exocytosis, vesicle coat recruitment, and budding from the Golgi apparatus 
(Liscovitch et al, 2000; Freyberg et al, 2003). Much of the research on has focused on the 
regulation of PLD activity by PKCa (Ca^^-dependent form of PKC), PKC5, rac- and 
Rlio-GTPases, and small GTP-binding proteins such as ARF (Cockcroft et al, 1994; 
Hammond et al, 1997; Han et al, 2002; Freyberg et al, 2003; Liscovitch et al, 2000).
Facilitative glucose carriers such as members of the SLC2A family enable the transport 
of hexoses across the plasma membrane, and are important mediatiors in body sugar 
homeostasis. A novel member of the SLC2A family, SLC2A9 (GLUT9), was recently 
identified and characterised (Augustia et al, 2004). This study showed that SLC2A9 was 
expressed in human kidney proximal tubules, predominantly in the basal lateral 
membrane.
As an up-regulation of phospholipase D (PLD) mRNA and down-regulation of SLC2A9 
mRNA was observed only following the overexpression of catalytically inactive 
PDE4D5, this suggests that the endogenous form of this PDE4 isoform, via control of 
cAMP levels, can influence the gene expression of signalling proteins of two different 
signalling pathways.
5.2.1.5 Common changes in levels of gene expression following overexpression 
of the catalytically inactive PDE4s.
Overexpression of catalytically inactive PDE4A4, PDE4D3 and PDE4D5 also provided 
identical changes in certain sets of genes that were either up-regulated or down-regulated. 
Common changes in gene expression are listed in table 5.5, along and I will discuss 
below a few examples of common changes of gene expression.
An 8-fold up-regulation in the expression of mRNA of secretogranin II (chromogranin C) 
was obseiwed following the overexpression of catalytically inactive PDE4A4, PDE4D3 
or PDE4E5 (table 5.5). Secretogranin II is a member of the secretogranin/chromogranin 
secretory protein family. Secretogranin/chromogranin secretory proteins are released 
from secretory vesicles together with hormones or neurotransmitters. Secretogranin II is
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the precursor of the neuropeptide secretoneurin (Fischer-Coibrie et al, 1995). It has been 
reported that the regulation of synthesis of secretogranin II can be influenced by various 
different second messengers, including cAMP, Ca^ ,^ cGMP (Fischer-Coibrie et al, 1995). 
Interestingly, up-regulation of the mRNA expression of secretogranin II was achieved in 
bovine chromaffin cells by forskolin treatment (Fischer-Coibrie et al, 1990). This up- 
regulation was thought to be due to presence of CRE in the promoter of secretogranin II 
(Schimmel et al, 1992). My observation of an up-regulation of the mRNA expression of 
secretogranin II following the overexpression of either catalytically inactive PDE4A4, 
PDE4D3 or PDE4E5 is most probably result of an increase of cAMP and subsequent 
activation of CRE .
The up-regulation of the mRNA expression of cytosolic phospholipase A2 gamma 
(cPLA2y) of 9-fold and 8-fold was evident following the overexpression of catalytically 
inactive PDE4A4 or PDE4D3 respectively (tables 5.1 & 5.4). Phospholipase A2 (PLA2) 
is a key mediator, via the liberation of arachidonic acid, in the synthesis of eicosanoids 
which include prostaglandins, thromboxanes and leukotrienes. So far three different 
isoforms of CPLA2 have been identified, cPLA2a, cPLA2y and CPLA213, Each isoform of 
CPLA2 possesses a consensus MAPK phosphorylation site (PXSP motif) and it has been 
shown that MAPK phosphorylation of cPLA2« increases its intrinsic enzymatic activity, 
augmenting Ca^^-induced arachidonic acid release (Hirabayashi & Shimizu, 2000). A 
variety of cytokines, IL-1, TNFa, epidermal growth factor and interferon-y have been 
shown to increase the synthesis of mRNA of cPLA2a in several cell models (Hirabayashi 
& Shimizu, 2000).
5.3 D iscussion
A spatially distinct elevation of cAMP and/or PKA activation, as achieved by 
replacement of an endogenous PDE4 by a catalytically inactive PDE4 species, could alter 
gene expression by a number of different ways. Proof of the dominant 
negative/catalytically inactive principle has already been shown, whereby overexpression 
of inactive PDE4D5 in cardiac myocytes, saturated the p-arrestin sites for PDE and
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enhanced isoproterenol-stimulated membrane associated PKA activity (Perry et al, 2002, 
Baillie et al, 2003).
PKA can exert long term effects on cellular functioning by altering the functions of a 
variety of nuclear proteins including a large number of transcription factors, nuclear 
hormone receptors, transcriptional activators/repressors and chromatin-associated 
proteins (Shabb, 2001). PKA can also indirectly exert effects upon transcriptional 
regulation via activation of the MAP kinase cascade. Also, it is possible that PKA may 
indirectly exert its effects upon transcription via the phosphorylation of another, 
unidentified signalling protein. In a recent review of physiological substrates of PKA 
(Shabb, 2001), it was shown that since the discovery of PKA in the 70s, the list of 
identified PKA substrates has quadrupled in the last decade and it is highly likely that 
many more PKA targets are yet to be identified. Research using the recently discovered 
Epac specific activator, 8-pCPT-2’-0-Me-cAMP, proposes that not all PKA-independeiit 
effects of cAMP can be attributed to Epac. This paves the way for the future discovery of 
further cAMP targets with cAMP binding domains not similar to that of Epac and PKA 
(Bos, 2003). Thus, there is a wide variety of identified and yet to be identified 
mechanisms by which cAMP can alter regulation of gene transcription, via direct or 
indirect actions.
My study, utilising the catalytically inactive PDE4 species as a form of manipulating 
different pools of cAMP did indeed provide data showing differential gene expression. 
The use of microarray technology allowed me to identify the changes in gene expression 
in a HEK293 cell model following the overexpression of catalytically inactive PDE4s. I 
identified, upon comparing the microarray data between the different inactive PDE4 
species, many differences in gene expression. As we believe that the different 
catalytically inactive PDE4s alter different pools of cAMP, one would expect the general 
PDE4 inhibitors, namely rolipram and ariflo, to ‘knock’ out all PDE4s and thus result in a 
more global increase in cAMP. Therefore, we would expect the inhibition of all PDE4s 
by rolipram and ariflo to encompass all changes in gene expression, with regards to those 
changes obseiwed following overexpression of the catalytically inactive PDE4s. However
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this was not the case, as shown in tables 5.6 and 5.7. Here, the actual gene changes 
observed following 48hr treatment of HEK cells with rolipram or with ariflo are listed in 
tables. It is quite clear from these data that ariflo or rolipram treatment resulted in quite 
different changes in gene expression compared to those observed with any of the 
catalytically inactive PDE4 isoforms. This suggests that not only do overexpression of 
catlytically inactive PDE4s subtly alter distinct cAMP pools, but that one cAMP pool 
may control another.
However, the non-physiological effects of the overexpression of the inactive species must 
be taken into account. It is possible that overexpressed PDE4 species bind aberrantly to 
other proteins allowing non-specific, non-physiological effects. If time had allowed, I 
would have confirmed the changes in gene observed by RT-PCR and northern blot 
analysis. Furthermore, I would have studied the effects of such gene expression at the 
level of protein expression by SDS-PAGE analysis. Finally, it would be interesting to 
further assess gene changes following the manipulation of cAMP pools by means of 
siRNA. Designing PDE4 isoform specific siRNA would provide a different approach to 
‘knocking out’ the PDE4 isoforms and studying their effects on gene expression.
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Figure 5.1 The PDE mRNA expression profile of HEK293 cells. The gel represents a typical PDE 
mRNA profile of HEK293 cells. Total RNA was isolated from HEK293 cells, synthesised to cDNA 
and subjected to PCR using primers designed to specific PDE Isoforms (see appendix for primer 
details).
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Fold change p-value Description
24.815 0.014907 gb;D26351.1 /DEF=Human mRNA for type 3 inositol 
1,4,5-trisphosphate receptor, complete cds.
21.037 0.001538 Consensus includes gb:AK000847.1 /DEF=Homo sapiens cDNA FLJ20840 fis, clone ADKA02336. zinc finger protein 236
11.395
9.510
0.033203
0.001942
gb:NM_004720.3 /DEF=Homo sapiens endothelial 
differentiation, lysophosphatidic acid G-protein-coupled 
receptor, 4 (EDG4), mRNA.
Consensus includes gb:NM_003530.1 /DEF=Homo sapiens 
H3 histone family, member B (H3FB), mRNA.
9.238 0.000583 gb;AF065214.1 /DEF=Homo sapiens cytosolic phospholipase A2 gamma (cPLA2 gamma) mRNA, complete cds
7.724 0.000723 gb;NM_003469.2 /DEF=Homo sapiens secretogranin II (chromogranin C) (SCG2), mRNA.
7.270 0.022009 gb:NM_005263.1 /DEF=Homo sapiens growth factor independent 1 (GFI1), mRNA.
7.262 0.001139 gb:AF133207.1 /DEF=Homo sapiens protein kinase (H11) mRNA, complete cds.
7.176 9.79E-05 gb:NM_030795.1 /DEF=Homo sapiens stathmin-like-protein RB3 (RB3), mRNA.
6.618 0.000201 Consensus includes gb:AA284829 /FEA=EST Weakly similar 
to Z139_HUMAN ZINC FINGER PROTEIN 13 H.sapiens
5.899 0.00023 gb:NM_005794.1 /DEF=Homo sapiens short-chain alcohol dehydrogenase family member (HEP27), mRNA.
5.653 0.035828 gb:NM_000783.1 /DEF=Homo sapiens cytochrome P450, subfamily XXVIA, polypeptide 1 (CYP26A1), mRNA
5.616 0.007183 gb:NM_005132.1 /DEF=Homo sapiens Rec8p, a meiotic recombination and sister chromatid cohesion phosphoprotein 
of the rad21p family (REC8), mRNA.
5.393 5.16E-05 gb:NM_016639.1 /DEF=Homo sapiens type 1 transmembrane protein Fn14 (FN14), mRNA
5.387 0.004982 gb:NM_001421,1 /DEF=Homo sapiens E74-like factor 4 (ets domain transcription factor) (ELF4), mRNA.
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Table 5.1 Changes in levels of mRNA levels following overexpression of catalytically 
Inactive PDE4A4.The fold change was calculated from the mean expression values between the 
PDE4A4 sample and the empty vector control sample (pcDNA). P-values were calculated by the 
heteroscedastic students t-test.
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Fold change p-value Description
5.378 0.004279 gb;NM_003543.2 /DEF=Homo sapiens H4 histone family, member H (H4FH), mRNA.
5.329 0.049943
Consensus includes gb:AK024281.1 /DEF=Homo sapiens 
cDNA FLJ14219 fis, clone NT2RP3003800, highly similar 
to Rattus norvegicus tyrosine protein kinase pp60-c-src mRNA.
5.165 0.015786 gb:NM_016184.1 /DEF=Homo sapiens C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily 
member 6 (CLECSF6), mRNA
5.132 0.001163 Moderately similar to ALU7 HUMAN ALU SUBFAMILY SQ SEQUENCE CONTAMINATION WARNING ENTRY H.sapiens
-5.403 0.025632
gb:NM„017417.1 /DEF=Homo sapiens UDP-N-acetyl-alpha-D 
-galactosamine:polypeptide N-acetylgalactosaminyltransferase 
8 (GalNAc-T8) (GALNT8), mRNA.
-5.951 0.021371 CLONE=IMAGE:4478872 /UG=Hs.155530 interferon, gamma- inducible protein 16 /FL=gb:AF208043.1
-6.468 0.0219 Consensus includes gb:AL133015.1 /DEF=Homo sapiens mRNA; cDNA DKFZp43402417 (from clone DKFZp43402417
-7.418 0.009077 Consensus includes gb:AI815033 CLONE=IMAGE:2420736 /UG=Hs.55947 KIAA0805 protein
-9.581 0.018937 Consensus includes gb:D50604 /DEF=Human beta-cytoplasmic actin (ACTBP9) pseudogene /FEA=CDS /DB_XREF=gi:2094759
-12.693 0.020161 gb:NM„004571.1 /DEF=Homo sapiens PBXknotted 1 hoemobox 1 (PKN0X1), mRNA.
-20.430 0.005259 gb:D28513.1 /DEF=Human mRNA for PACE4C (kexin-like protease), complete cds
-38.900 0.04771 Consensus includes gb:AF279774.1 /DEF=Homo sapiens clone N4 NTera2D1 teratocarcinoma mRNA.
i
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Fold change p-value Description
5.367127496 0.0042
gb:NM_005132.1 /DEF=Homo sapiens RecSp, a meiotic 
recombination and sister chromatid cohesion phosphoprotein 
of the rad21p family (REC8), mRNA.
-5.730308219 0.0060 gb:NM_030769.1 /DEF=Homo sapiens hypothetical protein 
similar to swine acylneuraminate lyase (C10RF13), mRNA.
-6.877358491 0.0009 Consensus includes gb:AF271088.1 /DEF=Homo sapiens deleted in azoospermia (DAZ) mRNA, partial cds.
-7.163461538 0.0004 gb:NM 006458.1 /DEF=Homo sapiens ring finger protein 22 (RNF22), mRNA.
-8.509615385 0.0074
Consensus includes gb:AW445040 CLONE=IMAGE:2733928 
^UG=Hs.300863 lethal (3) malignant brain tumor l(3)mbt protein 
Drosophila) homolog
Table 5.2 Changes in levels of mRNA levels following overexpression of catalytically 
inactive PDE4B2.The fold change was calculated from the mean expression values between the 
PDE4B2 sample and the empty vector control sample (pcDNA). P-values were calculated by the 
heteroscedastic students t-test.
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Fold change p-value Description
8.3821 0.0007 gb:AF065214.1 /DEF=Homo sapiens cytosolic phospholipase A2 gamma (cPLA2 gamma) mRNA, complete cds.
8.2313 0.0011 Consensus includes gb:NM_003530.1 /DEF=Homo sapiens H3 histone family, member B (H3FB), mRNA.
8.0520 0.0008 gb:AF133207.1 /DEF=Homo sapiens protein kinase (H11) 
mRNA, complete cds
7.9606 0.0074 gb:NM_003469.2 /DEF=Homo sapiens secretogranin 11 (chromogranin C) (SCG2), mRNA
6.2408 0.0001 gb:NM_030795.1 /DEF=Homo sapiens stathmin-like-protein RB3 (RB3), mRNA.
5.9783 0.0005 Consensus includes gb:AA284B29 Weakly similar to Z139 HUMAN ZINC FINGER PROTEIN 13 H.sapiens
5.2637 0.0002 gb:NM_003543.2 /DEF=Homo sapiens H4 histone family, member H (H4FH), mRNA.
5.0220 0.0005 gb:NM_016639.1 /DEF=Homo sapiens type 1 transmembrane protein Fn14 (FN14), mRNA.
-5.4160 0.0015 gb:U39196.1 /DEF=Human clone hGIRKI G-protein coupled 
inwardly rectifying potassium channel mRNA, complete cds.
-5.5022 0.0240
Consensus includes gb;AI986120 CLONE=IMAGE:2494024 
/UG=Hs.241257 latent transforming growth factor beta binding 
protein 1 /FL=gb:M34057.1 gb:NM_000627.1
-7.5607 0.0141 gb:AF062006.1 /DEF=Homo sapiens orphan G protein-coupled 
receptor HG38 mRNA, complete cds.
-7.7203 0.0247
Consensus includes gb:BG256677 /CL0NE=1MAGE:4478872 
/UG=Hs. 155530 interferon, gamma-inducible protein 16 
/FL=gb:AF208043.1
Table 5.3 Changes in levels of mRNA levels following overexpression of catalytically 
inactive PDE4D3.The fold change was calculated from the mean expression values between the 
PDE4D3 sample and the empty vector control sample (pcDNA). P-values were calculated by the 
heteroscedastic students t-test.
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Fold change p-value Description
11.1798 0.0045 gb:NM„018452.1 /DEF=Homo sapiens uncharacterized bone marrow protein BM033 (BM033), mRNA.
10.7529 0.0102 Consensus includes gb:AK000847.1 /DEF=Homo sapiens cDNA FLJ20840 DB_XREF=gi:7021168 /UG=Hs.283619 zinc 
finger protein 236
8.1575 0.0096 gb;NM„003469.2 /DEF=Homo sapiens secretogranin 11 
(chromogranin C) (SCG2), mRNA.
7.2607 0.0014 gb:AF133207.1 /DEF=Homo sapiens protein kinase (H11) mRNA, complete cds.
7.1487 0.0127 gb:NM_005794.1 /DEF=Homo sapiens short-chain alcohol dehydrogenase family member (HEP27), mRNA.
5.4997 0.0033 gb:NI\/l_001421.1 /DEF=Homo sapiens E74-like factor 4 
(ets domain transcription factor) (ELF4), mRNA.
5.4270 0.0004 gb:NM_030795.1 /DEF=Homo sapiens stathmin-like-protein 
RB3 (RB3), mRNA.
-6.0505 0.0000 Consensus includes gb:U78581.1 /DEF=Human type i phosphatidylinositol-4-phosphate 5-kinase beta (STM7) 
mRNA, partial cds.
-6.5605 0.0199 Consensus includes gb:A1983428/CLONE=1MAGE:2510766 /UG=Hs. 146428 collagen, type V, alpha 1
-7.0000 0.0480 gb:NM_020041.1 /DEF=Homo sapiens solute carrier family 2 (facilitated glucose transporter), member 9 (SLC2A9), mRNA.
-7.8070 0.0012 Consensus includes gb:AU147830 Homo sapiens cDNA 
F U 12295 fis, clone MAMMA1001818
-8.2156 0.0440 gb:L11702.1 /DEF=Human phospholipase D mRNA, 
complete cds.
-17.5996 0.0198 Consensus includes gb:BG256677 interferon, gamma-inducible protein 16 /FL=gb:AF208043.1
Table 5.4 Changes In levels of mRNA levels following overexpression of catalytically 
inactive PDE4D5 .The fold change was calculated from the mean expression values between 
the PDE4D5 sample and the empty vector control sample (pcDNA). P-values were calculated by 
the heteroscedastic students t-test.
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Fold change
Description 4A4 4B2 4D3 4D5
secretogranin II (chromogranin C) 7.724 7.9606 8.1575
H3 histone family, member B (H3FB) 9.510 8.2313 -
cytosolic phospholipase A2 gamma 
(cPLA2 gamma) 9.238 8.3821 -
protein kinase (H11) 7.262 8.052 7.2607
stathmin-like-protein RB3 (RB3), 7.176 6.2408 5.4270
Human zinc finger protein 13 6.618 5.9783 -
Human zinc finger protein 236 21.037 “ 10.729
short-chain alcohol dehydrogenase 
family member (HEP27). 5.899 7.1487
RecSp, a meiotic recombination and 
chromatid cohesion phosphoprotein
5.616 5.367 -
type 1 transmembrane protein Fn14 5.393 5.0220 «
E74-like factor 4 (ets domain 
transcription factor) (ELF4), 5.387 - 5.4997
H4 histone family, member H (H4FH) 5.387 5.2637 -
interferon, gamma-inducible protein 16 -5.951 -7.7203 -17.5996
Table 5.5 Common changes in mRNA levels following overexpression of catalytically 
inactive PDE4 isoforms .The fold change was calculated from the mean expression values 
between the PDE4 isoform sample and the empty vector control sample (pcDNA), The p-values 
are listed in the previous tables ( tables 5.2-5.5).
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Fold change p-value Description
6.9474 0.0003 gb:NM_021064.1 /DEF=Homo sapiens H2A histone family, member P (H2AFP), mRNA
5.2371 0.0035
gb:NM_014298.2 /DEF=Homo sapiens quinolinate 
phosphoribosyltransferase (nicotinate-nucleotide 
pyrophosphorylase (carboxylating)) (QPRT), 
mRNA.
5.2029 0.0071 gb:BC002439.1 /DEF=Homo sapiens, Tat- interacting protein (30kD), clone MGC:1318, 
mRNA,
-7.7763 0.0032 gb:NiVI_020193.1 /DEF=Homo sapiens GL002 protein (GL002), mRNA.
-8.3592 0.0059 Consensus includes gb:AK025352.1 /DEF=Homo sapiens cDNA: FLJ21699 fis, clone GOL09829.
-19.1500 0.0081 gb:AY014283.1 /DEF=Homo sapiens NYD-SP6 mRNA, complete cds.
Table 5.6 Changes in levels of mRNA levels following treatment of HEK293 cells with 
rolipram (lOplVI).The fold change was calculated from the mean expression values between the 
rolipram sample and the HEK293 sample (untreated cells). P-values were calculated by the 
heteroscedastic students t-test.
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Fold
change P-value Description
52.1667 0.0141 gb:NM 006410.1 /DEF=Homo sapiens Tat-interacting protein (30kD) (TIP30), mRNA.
6.3719 0.0287 gb:NM_021064.1 /DEF=Homo sapiens H2A histone family, member P (H2AFP), mRNA.
5.0319 0.0133 gb:BC002439.1 /DEF=Homo sapiens, Tat-interacting protein (30kD). clone MGC:1318, mRNA. complete cds.
-5.2119 0.0176 Consensus includes gb:BF508616 /FEA=ESTCLONE= IMAGE:3085646 UG=Hs.79347 KIAA0211gene product
-5.5766 0.0234 gb:NM_021094.1 /DEF=Homo sapiens solute carrier family 21 
(organic anion transporter), member 3 (SLC21A3), mRNA
-5.9844 0.0071 gb:AY014283.1 /DEF=Homo sapiens NYD-SP6 mRNA, 
complete cds. hypothetical protein /FL-gb:AY014283.1
-6.4173 0.0321 Consensus includes gb:AA017721 /FEA=EST /DB XREF=gi:1479910 DB XREF=est:ze39f11 .si 
/CLONE=IMAGE:361389
-6.4737 0.0054 Consensus includes gb:AK025352.1 /DEF=Homo sapiens cDNA: FLJ21699 fis, clone COL09829. /FEA=mRNA
-7.0661 0.0161 gb:NM_007345.1 /DEF=Homo sapiens zinc finger protein 236 
(ZNF236), mRNA. /FEA=mRNA
■7.1133 0.0017 Consensus includes gb:BG281679/CLONE=IMAGE:4544871 , Highly similar to YXHUT thymidylate synthase H.sapiens
-7.8990
-9.2475
0.0437
0.0026
Cluster Ind. AF007155:Homo sapiens clone 23763 unknown 
mRNA, partial cds /cds=(0,314) /gb=AF007155 /gi=2852635 
/ug=Hs.168694 /len=1369
Consensus includes gb:U80771.1 /DEF=Human EST clone 
25267 mariner transposon Hsmarl sequence.
-10.4778 0.0055 Consensus includes gb:AC004472 /DEF=Homo sapiens chromosome 9, P1 clone 11659 /FEA=CDS
-11.0465 0.0117 gb:BC004241.1 /DEF=Homo sapiens. Similar to laminin, alpha 4, clone MGC:10389, mRNA, complete cds.
-13.5385 0.0375 /CLONE=IMAGE:2421293 /UG=Hs.182982 golgin-67 
/FL=gb:NM_015003.1 gb:AF204231.
-15.2347 0.0075 aryl hydrocarbon receptor nuclear translocator-like 
/FL=gb;AB000812.1 gb:AF044288.1
-32.1667 0.0071 Consensus Includes gb:BE504895ATP-blnding cassette, 
sub-familv B fMDRTAPV member 9
Table 5.7. Changes in levels of mRNA levels following treatment of HEK293 cell 
with arlflo (please see next page for full table legend).
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Table 5.7 Changes in levels of mRNA levels following treatment of HEK293 cells with 
ariflo (lOpM).The fold change was calculated from the mean expression values between the ;
arlflo sample and the HEK293 sample (untreated cells).P-values were calculated by the 
heteroscedastic students t-test.
Chapter 6
Compartmentalîsation of cAMP phosphodiesterases in rat 
neonatal cardiac myocytes
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6.1 Introduction
Crosstalk between two second messenger pathways, Ca^  ^and cAMP plays an important 
role in controlling cardiac function (MacLennan & Ki'anias; Nature reviews 2003) 
(General Introduction, figure 1.13). The majority of the mass of the myocardium is 
comprised of cardiac myocytes, and alterations in cytosolic Ca^  ^ concentrations allow 
cardiac myocytes to contract and relax in dynamic fashion. The rate of relaxation and 
force of contraction (chronotropic response and inotropic response) can be influenced by 
cAMP through the phosphorylation of specific target proteins by PKA. Several channels, 
pumps and receptors involved in the Ca^  ^ fluxes within the cardiac myocytes are 
controlled through their PKA phosphoiylation status and thus are regulated by altered 
intracellular cAMP concentrations (Simmerman & Jones, 1998) (See main introduction). 
Additionally, the cyclic nucleotide cGMP has been shown to increase Ca^  ^ currents via 
L-type Ca^  ^ channels and thereby exert a chronotropic effect (Haynes et al, 1996; 
Musialek et al, 2000; Vandecasteele et al, 2001)
Various studies have shown that a range of different PDE variants are expressed within 
the cardiac myocytes. These include the PDEl, PDE2, PDE3, PDE4 and PDE5 families 
(Maurice et al, 2003). However, it is the PDE3 and PDE4 families that are believed to 
provide the major cAMP-hydrolysing phosphodiesterase activities present in heart 
(Takahashi et al, 2002; Wechsler et al, 2002; Mongillo et aï., 2004). In fact, it has been 
shown that enzymes of the PDE4 family provide over twice the cAMP-hydrolysing 
activity as the PDE3 family, with isoforms of the PDE4D sub-family providing over two 
thirds of the total PDE4 activity (Mongillo et al, 2004). Recently published studies 
utilising a fluorescence-resonance-energy-transfer (FRET) approach (Zaccolo & Pozzan, 
2002; Mongillo et al, 2004) have elegantly shown the presence of distinct pools of 
G AMP within cardiac myocytes. Additionally, the spatial confinement of different PDEs 
to discrete compartments has been shown using immunofluorescence coupled to analysis 
by confocal imaging techniques. In order to gain insight into the functional 
compartmentalîsation of particular PDEs within the cardiac myocytes, 1 chose to study 
the effect of the selective inhibition of specific cAMP-hydrolysing PDEs on two different
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cAMP targets, ERK and pliospholamban (PLB).These were chosen to probe distinct 
facets of cAMP signalling using spatially distinct target proteins as described below.
ERK can be both positively and negatively regulated by cAMP. This depends on the 
expression of various signalling networks including the presence of distinct isofbrms of 
Raf. Thus, elevated cAMP levels can lead to ERK activation through the action of B-Raf.
The mechanism through which this occurs is not unequivocally established, although 
current consensus is that it involves PKA action, possibly serving to phosphorylate Rapl, 
which then activates B-Raf (Dumaz et al, 2002; Dhillon et al, 2002; Bos, 2003). It had f
previously been suggested that activation of ERK can also occur in response to increased 
cellular cAMP level by a mechanism independent of PKA. This mechanism had been 
proposed to involve the activation of Rap-1 by cAMP-stimulated GTPase exchange 
proteins (Epac). Following the binding of Epac to Rapl, it was suggested that Rap-1 
binds to and activates B-Raf^ and also directly binds to and inactivates Raf-1 (Vossler et 
al, 1997; Schmitt & Stork, 2002). However, following the development of an Epac- 
specific cAMP analogue, these proposed mechanisms are doubted and remain 
controversial (Enseriiik et al, 2002; Bos, 2003). The use of this analogue supports the 
evidence that regulation Raf-1/B-Raf and ERK is mediated by PKA, in a manner 
independent of Rap-1. Also, the use of this analogue indicates that cAMP induced 
activation of Rapl is indeed mediated by Epac, but doubts that this activation results in 
the activation of ERK (Bos, 2003). PKA can also exert an inhibitoiy effect on ERK and 
does this in cells where Raf-1 is present and coupled to ERK activation. In such a system 
then inhibition ensues via the direct phosphorylation of Raf-1 by PKA (De Rooij et al,
1998; Kawasaki et al, 1998).
The MAPK signalling cascade is thought to play a role in regulating gene expression 
during hypertrophy (Gillespie-Brown et al, 1995). The cardiac myocyte is a terminally 
differentiated cell, however, in response to pathophysiological stress, it adapts 
hypertrophically as an initial compensatory mechanism. A number of characteristic 
modifications distinguish the hypertrophic cardiac myocyte from normal maturational 
growth (Chien et al, 1991). Following hypeitrophic stimulus, genes which are only 
normally expressed in the fetal ventricle are re-expressed such as atrial natriuretic factor
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(ANF), skeletal muscle a-actiii (SkM a-actin) and p-myosln heavy chain (P-MHC) 
(Chien et al, 1991). Hypertrophic agonists, such as phenylephirine, activate ERKs and 
MEKs (Bogoyevitch et al, 1995). It has been shown that the activation of MEK/ERK 
cascade can stimulate ANF, SkM a-actin, p-MHC and c-fos, promoter activity, and thus 
may play a role in the development of the hypertrophic phenotype in the cardiac 
myocytes (Gillespie-Brown etal, 1995).
Pliospholamban (PLB) is small transmembrane protein located on the sacroplasmic 
reticulum (SR) and is involved on the regulation of Ca^ "^  uptake into the SR. It is a 6.1 
kDa protein that forms a homopentamer, where it binds to and inhibits the sarcoplasmic 
reticulum Ca^ "* ATPase (SERCA2a). Upon phosphorylation of PLB by either PKA (Ser 
16) or CaM kinase (Thr 17), the inhibitory effect of PLB on SERCA2a is relieved and 
Ca^  ^ can now be pumped back into the SR (General introduction; figure 1.13). On a 
physiological setting, the dysfunction of PLB has been implicated in diminished 
contractility and cardiomyopathy (Hagemann & Xiao, 2002). Such studies have indicated 
that either enhanced phosphorylation of PLB or disruption of the PLB and SERCA2a 
interaction may prevent the progression of chronic heart failure (Minamisawa et al, 
1999; Haghighi et al, 2001; Sato et al, 2001; MacLennan & Kranias, 2003).
Both PLB and ERK 1/2 have quite different functional effects within cardiac myocytes, 
and their activity can both be regulated by PKA action. Briefly, the direct 
phosphoiylation of PLB by PKA allows the release of the inhibitory constraint upon 
SERCA2 and is an important factor in controlling cytosolic Ca^^ concentrations. In 
contrast to this, PKA can exert an indirect effect upon phosphorylation and activation of 
ERK 1/2 by MEK and is believed to regulate hypertrophy through the control of cardiac 
gene expression (Clerk et al, 1998). As the tethering of PKA to distinct subcellular 
compartments by AKAPs has also previously been reported within cardiac myocytes 
(Ruher, 2004), one could propose that the phosphorylation status of ERK 1/2 and PLB is 
influenced by different ‘pools’ of cAMP. Therefore, for my study, I set out to alter 
selectively both cAMP degradation, through inhibition of specific PDEs, and also to 
activate selectively different GPCRs in order to generate cAMP distinctly. In doing so, I
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hoped to either generate or manipulate functionally distinct pools of cAMP. As an output 
for these experiments I examined the effects upon ERK 1/2 and PLB phosphorylation.
Results
For each experiment within this chapter primary cultures of cardiac myocytes were 
isolated from 2-3 day old neonatal rat (Sprague Dawley) hearts.
6.1.1 cAMP phosphodiesterase activity in rat neonatal cardiac myocytes
The PDE activity of homogenates of rat neonatal cardiac myocytes was assayed (figure
6.1), and total PDE activity was found to be 102+/- 8 pmol min'^ mg protein (mean +/- SD; 
n=8) (Mongillo et al, 2004). In order to obtain a PDE activity profile, the PDE2, PDE3 
and PDE4 was determined by the use of selective PDE inhibitors, EHNA (20pM), 
cilostamide (lOpM) and rolipram (lOpM), respectively. The presence of PDEl activity 
was determined by the addition of Ca^^CaM or addition of EGTA to asses whether this 
would cause an increase in PDE activity.
This approach showed that around 90% of total PDE activity was due to PDE3 and PDE4 
activity, with around two thirds of the total being provided by PDE4 alone (figure 6.1). 
Less than 10% of total PDE activity was provided by other PDE families of which PDE2 
provides over half (data not shown), PDEl activity was negligible.
Mongillo et al also show that PDE4 provided almost 60% of total PDE activity and this 
was dissected into PDE4 sub-family specific activity. This was done by 
immunopurification using sub-family specific antisera. It was found that isoforms of the 
PDE4A and PDE4B family contributed less than 10% of total PDE4 activity, whereas 
PDE4D contributed some 60% and PDEB to some 30% (Mongillo et al, 2004)
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6.1.1.1 Selective PDE inhibition and phosphorylation of phospholamban and 
ERK1/2
Ill the following experiments, the PKA phosphorylation status of phospholamban (PLB) 
was detected by a commercially available polyclonal antibody (Upstate Technology). 
This antibody is specific to PKA phosphorylated PLB and is generated to a synthetic 
peptide (RAS*TIEMPQQAR), where the phosphorylated Ser 16 is indicated by \  The 
phosphorylation status of Erkl and Erk2 (ERK 1/2) was detected by a commercially 
available antibody (New England Biolabs). This antibody detects the phosphorylation of 
ThrI83 and TyiT85 of rat Erk2 by MAP kinase kinase (MEK) or the phosphorylation of 
Thr202 and Tyr204 of human Erkl. The use of such antibodies allowed me to study the 
direct effect of PKA upon the phosphoiylation status of PLB, and the MEK mediated 
phosphorylation status of ERK 1/2, thus the indirect possible effect of PKA upon ERKl/2.
Myocytes were incubated for 10 min with specific PDE inhibitors EHNA (20pM) for 
PDE2, cilostamide (10p,M) for PDE3 and rolipram (10p,M) for PDE4, or different 
combinations of these inhibitors (figure 6.2). The lysates were separated by 
electrophoresis and immunoblotted to detect phosphoiylation of ERK 1/2 by MEK and 
the phosphoiylation of the monomeric form of PLB by PKA. So as to provide loading 
and normalization controls, blots were stripped and re-probed with antibodies specific 
ERK2 and antibodies specific to PLB. Densitometry analysis was performed with 
Quantity One software (BioRad) and normalized using the total ERK and total PLB 
control blots. With respect to PLB, a small increase in its phosphorylation was observed 
with PDE3 inhibition (cilostamide) or PDE4 inhibition (rolipram), whilst PDE2 
inhibition (EHNA) had no effect. However, in contrast to this, a 3 to 5 fold increase in the 
PKA phosphorylation status of PLB was observed upon the addition of both PDE2 and 
PDE3 inhibitors together. Most strikingly, however, a 12 to 15 fold increase in the level 
of phosphoiylation of PLB by PKA was seen upon PDE3 and PDE4 inhibition.
With respect to phosphorylation of ERK 1/2 by MEK, selective inhibition of PDE2 
(EHNA), PDE3 (cilostamide) or PDE4 (rolipram) alone had negligible effects (figure
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6.2). However, a more pronounced effect was observed upon the inhibition of both PDE2 
and PDE3, and upon inhibition of both PDE3 and PDE4. The inhibition of both PDE2 
and PDE3 provided a 2-3 fold increase in ERK 1/2 phosphorylation by MEK, and 
inhibition of both PDE3 and PDE4 also provided a 2-3 fold increase in the level of 
phosphorylation of ERK 1/2 by MEK. In eontrast, a small increase in ERK 1/2 
phosphoiylation was observed following the inhibition of both PDE2 and PDE4.
activation, adenosine receptor activation and EP receptor activation.
It has been reported by many laboratories that stimulatory pi and P2 adrenergic receptors 
are coupled to different functional outputs in cells, although both receptors activate 
adenylyl cyclases. The p-adrenergic receptor (p-AR)-mediated cAMP signalling 
pathway is one of the best characterized signalling systems in cardiac myocytes. 
Catecholamines released by the sympathetic nervous system act through the p-ARs to 
influence the contractile state of the heart as a compensatory mechanism to preserve the 
function of the heart in response to stress. Both pi AR receptors, and p2 AR receptors 
couple to Gs leading to the activation of adenylyl cyclase. However, it has been 
suggested that different signalling properties exist between the two receptors as only the 
pathway of p i-A R  mediated activation of adenylyl cyclase can be inhibited by M2 
muscarinic cholinergic receptor activation (Aprigliano et al, 1997). Differences in 
distribution of (3 AR-receptors to the plasma membrane of cardiac myocytes have been 
shown (Rybin et al, 2000). All P2 AR receptors have been shown to be enriched in 
caveloae (flask-shaped invaginations of the plasma membrane), whereas only a fraction 
of the pi AR receptors are found in caveloae (Rybin et al, 2000).
Prostaglandin PGE2, which is released from a variety cells, can act on cardiac function 
via EPl, EP2, EP3 or EP4 receptors. It has been shown that PGE2 can increase cAMP 
levels within cardiac myocytes and thereby induce hypertrophic cell growth (Mendez & 
Lapointe, 2001). In contrast to this, adenosine has been reported to exert a contractile
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I6.1.2 Time-dependent changes in phosphorylation of ERK1/2 and 
phospholamban in response to selective pi and p2 adrenergic receptor
effect on the heart through simulation of the Gs-coupled adenosine A2a receptor, 
expressed in cardiac myocytes (Liang & Morley, 1996; Marla & Mustafa, 1998). 
However, the stimulation of the A2a receptor has been shown to exhibit a distinct 
inotropic response compared to that of the p AR receptor, suggesting that although the 
P AR and A2a receptors are both Gs-eoupled they exert distinct cellular actions, which 
may reflect actions exerted through eompartmentalised cAMP signalling (Liang & 
Morley, 1996).
As a prelude to studying the phosphorylation status of ERK 1/2 and PLB, following the 
manipulation of cAMP levels using either selective GPCR activation or selective PDE 
inliibition, I started by studying the time-dependent phosphoiylation status of both PLB 
and ERK 1/2 following pi and p2 adrenergic receptor activation, adenosine activation and 
EP receptor activation. I also determined the total PDE activity, PDE4 activity alone and 
PDE3 activity alone over the time period of such pi and P2 adrenergic receptor 
activation.
Cardiac myocytes were treated over the same time period with the selective partial pi AR 
agonist, xametrol hexifumarate (lOpM) (Tocris, USA) or with the specific p2 AR 
agonist, procaterol hydrochloride (10p.M) (Tocris, USA) in order to study the time- 
dependent phosphoiylation status of both PLB and ERK 1/2 (figure 6.3a). Lysates were 
collected at the indicated times and subjected to electrophoretic separation. The 
antibodies specific to phosphoiylated ERK 1/2 and phosphorylated PLB (described in 
section 6.1.2) were used to detect the MEK phosphoiylation status of ERK 1/2 and the 
PKA phosphorylation status of PLB. So as to provide loading controls, blots were 
stripped and reprobed with antibodies specific ERK2 and antibodies speeific to PLB.
Phosphoiylation of ERK 1/2 was seen in untreated cells and in the case of challenge of 
myocytes with either the pi AR agonist (xameterol) and the P2 AR agonist (procaterol) 
agonists, a similar small time-dependent increase in ERK 1/2 phosphoiylation was 
observed (figure 6.3a).
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PKA phosphorylated PLB species was not detected in untreated cells (figure 6.3a). 
However, following the challenge of the cardiac myocytes either the pi AR agonist 
(xameterol) or the p2 AR agonist (procaterol), PLB appeared to undergo phosphorylation 
to similar levels (figure 6.3a).
In order to assess the total PDE activity, specific PDE4 activity and the specific PDE3 
activity over the time period of treatment with the selective P receptor agonists, lysates 
were collected at the indicated time points and PDE assays performed (figure 6.3b) 
(Marchmont and Houslay, 1980). Compared to treatment of cardiac myocytes with 
xameterol, treatment with procaterol provided a larger change in PDE3 and PDE4 
activities over the same time period (figure 6.3b).
In order to study time-dependent phosphorylation status of both PLB and ERK 1/2 
following adenosine A2a receptor activation and EP receptor activation, cardiac 
myocytes were challenged over the same time period with PGE2 (lp.M) (SIGMA) and 
CGS 21680 (lOpM) (SIGMA) (figure 6.4a). Cell lysates were collected at the indicated 
time points, subjected to gel electrophoresis and immunoblotted with the antibodies 
specific to MEK phosphorylated ERK 1/2 and PKA phosphorylated PLB (figure 6.4a). To 
provide loading controls, blots were stripped and reprobed with antibodies specific ERK2 
and antibodies specific to PLB.
After 5 min of stimulation with A2a receptor agonist (CGS 21680), it is clear that 
ERK 1/2 becomes phosphorylated with a maximum phosphorylation achieved after 10 
min (figure 6.4a). However, after 20 min challenge with CGS 21680, the phosphorylation 
status of ERK 1/2 was attenuated (figure 6.4a). In contrast to this, a maximum level of 
phosphorylation of ERK 1/2 was observed at some 2 min after challenge of caidiac 
myocytes with PGE2 and this level was maintained throughout the time period (figure 
6.4a).
PKA phosphoiylation of PLB was observed in lysates from untreated cells (figure 6.4a). 
However, treatment of cardiac myocytes over the same time period with either
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CGS21680 or PGE2 resulted in a similar increase in phosphoiylation state of PLB. This 
level was maintained using challenge with either CGS 21680 or PGE2 (figure 6.4a).
The total PDE activity, specific PDE4 activity and the specific PDE3 activity was 
assessed over the time period of CGS 21680 and PGE2 treatment. The lysates were 
collected at the indicated time points and PDE assays performed (figure 6.4b) 
(Marchmont and Houslay, 1980). Treatment of cardiac myocytes over a time period with 
CGS 21680 provided a minimal change in PDE3 activity (figure 6.4b). However, an 
initial decrease in PDE4 activity, was observed upon CGS 21680 treatment, which 
rapidly increased some 10 min after initial exposure to CGS 21680 treatment. In contrast, 
treatment of cardiac myocytes over the same time period with PGE2 provided a 
noticeable increase in PDE3 activity, as well as an increase in PDE4 activity (figure 
6.5b).
6.1.3 Global cAMP levels following selective GPCR activation
Cardiac myocytes were subjected to treatment for the same time period with one of either 
procaterol, xameterol, CGS 21680 or PGE2 in order to assess changes in global levels of 
cAMP following the selective activation of (31 and p2 adrenergic receptors, adenosine 
A2a receptor and EP receptors, respectively. Lysates were collected at the indicated time 
points and cAMP assays performed (figure 6.5) (Materials and methods). The results are 
represented here as fold change over basal levels (figure 6.5) with cAMP concentration 
measured in pmol per well of myocytes. For each agonist 1-3 fold changes were observed 
at 5 min stimulation, and generally the changes in cAMP levels for treatment of each 
agonist over the same time period were veiy similar.
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i6.1.4 Differential effects of selective PDE inhibition and Gs-coupled agonist 
stimulation upon ERK1/2 and phospholamban phosphorylation status
Figure 6.2 of this chapter, shows the effect of selective PDE inhibition on f
phosphoiylation of ERK 1/2 by MEK and phosphorylation of PLB by PKA at resting 
cAMP levels (unstimulated cells). In order to manipulate distinct pools of cAMP in 
cardiac myocytes and study this effect upon the phosphorylation status of ERK 1/2 and 
PLB, I chose to alter cAMP degradation through selective PDE inhibition with activation 
of distinct GPCRs.
Cardiac myocytes were pretreated for 5 min with either the PDE2 inhibitor (EHNA) 
(20pM), PDE3 inhibitor (cilostamide) (lOpM) or the PDE4 inhibitor rolipram (lOpM) 
(figure 6.6a). Following selective PDE inhibition, cardiac myocytes were subjected to 10 
min stimulation with either the adenosine receptor agonist CGS 21680 or with PGE2 
(figure 6.6a), and 10 min stimulation with the (31 or (32 agonists (figure 6.6b). Lysates 
were harvested, subjected to gel electrophoresis and analysed by immunoblotting with the 
antibodies spécifié to MEK phosphorylated ERKl/2 and PKA phosphorylated PLB 
(figures 6.6a & 6.6b). In order to provide loading controls, blots were stripped and 
reprobed with antibodies speeific ERK2 and antibodies specific to PLB.
■Following PDE4 inhibition (rolipram) and CGS 21680 treatment, a prominent increase 
ERKl/2 phosphorylation was obseiwed. However, in contrast, a veiy small increase in 
ERKl/2 phosphorylation was observed following PDE4 inhibition and PGE2 treatment 
(figure 6.6a). The most striking increase in ERKl/2 phosphorylation was observed 
following PDE2 inhibition (EHNA) and PGE2 treatment (figure 6.6a).
111 the case of PLB, contrasting results were observed following the analysis of the PKA 
phosphorylation status. An increase in the PKA phosphorylation status of PLB was 
observed following PDE2, PDE3 or PDE4 inhibition, upon a subsequent treatment of the 
cardiac myocytes with CGS 21680 (figure 6.6a). The largest increase in the PKA 
phosphorylation status PLB was observed following PDE4 inhibition and tieatment with 
CGS 21680 (figure 6.6a). However, pretreatment of cardiac myocytes with the PDE3, %
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PDE3 or PDE4 inhibitors and subsequent PGE2 treatment resulted in minimal increases 
in PLB phosphoiylation (figure 6.6a). Interestingly, upon the direct comparison of the 
phosphorylation of PLB to the phosphorylation of ERKl/2, it appears that only PGE2 
treatment and inhibition of PDEs indicate differential regulation of the phosphoiylation 
of PLB and ERKl/2 (figure 6.6a). Most strikingly, EHNA and PGE2 treatment resulted 
in a large increase in ERKl/2 phosphoiylation, yet had no effect on PLB phosphorylation 
(figure 6.6a).
Cardiac myocytes were pretreated with PDE2, PDE3 or PDE4 inhibitors and then 
subjected to selective [31 and [32 adrenergic stimulation (procaterol and xameterol 
respectively). Lysates were separated by gel electrophoresis and the MEK 
phosphoiylation status of ERKl/2 and PKA phosphorylation status of PLB was analysed 
by immunoblot (figure 6.6b). Only small differences were observed comparing the 
phosphoiylation status of ERKl/2 following procaterol or xameterol treatments. PDE4 
inhibition (rolipram) and xameterol or procaterol treatment, however, resulted in an 
increase in the phosphorylation status of ERKl/2 through the action of these (3 adrenergic 
agonists (figure 6.6b). Intriguingly, pretreatment of myocytes with the PDE3 inhibitor 
and subsequent stimulation with either procaterol or xameterol resulted in an attenuation 
of ERKl/2 phosphoiylation compared to agonist only treatment (figure 6.6b). PDE2 
inhibition (EHNA) of cardiac myocytes and treatment with procaterol or xameterol did 
not provide any increase in the phosphoiylation of ERKl/2 compared procaterol or 
xameterol treatment alone (figure 6.6b)
Analysis of PLB phosphorylation identified some differences between treatment with 
selective pi and p2 adrenergic agonists, procaterol and xameterol, but only with prior 
PDE inhibition. High levels of phosphoiylation of PLB were observed with treatment of 
myocytes with either procaterol or xameterol. However, only upon the pre-incubation of 
cardiac myocytes with rolipram (PDE4 inhibition) and subsequent treatment with 
procaterol (p2 receptor agonist) was there an increase in PLB phosphoiylation compared 
to procaterol only (figure 6.6b).
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Pretreatment with the PDE3 inhibitor and procaterol or xameterol treatment resulted in a 
decrease in PLB phosphorylation compared to agonist only (figure 6.6b).
6.2 D iscussion
It is now widely accepted that cAMP signalling in cardiac myocytes is 
compartmentalised (Steinberg & Brunton, 2001; Kapiloff, 2003). These studies 
originated from funetional ones comparing the action of noii-selective p adrenergic 
receptor agonist isoproterenol with PGE2. More recently, studies using selective PDE 
inhibitors following Ca^”^ signalling and direct visualization of cAMP have furthered the 
notion of compartmentalisation. In these studies, I have extended this notion to look and 
see whether compartmentalisation has relevance to important PLB and ERKl/2 signalling 
proteins. Furthermore, I have extended the range of GPCRs analysed to cover not only 
the adenosine A2a receptor and EP receptors, but also to discriminate between the pi and 
p2 adrenergic receptors and undertaken an appraisal of regulation by the important 
PDE2/3/4 families.
Using this strategy 1 show that, depending on which PDE family is inhibited, or indeed 
depending on which PDE families are inhibited together, differential effects are observed 
upon phosphoiylation of ERKl/2 by MEK and phosphorylation of PLB by PKA. 1 also 
show that the generation of distinct pools by selective PDE inhibition and subsequent 
activation of different G-protein coupled receptors provide differential effects upon 
ERKl/2 phosphorylation and PLB phosphorylation.
Cardiac myocytes account for approximately 60 percent of cell mass of the heart and the 
search for novel therapeutics to treat cardiac myopathies is of much current interest. The 
PDE profiles have been characterized for cardiac tissue from several different species. I 
chose to use the rat neonatal cardiac myocytes for my study as the well understood 
PDEl, PDE2, PDE3, and PDE4 isoforms have all been reported to be expressed there 
(Kostic et al, 1997; Zhao et al, 1997; Kakkar et al, 1999; Sadhu et al, 1999; Movesian, 
2002; Wechsler et al, 2002; Baillie et al, 2001; Houslay & Adams, 2003; Maurice et al,
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2003; Mongillo et al, 2004) and for which there aie selective inhibitors (Francis et al, 
2001).
Firstly, the total PDE activity was measured and by use of the selective inhibitors 
available for the PDEl, PDE2, PDE3 and PDE4 families, eaeh family’s percentage 
contribution to total PDE activity in myocytes was calculated. PDE4 was found to 
contribute to approximately 60% of total PDE activity, PDE3 contributed to 
approximately 30%, PDEl and PDE2 combining to provide less than 10% of total PDE 
activity. These data indicate PDE4, which exclusively hydrolyses cAMP, to be the most 
abundant PDE in rat neonatal cardiac myocytes.
By use of selective PDE inhibitors, I also studied the influence of PDE2, PDE3 and 
PDE4 families upon the regulation of different pools of cAMP under basal adenylyl 
cyclase activity (figure 6.2). Treatment of cardiac myocytes with PDE2, PDE3 or PDE4 
inhibitors resulted in minimal increases in phosphorylation of ERKl/2 by MEK. 
However, inhibition of both PDE3 and PDE4 enzymes together provided a clear increase 
in ERKl/2 phosphoiylation. The inhibition of PDE2 and PDE3 together, also provided an 
increase in ERKl/2 phosphoiylation. The selective inhibition of the PDE2, PDE3 or 
PDE4 families did not increase phosphoiylation of ERKl/2 and suggests that at basal 
cAMP levels individual PDE enzyme families are not responsible for the regulation of 
the cAMP pool associated with the ERK MAP kinase cascade. However, the selected 
inhibition of combinations of the PDE families resulted in increases in ERKl/2 
phosphoiylation. PDE2 and PDE3, PDE3 and PDE4 inhibition provided increases in 
ERKl/2 phosphorylation but, interestingly, the inhibition of PDE2 and PDE4 had no 
effect on ERKl/2 phosphorylation. This suggests that the PDE3 enzymes act only in 
conceit with enzymes of the PDE2 and/or PDE4 families to regulate ERK 
phosphoiylation and activation.
Different effects of selective PDE inhibition on PLB phosphorylation by PKA were 
observed. The inhibition of the PDE3 enzymes only resulted in a small increase in PLB 
phosphorylation. PDE4 inhibition also provided an increase in phosphorylation but was 
less than that of PDE3 inhibition. Most strikingly, a 10-fold increase in phosphorylation
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of PLB was evident following the inhibition of both PDE3 and PDE4 enzymes. Again, 
such an additive effect of PDE3 and PDE4 inhibition suggest that enzymes these two 
PDE families may act in conceit to tailor the ‘pool’ of cAMP influencing the 
phosphorylation of PLB and may be involved in the regulation the uptake of Ca^ "^  into the 
SR.
The second messenger cAMP can influence, in the short term, the rate of excitation- 
contraction coupling of the heart. Several pharmacological effectors can activate Gs- 
coupled receptors on cells of the cardiovasculai" system and thus stimulate adenylyl 
cyclase (AC) to produce cAMP. In order to alter distinct ‘pools’ of cAMP, and thus to 
study the effect upon PLB phosphorylation by PKA and of ERKl/2 phosphorylation by 
MEK, I used selective PDE inhibitors and either the pi or p2 receptor selective agonists 
(xametrol and procaterol), or the adenosine A2a receptor agonist (CGS 21680) or the EP 
receptor agonist (PGE2) to activate AC.
I show, through treatment of cardiac myocytes over the same time periods, that 
xameterol, procaterol, CGS 21680 and PGE2 agonists provided increases in the PKA 
phosphoiylation of PLB and MEK phosphoiylation of ERKl/2 (figures 6.2-6.5). Also, I 
show that treatment of cardiac myocytes with the same agonists over the same time 
periods resulted in similar increases (several fold) in global cAMP levels. Transient 
increases in the PDE3 and PDE4 activity are also observed following challenge of 
myocytes over the same time period with each of the agonists. These data indicate that 
selective activation of pi and P2 adrenergic receptors, adenosine A2a receptor and EP 
reeeptors each stimulated the production of cAMP which results in the PKA 
phosphoiylation of PLB and MEK phosphoiylation of ERKl/2.
Distinct pools of cAMP in the cardiac myocytes were manipulated by selective PDE 
inhibition and activation of different GPCRs (figures 6.6a and figures 6.6b). The most 
striking differences in the phosphorylation of PLB and phosphorylation of ERKl/2 were 
observed following specific PDE inhibition and then subsequent treatment of cardiac
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myocytes with either the A2a receptor agonist (CGS 21680) or the EP reeeptors agonist 
(PGE2).
Pretreatment with the PDE4 inhibitor (rolipram) and then treatment of cardiac myocytes 
with CGS 21680, provided a pronounced increase in phosphorylation of ERKl/2 by 
MEK and phosphoiylation of PLB by PKA (figure 6.6a). Whereas, PDE2 or PDE4 
inhibition and treatment with CG 21680 had a small effect on PLB phosphorylation but 
had no effect on ERKl/2 phosphorylation (figure 6.6a). However, in contrast, only 
pretreatment of cardiac myocytes with the PDE2 inhibitor and subsequent treatment with 
PGE2 resulted in an increase in ERKl/2 phosphorylation. Interestingly, PDE2 inhibition 
and PGE2 treatment did not provide an increase in PLB phosphorylation (figure 6.6b). 
Pretreatment with PDE3 or PDE4 inhibitors and subsequent PGE2 challenge did not 
provide an increase in ERK 1/2 phosphorylation although small increases in PLB 
phosphorylation were observed (figure 6.6b).
To gain functional insight into the compartmentalisation of PDEs within cardiac 
myocytes, I manipulated levels of cAMP within distinct ‘pools’ by using selective PDE 
inhibitors to alter cAMP degradation and activated different GPCRs to stimulate adenylyl 
cyclase. I chose to study the PKA phosphoiylation of PLB and MEK phosphorylation of 
ERKl/2 (indirectly activated by PKA) as outputs. The differences in phosphorylation of 
PLB and phosphorylation of ERKl/2 I observed following such manipulation of cAMP 
with PDE inhibitors alone, or with PDE inhibition and selected GPCR activation, 
provides further evidence of PDE compartmentalisation within cardiac myocytes.
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Figure 6.1 cAMP PDE activity in rat neonatal cardiac myocytes. Graph is taken from 
published data (Mongillo et al., 2004). Data are means +/- SD of 6 separate experiments from 
different cardiac myocyte preparations. Lysates from neonatal myocytes (1-3 day old) were 
assayed for PDE activity. Lysates expressed a level of cAMP PDE activity of 102 +/- 8 pmol 
min'^mg protein L PDE3 activity was calculated from the fraction of total PDE activity inhibited 
by cilostamide (1 OpM) and PDE4 activity was calculated from the fraction inhibited by rolipram 
(lOpM).
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Figure 6.2 Effect of selective PDE inhibition on ERK and phospholamban 
phosphorylation. See next page for full figure legend.
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Figure 6.2 Effect of selective PDE Inhibition on ERK and phospholamban 
phosphorylation. Neonatal cardiac myocytes were incubated for 10 min with the indicated 
PDE inhibitors; ciloastamide (IpM), rolipram (lOpM), EHNA (30pM). Lysates were separated 
by electrophoresis. (A) The phosphorylation of ERK1/ERK2 and phospholamban was analysed 
by western blotting. (B) Densitometry analysis of western blots was performed with Quantity 
One software. Data was normalised by the ‘total’ ERK and ‘total’ phospholamban bands. The 
effect of the inhibitors are compared to basal (untreated cells). N=3 +/- S.E.
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Figure 6.3a Determination of ERK and phospholamban phosphorylation following p., 
and P2 agonist challenge. Neonatal myocytes were incubated with Xameterol hemifumarate 
(10|iM) (a Pi selective partial agonist) and Procaterol hydrochloride (10pM) (a specific Pg 
agonist) for the indicated time points. Lysates were separated by electrophoresis. The 
phosphorylation of ERK1/ERK2 and phospholamban was analysed by western blotting. Blots 
represent typical time courses.
159
re(/)re.ao>O)cre.co0O)Bc020O.
200
150
100'
50
0 • 0
(A) Total PDE activity
10 15 20
(B) PDE4 activity
300
250
200
150
100
50
(C) PDE3 activity
10 15 20
Procaterol
Xameterol
Time (min)
Figure 6.3b Determination of total PDE activity, PDE4 and PDE3 activity following p, and 
Pz agonist challenge. Neonatal cardiac myocytes were harvested at the indicated time points 
and whole cell lysates were analysed for PDE activity. PDE3 activity was calculated from the 
fraction of total PDE activity inhibited by cilostamide (lOpM) and PDE4 activity was calculated 
from the fraction inhibited by rolipram (lOpM). N=3 +/- S.E
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Figure 6.4a Determination of ERK and phospholamban phosphorylation following 
adenosine A2a receptor and EP receptor activation. Neonatal myocytes were Incubated 
with CGS 21680 (lOpM) (selective A2a receptor agonist) and PGE2 (IpM) (EP receptor 
agonist) for the indicated time points. Lysates were separated by electrophoresis. The 
phosphorylation of ERK1/ERK2 and phospholamban was analysed by western blotting. Blots 
represent a typical time course which were performed at least three times.
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Figure 6.4b Determination of total PDE activity, PDE4 and PDE3 activity adenosine A2a 
receptor and EP receptor activation. Neonatal cardiac myocytes were harvested at the 
indicated time points and whole cell lysates were analysed for PDE activity. PDE3 activity w as 
calculated from the fraction of total PDE activity inhibited by cilostamide (lOpM) and PDE4 
activity was calculated from the fraction inhibited by rolipram (lOpM). The activity following 
agonist challenge is compared to basal (untreated cells) and is represented here as  a 
percentage change. N=3 +/- S.E
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Figure 6.5 Analysis of cAMP levels following different Gs-coupled receptor activation.
Neonatal cardiac myocytes were incubated with the following agonists: Procaterol (10|aM), 
Xameterol (lO^IVI), PGE2 (1|.iM) and CGS 21680 (lO^iM) for the indicated time points. cAMP 
levels per well (6 well plate) were m easured and the data represented as  fold change basal. 
N=3 +/-S.E.
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Figure 6.6a ERK and phospholamban phosphorylation following selective PDE 
inhibition and adenosine A2a receptor activation or EP receptor activation. Neonatal 
myocytes were pretreated with the specific PDE inhibitors and incubated with CGS 21680 
(lOpM) and PGE2 (IpM) for the indicated time points. Lysates were separated by 
electrophoresis. The phosphorylation of ERK1/ERK2 and phospholamban was analysed by 
western blotting, data n=2
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Figure 6.6b ERK and phospholamban phosphorylation following selective PDE 
inhibition and p, or p^  adrenergic receptor activation. Neonatal myocytes were pretreated 
with the specific PDE inhibitors and incubated with procaterol (lOpM) or xameterol (10pM) for 
the indicated time points. Lysates were separated by electrophoresis. The phosphorylation of 
ERK1/ERK2 and phospholamban was analysed by western blotting. Data n=2
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Chapter 7
General discussion and future directions
1 6 6
Discussion
The phosphorylation of cellular proteins by protein kinases produces a conformational #
change which can affect the protein's function. Within the cAMP signalling system, 
cAMP is detected by protein kinase A (PKA) which serves to phosphoiylate, and alter the 
function of a wide array of proteins.
It had been previously established the long isofbrm PDE4D3 is a target for 
phosphorylation and activation by PKA, and this rapid activation has been postulated to 
act as means of desensitization to the cellular cAMP response, (Sette et a l, 1994; Alvarez 
et a l, 1995; Sette and Conti, 1996; Hoffman et al., 1998). Biochemical analysis of 
PDE4D3 has shown that the Ser 13 within the unique N-terminal and Ser 54 site within J
the UCRl are phosphorylated by PKA (Sette and Conti, 1996; Hoffman et al., 1998).
However, mutational studies have also shown that only PKA phosphorylation of Ser 54 is 
required for activation (Sette and Conti, 1996), with the role of Ser 13 unknown. Also it 
has been reported that the PKA phosphorylation of PDE4D3 results in an altered 
electrophoretic mobility on SDS-PAGE (Sette and Conti, 1996; Hoffman et al., 1998).
The reason for this mobility ‘shift', which has been suggested to indicate the activation of 
this enzyme, has yet to be explained (Sette and Conti, 1996; Oki et al, 1998). For the first 
time antiserum has been developed to the two specific PKA sites in PDE4D3, (namely 
Ser 54 and Ser 13), providing the means to study the PKA phosphorylation of PDE4D3 at 
these two sites in response to cell activation.
In chapter 3, I show, subsequent to activation of adenylyl cyclase, a time-dependent 
decrease in the mobility of PDE4D3. At 1 min of IBMX and forskolin challenge both a 
low mobility and high mobility species existed and for the remainder of the time points, 
the majority of PDE4D3 shifts to a low mobility species. Within the same time course, 
this ‘band shift’ was paralleled by a similar one detected using the antisera specific for 
PKA phosphorylated Ser 54 (PS54-UCR1) within UCRl. At the 1 min time point, PS54- 
UCRl detected a ‘band-shiff which is akin to both de-phosphorylated and
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phosphoiylated PDE4D3. However, the antiserum specific for PKA phosphoiylated Ser 
13 (PS13-4D3), within the unique N-terminal, only detected a single low mobility species 
at all time points. A time-dependent increase in phosphorylation was also observed with 
PS13-UCR1. This suggests that in COSl cells the PKA phosphoiylation of both sites are 
required for the mobility shift and that the phosphorylation of Ser 54 may even precede 
that of Ser 13. The notion that the phosphoiylation of both sites is required for the ‘band- 
shiff is further suggested by mutation of either of these sites to alanine preventing the 
PKA mediated change in mobility of long-form PD4D3 (MacKenzie et aï, 2002). The 
mobility shift observed indicates a conformational change. This is extremely interesting 
as a recent paper (Michel et al, 2004) suggests a function of this conformational change. 
This paper suggests that PKA phosphoiylation of Ser 13 within the N-terminal of 
PDE4D3 facilitates the interaction of PDE4D3 with inAKAP. They propose a model 
where under resting conditions PDE4D3 binds to inAKAP and following hormonal 
stimulation of the cell, mAKAP-bound PKA is activated. The catalytic subunits of PKA 
phosphoiylate local substrates including the mAKAP bound PDE4D3. The 
phosphorylation of Ser 13 increases the affinity of PDE4D3 for inAKAP and 
phosphorylation or Ser 54 causes a 2-fold increase in the activity of PDE4D3, resulting in 
hydrolysis of cAMP. The signalling system is reset with the return to basal cAMP levels. 
As my data indicates that Ser 54 is phosphorylated before Ser 13, it could be possible that 
PDE4D3 is phosphorylated and activated in the cytosol and is then recruited to inAKAP 
to lower local cAMP levels. Thus, I would like to have studied the recruitment of 
PDE4D3 to inAKAP in whole cells.
Three other PDE4 gene families (A, B and C) generate a range of long-form PDE4s and 
all long-forms contain a PKA consensus sequence Arg-Arg-Glu-Ser-Phe. I show that 
PKA can phosphoiylate the cognate target serine within the UCRl of long-form PDE4s 
from each sub-family. In COSl cells the PS54-UCR1 antibody detected the PKA 
phosphorylation of transiently transfected PDE4A8, PDE4B1, PDE4C2 and PDE4D5 
following the activation of adenylyl cyclase. For each long-form, this phosphoiylation 
was ablated using the PKA inhibitor H89 and by mutating the putative target serine to 
alanine. This analysis may sei-ve as a model of the phosphorylation and activation of
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endogenous PDE4s where PKA is activated in response to localised increases in cAMP. 
As it is now known that PKA can phosphorylate and activate long forms from each of the 
four subfamilies, and different PDE4 isoforms can be targeted to specific subcellular 
regions, one could suggest that this PKA-mediated activation could serve to control 
distinct pools of cAMP. In cardiac myocytes, the recruitment of PDE4D3 and PDE4D5 
by p-arrestin (Perry et al, 2002, Baillie et al, 2003) to the p2-adrenergic receptor 
upon isoproterenol stimulation provides a source of cAMP degradation directly to the site 
of cAMP generation. The interaction of PDE4D3 with mAKAP (Kapiloff et al, 1999; 
Dodge et al, 2001; Michel et al, 2004) allows a negative feedback loop whereby local 
increases in cAMP result in activation of PKA, phosphorylation of the local PKA 
substrates, including phosphoiylation and activation of PDE4D3, which in turn degrades 
cAMP and allows a return to resting cAMP levels. It is also possible that other long PDE 
isoforms also serve to function as a means of desensitisation to local increases in cAMP. 
As AKAPs play a pivotal role in the coinpartmentalisation of signalling modules, and 
PDE4D3 has already been reported to interact with several AKAPs, one could assume 
that other PDE4s interact with such signalling complexes to provide control of local 
cAMP pools.
Over the decades, researchers in the field of cellular signalling have been posed with the 
question of ‘how do diffusible second messengers such as cAMP achieve specificity of 
their action?’ (Brunton, 2003).Growing evidence of compartmentalisation seems to 
address this question. An early series of experiments performed cardiac myocytes led the 
hypothesis that (i) not all cAMP gains access to all PKA, (ii) not all PKA has access to all 
possible substrates and (iii) not all cAMP has access to all cellular PDEs (Steinberg & 
Brunton, 2001; Brunton, 2003). These experiments involved stimulating different GPCRs 
on cardiac myocytes with two different agonists, PGEl and isoproterenol. Both agonists 
resulted in an activation of adenylyl cyclase (AC) and subsequent production of cAMP. 
However the down-stream effects of PKA activation was quite different for each agonist. 
Isoproterenol treatment resulted in phosphorylation of troponin I and proteins involved in 
glycogen metabolism, whereas PGEl treatment resulted in cAMP accumulation and PKA 
activation, but phosphoiylation of troponin I or glycogen metabolism proteins was not
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observed (Brunton et al, 1981). The addition of PDE inhibitors and PGEl allowed the 
PKA-dependent phosphorylation of such proteins. These basic observations paved the 
way for the postulate of compartmentalisation of cAMP signalling molecules. The 
structural basis for sub-cellular compartmentalisation underpinning cAMP signalling in 
cells is only, now, beginning to be understood.
Recently, it has been shown that GPCRs, G-proteins and AC may be localized to specific 
membrane compartments by the enrichment in or exclusion Rom caveolae (invaginations 
of the plasma membranes classed as a subset of lipid rafts) (Dodge et al, 2001; Ostrom et 
al 2004). PKA can be confined to distinct subcellular compartments, along with 
phosphatases, different substrates of PKA, and other proteins, by association with A- 
kinase anchoring proteins (AKAPs) (Scott Review, 2003). The spatially distinct 
localisation of PDEs, in particular PDE4s, has been show to be achieved through their 
interaction with a variety of subcellular structures. For example, PDE4 isoforms can 
interact with phosphatidic acid, the imniunophillin XAP2, receptor associated with C 
kinase 1 (RACKl), (3-arrestin, AKAPs, myomegalin and also SRC family tyrosine 
kinases through their SH3 domains (Periy et al 2002; Baillie et al 2003; Houslay 
Review, 2003; Bolger et al, 2003).
The steady state levels of cAMP that is reached in resting cells will depend not only on 
AC activity but also on PDE activity. As AC is localised with its active site at the cytosol 
surface of the plasma membrane, in some cases to different compartments of the plasma 
membrane, PDEs will have the key role in generating and tailoring intracellular cAMP 
gradients from the point source(s) of cAMP produced by AC. These gradients can then be 
expected to control selectively anchored Epac and PKA activity within the cell. We 
hypothesized that in resting cells, PDE4s anchored indirectly or directly to AKAPs will 
be poised to control cAMP levels and thus exert effects on AKAP-anchored PKA. In 
order to investigate this possibility, I needed a read out specific for PDE4 isoform action 
and for PKA activation. What better target to choose that long PDE4 isoforms, whose 
UCRl can be phosphoiylated by PKA and whose activity one would surmise could 
regulate cAMP gradients. In order to specifically gauge phosphoiylation at this site by
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PKA I took advantage of the PS54-UCR1 antibody which detects PKA phosphorylation 
of all long PDE4 isoforms, hence providing an immediate readout for the action of PKA 
on a specific PDE.
Secondly, we developed an approach to render PDE4s catalytically inactive by a single 
point mutation, which allowed us to develop a dominant negative strategy. We surmised 
that such a discrete mutation should have little or no effect on the gross structure of the 
PDE4. Thus the chronic overexpression of the inactive PDE4s can be expected to 
displace and thereby replace, the cognate, active endogenous PDE4s. In doing this, there 
now would be no active anchored PDE4 to constrain PKA activity and the recombinant 
inactive PDE4 would itself provide a readout of this by offering a localised specific 
substrate to be phosphoiylated by the appropriately active PKA. This approach allowed 
me to identify particular PDE4 isoforms as being specifically involved in constraining the 
activity of a distinct pool of PKA. Cells have been suggested as being either Tow’ or 
‘high’ cycling conditions for cAMP signalling (Houslay & Milligan, 1997). This reflects 
cells that vary in their basal levels for adenylyl cyclase activity. Thus, low cycling cells 
have low basal AC activity, whereupon challenge with PDE inhibitors has little effect on 
global cAMP levels, whilst these are elevated upon GPCR stimulation of AC. In contrast 
to this, high cycling cells have active cAMP generation, with levels kept low by active 
PDE activity. In these cells even at basal conditions PDE inhibitors cause a profound 
increase in cAMP levels. In both instances, however, little is known about what regulates 
basal cAMP levels compared to GPCR-stimulated cAMP levels. This is despite the fact 
that in most cells there is a measurable PKA activity that, perhaps, reflects 
compartmentalised activation. Here then I set out to evaluate the ability of PKA to 
phosphorylate catalytically inactive/dominant negative PDE4 isoforms under basal and 
stimulated conditions to obtain an insight into the possible importance of various PDE4 
isoforms to these distinet scenarios and thus identify selective actions.
My study, utilising a range of catalytically inactive PDE4 isoforms, shows that in the 
model COSl cell line then the dominant negative PDE4C2 and PDE4D3 are able to be 
phosphoiylated by PKA by basal adenylyl cyclase activity. This suggests that out of the
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four different PDE4 isoforms evaluated here, namely PDE4A4, PDE4A10, PDE4C2 and 
PDE4D3, only PDE4C2 and PDE4D3 are held in close proximity to and regulate discrete 
sub-populations of PKA under basal levels of cAMP generation. Interestingly, it has been 
suggested that at least in some cells the actions of PDE3 and PDE4 may synergise with
Éeach other (Dousa, 1999). In order to explore this I decide to evaluate whether the PDE3 
selective inhibitor, cilostamide could alter the phosphorylation of these two isoforms 
under basal conditions. In doing this I found out that the selective PDE3 inhibitor 
cilostamide increased the PKA phosphorylation of inactive PDE4C2 but not of inactive 
PDE4D3. This suggests that under conditions of basal cAMP production the actions of 
PDE4C2 and PDE3 may act synergistically on the same cAMP pool, but this is different 
from the pool regulated by PDE4D3. Interestingly, whilst addition of the selective PDE4 
inhibitor had potentiating effect on the phosphoiylation status of PDE4C2, it selectively 
increased the phosphorylation status of PDE4D3. This suggests that PDE4D3 controls a 
pool of cAMP that is also regulated by an endogenous PDE4 species in COSl cells that is 
not PDE4C2. Thus, both PDE4C2 and PDE4D3 appear to be anchored close to PKA that 
is able to access cAMP in resting cells. Thereby, the activity of these PDE4 species must 
be crueial in controlling the associated PKA activity. It would seem that these two 
isoforms control distinct pools, one of which is shared with PDE3 and another shared 
with a different PDE4 isoform in these cells.
Next, I set out to investigate whether the activation of different Gs-coupled receptors 
could selectively perturb the phosphoiylation status of individual catalytically inactive 
PDE4 isoforms. The two different Gs coupled agonists were used here, namely 
isoproterenol and PGE2 were selected, as it had previously reported that these agonists 
can activate AC and PKA but generate different cellular responses at least in cardiac 
myocytes (Steinberg & Brunton, 2001; Brunton, 2003). Interestingly, I found that the 
PKA phosphorylation status of inactive PDE4A4 and PDE4B1 was quite different 
depending agonist stimulation. In doing this I found that PGE2 and isoproterenol had a 
similar effect on PDE4A4 phosphorylation status, on isoproterenol stimulation, there 
resulted an increased phosphorylation of PDE4B1 that was not seen with PGE2. This data
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indicates that tliese PDE4s are able to sample different pools of cAMP conti’olled by 
PGE2 and isoproterenol stimulation
As discussed previously, the PDE4D3 isoform has been shown to be capable of 
interacting with the AKAP, mAKAP in cardiac myocytes where it can regulate the 
activity of PKA (Dodge et al, 2001, Tasken et al, 2001). As I observed PKA 
phosphorylation of both inactive PDE4D3 and inactive PDE4C2 at basal cAMP levels, 1 
hypothesised that this may be due to the close proximity of PKA. Thus, I decided to 
investigate the possibility of an AKAP involvement in the PKA phosphorylation and 
control of PDE4C2 activity. To do this I utilised Ht31, an established tool that has been 
used to disrupt PKA-AKAP anchoring specifically. Thus, using this I set out to tiy and 
disrupt the PKA phosphorylation of inactive PDE4C2. Using this, I found that the co­
expression of Ht31 and inactive PDE4C2 did indeed reduce the ability of PKA to 
phosphoiylate inactive PDE4C2 species at basal cAMP levels. This suggests that 
PDE4C2 is either anchored to an AKAP complex, or is in close proximity to a PKA- 
AKAP complex able to regulate this PKA isoform or is able to reversibly and specifically 
interact with an active AKAP bound PKA fraction. I also show that, by utilising a 
selective RI-PKA agonist and a selective RII-PKA agonist, that the RI-PKA form is the 
predominant form responsible for the PKA phosphoiylation of PDE4C2.
Following the Ht31 experiments, I investigated the possibility of an actual interaction of 
the PDE4C2 isoform with a PKA-AKAP complex. Immunoprecipitates of PDE4C2 were 
sent to two separate AKAP laboratories (Klussmann, FMP, Berlin. & Tasken, Oslo) for 
overlay analysis. Both RI and RH overlay assays were performed, and these tentatively 
identified a putative AKAP of about 250 kD co-immunoprecipitated with PDE4C2. I 
have not shown the overlay results in this chapter as these are preliminary data done by 
others and the results are not clear. Nevertheless, they provide initial promising evidence 
of a possible PDE4C2-PKA-AKAP complex. To date, the only PDE4 isoform to be 
shown to interact with an AKAP is long form PDE4D3. The PDE4C2 isofbrm is also a 
long form which has shown to be phosphorylated and activated by PKA (MacKenzie et 
al, 2001), thereby an interaction with an AKAP would allow another means of specific
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targeting and degradation of local cAMP. In order to clarify such a complex, 
immunoprécipitations of PDE4C2 should be repeated and the presence of any AKAPs 
should be clarified by overlay assay. If an AKAP of a defined size is present, one could 
first see if this AKAP is a known AKAP by western blotting with commercially available 
antibodies. The co-immunoprecipitation of an AKAP with PDE4C2 could be fiirther 
clarified by SDS PAGE and analysis of any bands present in the gel by mass 
spectrometry.
If I was able to pursue this project then I would have liked to identify the specific type of 
PKA isofbrm which serves to phosphorylate PDE4C2 in these cells. My initial data 
suggests that an RI isofbrm was responsible, and I would plan to further investigate this 
further using an approach involving small interfering RNA (siRNA) to knock down 
specifically and selectively each PKA isofbrm. As veiy few RI binding AKAPs have 
been characterized, the identification of a PDE4C2/RI-PKA-AKAP cellular complex 
would potentially be veiy exciting. The identification of such a complex would show for 
the first time an AKAP-PDE4 interaction involving a PDE4 isofbrm other than PDE4D3, 
it also would show for the first time a RI-PKA-AKAP to bind a PDE4.
As a means to study the compartmentalisation of cAMP signalling and regulation of gene 
expression, I overexpressed selected catalytically inactive PDE4 isoforms in HEK293 
cells, and subsequent microarray analysis to determine changes in levels of the transcripts 
of a wide range of genes. I hypothesised that, according to the dominant negative strategy 
discussed earlier, if I overexpressed an inactive PDE4 it would replace its endogenous 
counterpart. This displacement of an anchored pool of active endogenous PDE4 by the 
cognate inactive recombinant PDE4 might, in certain situations, result in increases in 
levels of distinct pools of cAMP and thus subsequent activation of specific sub­
populations of PKA. In phosphorylating sets of anchored target proteins this might lead 
to changes in the expression of distinct subsets of genes.
A spatially distinct elevation of cAMP and/or PKA activation might be expected to alter 
gene expression in a number of different ways. PKA can exert long term effects on 
cellular functioning by altering the functions of a variety of nuclear proteins including
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%various transcription factors, nuclear hormone receptors, transcriptional
Iactivators/repressors and chromatin-associated proteins (Shabb, 2001). The most 
common promoter element to exert transcriptional effects via cAMP is the cAMP- 
responsive element CRE. Nevertheless, this would be expected to give a single output 
irrespective of the source of PKA acting to phosphorylate CREB, unless the 
compartmentalised signal exerted effects on other signalling factors that impinged on 
CRE-bearing promoters such as to alter their functioning. NF-kB is another 
transcriptional factor regulated by PKA phosphoiylation (Shabb, 2001). In its inactive 
state, NF-kB is tethered to the inhibitor protein I-icB in the cystosol. I-kB also binds to 
the C subunit of PKA. Activation of NF-kB is triggered when I-kB is targeted for 
degradation by in a phosphorylation-dependent manner by the ubiquitin-26S proteosome 
pathway. NF-kB is then free to translocate to the nucleus and its transcriptional activity is |
Stimulated by PKA phosphorylation by the PKA released from I-KB. PKA can also 
indirectly exert effects upon transcriptional regulation via activation of the MAP kinase 
cascade. PKA-dependent activation of ERK 1/2 can occur via B-Raf. Once ERK is 
activated it phosphorylates RSK and both translocate to the nucleus where they activate 
CREB (Wang et al, 2003). Also, it is possible that PKA may indirectly exert effects 
upon ti’anscription via the phosphorylation of other, as yet, unidentified signalling 
protein(s). In a recent review of physiological substrates of PKA (Shabb, 2001), it was 
shown that since the discovery of PKA in the 70’s, the list of identified PKA substrates 
has quadrupled over the last decade. It is highly likely that many more PKA targets are 
yet to be identified. Recently, Epacs have been discovered as new routes through which 
cAMP can exert effects on cells. However, the precise way in which Epacs signal into 
cells is not clear and, its effects on gene expression have yet to be elucidated.
Furthermore, since the discoveiy of the Epac specific activator, 8-pCPT-2’-(7-Me-cAMP, 
it has now been postulated that not all PKA-independent effects of cAMP can be 
attributed to Epac but may involve as yet unknown additional cAMP signalling entities.
In the friture, this might lead to the discoveiy of further cAMP targets with cAMP 
binding domains not similar to that of Epac and PKA (Bos, 2003). Thus, there are a 
number of distinct way through which cAMP may be able to alter gene expression in 
cells via both direct and indirect actions.
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My study utilising the catalytically inactive PDE4 species as a form of manipulating 
different pools of cAMP does indeed provide data indicating differential gene expression. 
This suggests that different pools of cAMP controlled by specific PDE4 isoforms may 
exert differential effects upon transcriptional regulation. However, it must be taken to 
account that the overexpression of the inactive PDE4 species may bind aberrantly to 
other proteins, allowing non-physiological effects. Additionally, as the half lives of 
mRNA differ, the efficacy and efficiency of translation and other post-translational 
events affecting mRNA also differs, one cannot simply assume that the mRNA levels 
correlates directly to protein levels. Thus, the next step of ray study would have been to 
investigate whether the implied changes in mRNA expressions levels obsei*ved here 
caused changes at the level of protein expression. I would also like to confirm the 
indicated changes in transcript levels using Northern blotting and RT-PCR.
As mentioned at the start of this discussion, a set of simple experiments involving 
treatment of cardiac myocytes with different Gs-coupled agonists and the subsequent 
read-out of PKA action, led to the postulate that compartmentalisation of signalling 
molecules exists within a physiologically relevant cell model. Recently data published 
by Zaccolo et al, has elegantly shown the spatial confinement of PDEs and the presence 
of distinct pools of cAMP within cardiac myocytes (Zaccolo & Pozzan, 2002; Mongillo 
et al., 2004). Therefore a growing body of convincing evidence is accruing to show that 
cardiac myocytes, which comprise the majority of the mass of the myocardium, are 
highly compartmentalised cells as regards to cAMP signalling.
To gain functional insight into the compartmentalisation of PDEs within cardiac 
myocytes, I decide to perform a set of experiments where I manipulated levels of distinct 
‘pools’ of cAMP. I did this by using selective PDE inhibitors to alter cAMP degradation 
and then activated different GPCRs to stimulate adenylyl cyclase. In order to probe 
distinct facets of cAMP signalling, I chose to study the PKA phosphoiylation of PLB and 
the MEK phosphorylation of ERK 1/2 (indirectly activated by PKA) as outputs. In short, I 
observed differences in phosphorylation of PLB and phosphorylation of ERK 1/2 
following such manipulation of cAMP with PDE inhibitors alone, or with PDE inhibition
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and selected GPCR activation. My data provides further evidence of PDE 
compartmentalisation within cardiac myocytes. If time had prevailed, I would have liked 
to have used catalytically inactive PDE4 species, or siRNA to observe the functional 
effects of specific PDE4 isoforms upon the regulation of PKA phosphorylation of 
phospholamban. The PKA phosphorylation of phospholamban (PLB) is an important 
mediator of Ca^  ^uptake into the sarcoplasmic reticulum (SR), and it is involved in the 
regulation of relaxation and contraction (MacLeniia & Kranias, 2003). This small protein 
binds to and inhibits the sarcoplasmic reticulum Ca^  ^ATPase (SERCA2A). Following 
hormonal stimulation of the p-adrenergic receptors, PLB has been shown to be 
phosphoiylated by PKA. A conformational change then ensues, and the inhibition of 
SERCA2A is relieved, allowing an increase of conductance of Ca^  ^into the SR and it is 
the removal of Ca^  ^ from the cytosol which triggers relaxation. With respect to 
contraction and relaxation, signalling events in cardiac myocytes in response to hormonal 
stimulation must occur on a millisecond timescale. Several channels and pumps involved 
in the regulation of the cytosolic Ca^  ^ transients can be phosphorylated by PKA, also 
contractile proteins such as Troponin I have been shown to be substrates of PKA. 
Therefore, with such a short timescale, one could propose that pre-programmed 
signalling modules may serve to allow a distinct and rapid response to the elevation of 
cAMP. A specifically anchored PDE, in the case of PDE-AKAP interaction, may provide 
a means of cAMP degradation direct to the site of PKA action. As PLB plays such an 
important role in the regulation of relaxation, it would be veiy exciting to show that 
PDE(s) are involved in the regulation of the phosphorylation status of PLB.
Initially, I studied the PKA phosphorylation of the two PKA sites found with PDE4D3 
and found that the phosphorylation of the Ser 54 (responsible for activation) precedes that 
of Ser 13. Then, I show by using the using the antisera specific for PKA phosphorylated 
UCRl (PS54-UCR1) that long form PDE4s from each subfamily are phosphoiylated by 
PKA in vivo. Overall, I hoped to show by a novel approach, the compartmentalisation of 
cAMP phosphodiesterases within a cellular system. I hypothesised that different 
catalytically inactive long form PDE4s would alter distinct cAMP ‘pools’ by displacing 
their endogenous active counterparts. By detecting the PKA phosphorylation of the
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inactive PDE4 through use of the novel PS54-UCR1 antibody, I employed the 
catalytically inactive PDE4 itself as a readout of PKA activity. In doing so, I found that 
different PDE4s are capable of sampling different pools of cAMP generated by different 
Gs-coupled agonists. Also, my data indicates that PDE4D3 and PDE4C2 may be held in 
close proximity to, and play a role in the regulation of discrete sub-populations of PKA 
under basal levels of cAMP. Furthermore, 1 studied the effect of altering the 
concentration of discrete compartments of cAMP on gene expression by overexpressing 
catalytically inactive PDE4s in HEK293 cells and performing microarray analysis. This 
study demonstrated the influence of specific PDE4 isoforms on gene regulation 
controlled by compaitmentalised cAMP signalling. Finally, on a more physiological 
scale, I chose to study the function of compartmentalised PDEs within cardiac myocytes. 
In doing so, I selected two different PKA targets as outputs (PLB and ERK 1/2) and show 
that manipulation of cAMP levels with PDE inhibitors alone, or with PDE inhibitors and 
selected GPCR activation, that the PKA status of PLB and ERK 1/2 are differentially 
controlled by specific PDE families.
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PDE
v a r i a n t PRIMER NAME PRIMER SEQUENCES (5’ - 3’)
FRAGN'IENT 
LENG'I'11 
(b,))
4A
4A(3)F
4A(2&3)R
ATA TCA ATG GCC CAG ATA CCG T 
GCA TGC TCT GAA ACA GAC AGG
338
4A4B
4A4B(4&5)F
4A4B(5)R
CGG AAA GGA GCC TGT CTC TG 
AGT GCC ATG GAA GGA CGA GG 257
4AI0
4A10(5&6)F
4AI0(5)R
AGA TCT GTC AGC TTC GAG GCA G 
AGT GAG AAG TTG CTA CGG ACG C
281
2EL
2EL(3)F
2EL(3)R
GTC CAA GCA CAT GAC CCT CCT 
CCG AGC CTG TAC CTG AGA CTT
301
4B
4B(4)F
4B(2&4)R
TCT GAA GGA CCT GAG AAG GAG 
ACA CAG GTT GGC AGA CAA AGG
546
4BÎ
4B1(4)F
4B1(3&4)R
AAA GCA GGA GTG TGA TGA CGG 
CGT TGT CAA AGG CAG TGT GGT
236
4B2
4B2(2)F
4B2(2)R
CCT TGA GAT GGC AAA GCA CTC 
AAT CAC AGT GGT GCT CTG CCT
264
4B3
4B3(3)F
4B3(3)R
AAA AGC ATT CGG CAG CGT C 
TCG ACA TCG CCT TTG GTG A
214
4C
4CF
4CR
ATG GAT GGT AAA GCC CTT TGG CTC TTG G 
GTC TCC CTA AAT GGG TGG GAA AGT GAA G
95
4DF
40R
CCC TTG ACT GTT ATC ATG CAC ACC 
GAT CTA CAT CAT GTA TTG CAC TGG C 262
401
401(3)F
401(2&3)R
CTT TCC CTG TCT CTT CGC AGA 
GTG AGC TCC CGA TTA AGC ATC
163
■ ■■ 401/2  : .
401/2(2)F
401/2(2&3)R
ATA TGA AGG AGC AGC CCT CAT G 
CCA GAC CGA CTC ATT TCA GAG A 221 &307
403
403(5)F  
403 (5)R
GCG AAC ATG ATG CAC GTG AA 
TGG CCA AGA CCT GAG CAA AT 292
4 04
404(6)F
4D4(5&6)R
AGA AAT CCA GGA TGT CCT GGC 
TGC TAG GTG CTC GAT CTT GCA 347
405
405(6)F
405(6)R
TGC CAG CTG TAC AAA GTT GAC C 
TTC TCG GAG AGA TCA CTG GAG A 212
3A
3A(2)F
3A(2)R
GCA GGC ATA GAA AAT CAA TCC C 
CTG GTG TTG CAA TGT GAA AGC T 353
311
3B(2)F
3B(2)R
TAC AAA TGC CCC TCA GGC AGT 
CTG CCA GTT TGA TGC ACA CCT 305
7A(2)F
7A(2)R
AGA CAAT GCT TGG ACA CGT GG 
GCT GGC ATC ACT CAC TTG GAA 254
IP
TF.F
TF.R
TTA CAG TGG CTG TAT TCT GCT CG 
TGC TGT TCT CAT GGA AGC TAT GG 401
BA
BAF
BAR
CAT CGT CAC CAA CTG GGA CGA C 
CGT GGC CAT CTC TTG CTC GAA G
465
Primer sequences used for mRNA expression profiles of HEK293 cells and COSl cells
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